Amyloid Disease: Are the oligomeric species a good therapeutic target? by Irvine, Amy
	   1	  
Amyloid Disease: Are the 
oligomeric species a good 
therapeutic target? 	  
Amy Irvine 
 
A thesis submitted for the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
Department of Molecular Biology and Biotechnology 
University of Sheffield 
 
 
 
	   2	  
Abstract 
It is believed that in many amyloid diseases, including Alzheimer’s, the 
primary toxic species responsible for neurodegeneration are small oligomers 
of the causative protein, rather than the fibres that often define the disease. 
Oligomers of our model protein cystatin B have, therefore, been prepared in 
order to characterise them.  
 
Conversion of these oligomers into non-toxic aggregates could be a good 
therapeutic strategy. I have, therefore, been looking at agents that facilitate 
oligomer detoxification as this therapeutic approach would address the 
underlying mechanism of disease, not just alleviate the symptoms.  
 
One example is the sage plant, Salvia sclareoides. Salvia species have been 
used in folk medicine as a treatment for memory loss and insomnia, as well as 
an antiseptic.   
 
Extracts from S. sclareoides (partitioned according to their hydrophobicity) 
can stop amyloid formation by converting amyloidogenic forms of cystatin B, 
α-synuclein and Amyloid β into non- amyloidogenic aggregates.  However, 
compounds within the Salvia extracts do not stabilise soluble oligomeric forms 
of these proteins directly. The extracts remodel amyloid fibrils into amorphous 
aggregates. The extracts are also effective in Creutzfeld-Jakob Disease, 
where they reduce levels of infectious PrPSc in scrapie-infected mouse 
neuronal cells. The extracts, themselves, show no toxicity towards human 
neuronal cells. 	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Chapter 1: Introduction 
1.1 Amyloid 
 
How and why normally soluble, functional proteins are converted into amyloid 
deposits are now questions of fundamental importance. Such conversion of 
misfolded proteins into the amyloid state is generally avoided in living 
organisms through a variety of mechanisms such as molecular chaperones to 
assist with folding, and protein degradation pathways to destroy proteins 
which are not folded into their correct native structure (Nelson & Cox, 2013).  
 
However, changes in the cellular environment can drastically affect the cell’s 
ability to deal with misfolded proteins and therefore protect the organism from 
damage and disease. Oxidative stress, ageing and changes in the proteins 
being produced, such as mutations, are all thought to be key factors in this 
process.  
 
There are now thought to be over 50 diseases and disorders associated with 
misfolded proteins forming amyloid aggregates, the amyloid fibrils being the 
hallmark of these diseases (Knowles et al. 2014). Many of these disorders or 
amyloidoses are now some of the most common and debilitating medical 
conditions facing the world’s population as they are often associated with 
ageing and modern lifestyles e.g. Alzheimer’s Disease and Type II Diabetes. 
Indeed, the UN has declared, “the global burden and threat of non-
communicable diseases constitutes one of the major challenges for 
development in the twenty-first century” (WHO, 2012).  
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Disease Aggregating protein Number of 
residues 
Native structure 
of protein 
Neurodegenerative diseases 
 
Alzheimer’s Disease Amyloid β peptide 40-42• Unfolded 
Spongiform encephalo-
pathies 
Prion 253 Unfolded(1-120), 
α-helical (121-
230) 
Parkinson’s disease α-Synuclein 140 unfolded 
Dementia with lewy 
bodies 
α-Synuclein 140 unfolded 
Huntington’s disease Huntington with poly-
q expansion 
3144+ Largely unfolded 
Amyotrophic lateral 
sclerosis 
Superoxide 
dismutase 1 
153 All β-sheet 
Systemic amyloidoses 
Hemodialysis-related 
amyloidosis 
β2-microglobulin 99 All β-sheet 
Icelandic hereditary 
cerebral amyloid 
angiopathy 
Mutant of Cystatin C 120 α-helix and β-
sheet 
Senile systemic 
amyloidosis 
Transthyretin 127 All β-sheet 
Familial amyloidotic 
polyneuropathy 
Mutant Transthyretin 127 All β-sheet 
Type II diabetes Amylin 37 Unfolded 
Hereditary cerebral 
hemorrhage with 
amyloidosis  
Mutants of Aβ 
peptide 
40-42• Unfolded 
 
Table 1.1: Human amyloid diseases associated with formation of extracellular amyloid 
deposits or intracellular inclusions 
*Other fragments of various lengths have also been shown to be present in amyloid fibrils 
(Table adapted from Chiti & Dobson, 2006). 
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1.2 Classification of Amyloids 	  
Amyloid diseases can be split into two broad categories-neurodegenerative 
diseases in which the aggregation occurs in the brain, and systemic 
amyloidoses in which aggregation occurs in tissues other than the brain.  
 
A well-studied example of a systemic amyloidosis is Haemodialysis related 
amyloidosis which is caused by β2-Microglobulin (β2m) -a component of the 
class I major histocompatibility complex (MHC). β2m is normally broken down 
and excreted by the kidney. However, in patients suffering from renal failure 
β2m is not degraded and the concentration of β2m in the serum can increase 
by up to 60-fold. This leads to association of freely circulating β2m into 
insoluble amyloid fibrils, which often accumulate in the musculoskeletal 
system, particularly at synovial joints (Morten et al. 2007).  
 
However, it is neurodegenerative disease which has really made amyloid a 
key area of research in the biochemistry field (Selkoe, 2003). Alzheimer’s 
disease is the most prevalent neurodegenerative disease (Caughey & 
Landsbury, 2003). The pathology of Alzheimer’s was first decribed by Alois 
Alzheimer who described plaques and tangles in the cerebral cortex of the 
brain. The plaques are extracellular and are composed of a protein called 
Amyloid β. The tangles are located inside neurons, axons and dendrites and 
are composed of Tau (Wolfe, 2006). Such plaques and tangles in brain 
sections can be stained using silver (the Bielschowsky technique) as shown in 
Figure 1.1 below.  
 
 
 
 
 
 
Figure 1.1:  Neuritic plaques in a section of the temporal cortex from an AD 
patient stained with the Bielschowsky technique (left). Neurofibrillary tangles 
can also be seen. (Right) Section of AD cortex immunostained with an antibody to 
Aβ42. (Figure taken with permission from Cummings et al. 1998)   
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It should also be noted that there are functional Amyloids, not associated with 
disease. A well-characterised example is the protein curlin used by 
Escherichia coli to colonise inert surfaces (biofilm production) and initiate 
binding to host proteins (Chiti & Dobson, 2006).  
 
Proteins which form amyloids can also be categorized into three groups:  
 
1. Non Structured proteins:  
Many of the peptides and proteins involved in amyloid diseases are 
intrinsically disordered under normal physiological conditions, such as 
amyloid-β (Aβ) peptide in Alzheimer’s disease. Aβ is a short peptide of 
between 39-43 amino acid residues (Serpell, 2000). The longer the Aβ variant 
the more prone to aggregation it is (Schnabel, 2011). The peptide is produced 
from the proteolysis of amyloid β precursor protein (APP) by γ and β 
secretase. Figure 1.2 shows the cleavage sites for proteolysis of APP. 
Mutations which increase Aβ production (e.g. Swedish) or change its 
aggregation properties (e.g. arctic), and, therefore, are linked to early onset 
Alzheimer’s disease, are also shown.  The exact physiological role of APP or 
its Aβ fragments in healthy individuals has not been clearly defined but APP 
has been linked to the regulation of synapse structure and function (Tyan, 
2012). Neurons from APP deficient mice have deficient survival and growth 
suggesting that APP plays a role in neuron viability, axonogenesis and 
dendritic branching (Perez et al. 1997, De Stooper and Annaert, 2000) 
 
Figure 1.2: β- and γ-secretase cleave APP. The transmembrane domain of 
APP is highlighted in grey. γ-cleavage produces Aβ fragments that vary in 
length and hydrophobicity. Mutations in APP can increase the total Aβ 
production (blue) or alter the Aβ aggregation properties (black and green) 
Taken from Benilova et al. (2012) with permission 
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Another key example of an intrinsically disordered protein responsible for an 
amyloid disease is α-synuclein. α-synuclein is the major fibrillar component of 
the Lewy bodies found in the substantia nigra of Parkinson’s disease patients 
(Caughey & Landsbury, 2003). Such Lewy bodies can be seen in Figure 1.3.   
α-synuclein is a 140 residue protein and is predominantly expressed in the 
brain. It is still unclear what the main role of α-synclein is although there are 
many proposed functions; signal transduction, vesicular trafficking, synaptic 
plasticity, oxidative stress regulation and mitochondrial behaviour.  Early 
onset Parkinson’s disease is caused by mutations in the α-synuclein gene, 
the most common being A53T and A30P.  
 
 
Figure 1.3: Immunostained lewy bodies containing α -synuclein. a, Nerve cells 
and neuritis containg lewy bodies. b, Nerve cell with two lewy bodies. c,  
extracellular lewy body. Taken with permission from Spillantini et al. 1997.  
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2.  Partially folded proteins:  
Prion diseases such as Creutzfeldt-Jakob disease in humans and bovine 
spongiform encephalopathy in animals are caused by the accumulation of 
aggregates of the disease-associated scrapie isoform of prion, PrPSc,  in the 
brain. PrPSc is derived from the host-encoded glycoprotein PrPc. The NMR 
structure of the cellular prion isoform (PrPC) consists of an unstructured N-
terminal region of about 100 amino acids and a structured C-terminal of a 
similar length (three α-helices and a short β-sheet). The role of PrPC in vivo is 
unknown but PrPC is associated with prion pathogenesis as mutations in the 
human prion protein gene result in inherited prion diseases. Prion propagation 
requires conformational change of PrPC, primarily an α-helical structure, to a 
β-sheet rich structure (PrPSc) (Trevitt & Collinge, 2006).  PrPSc can then act as 
a template which promotes further conversion of PrPC to PrPSc.  
 
The exact link between the different prion disease pathologies and the 
kinetics of prion propagation is still to be determined. However, the Collinge 
group has shown the prion strain type (the dominant PrPSc polymer) to be 
important in this process. An intermediate species between PrPc and PrPSc 
which they call PrPL is thought to mediate neurotoxicty.  
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3. Structured proteins:  
Our group for many years has been studying cystatins, a superfamily of 
cysteine proteinase inhibitors. Cystatins are a useful tool in the study of 
amyloid at a molecular level; NMR and crystal structures have been 
determined for many of the cystatins and their folding pathways are well-
defined.  
 
Animal cystatins can be categorized into three groups: type 1 which are 
intracellular (cystatin A and B), extracellular type 2 cystatins (C, D, E, F, S, 
SN, SA) and type 3 also known as the high and low molecular weight 
kininogens (Turk & Bode, 1991). Structurally, type 1 and type 2 cystatins (the 
most characterized) are highly homologous. They all have a five stranded β-
sheet overlaid by an α-helix-“the hot dog fold” (Zerovnik et al. 2002). Type 2 
cystatins e.g. cystatin c (hCC) can be distinguished from type 1 by the 
presence of two disulphide bonds and an unstructured region of ~ 20 residues 
between strands 3 and 4.  
 
Interest in the amyloidogenic properties of cystatins came with the discovery 
that hCC, cystatin B and cystatin A form inactive dimers (Ekiel and 
Abrahamson, 1996; Jerala and Zerovnik, 1999; Zerovnik et al. 1997). NMR 
chemical shift changes revealed that this dimerization involved no major 
structural rearrangement apart from changes to the active site region between 
strands 2 and 3. The high kinetic barrier of this reaction led to the realisation 
that cystatins form domain swapped dimers (Ekiel et al. 1997; Jerala and 
Zerovnik, 1999). NMR and crystallographic studies of cystatin A and cystatin 
C provided further evidence of this (Staniforth et al. 2001; Janowski et al. 
2001).   
 
This domain swapped dimer is intriguing to those working on amyloid fibril 
structures as it is an attractive candidate for the individual units which make 
up the highly extended β-sheet structure (see 1.3). Domain swapping requires 
extension of β-strands 2 and 3, meaning the β-sheets of the two cystatin 
molecules can hydrogen bond.  
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A mutant form of hCC (L68Q) causes the amyloidogenic disease, hereditary 
cystatin C amyloid angiopathy. Deposits of hCC in the cerebral blood vessels 
cause repeated hemorrhaging, dementia, paralysis and eventually death 
(Abrahamson, 1996).  
 
Amyloid studies of hCC, especially the mutant form, are hampered by 
difficulties in purification and manipulation (Ekiel et al. 1997). However, due to 
structural homology, cystatin B is a useful model for the study of cystatin 
amyloids. Cystatin B is expressed in most human tissues and is localized to 
both the nucleus and cytoplasm where it inhibits cysteine cathepsins. Cystatin 
B is a protein of 98 amino acids and its 3D structure has been determined 
(Figure 5). Mutations in cystatin B are linked to a hereditary form of 
myoclonus epilepsy called Unverricht-Lundborg disease also known as EPM1 
(Genton, 2010). Although an uncommon autosomal recessive disease, it is 
devastating for sufferers. Patients suffer from frequent tonic-clonic seizures, 
myoclonic jerks and progressive cognitive decline. In most EPM1 cases (90%) 
the mutation is an unstable dodecamer repeat expansion in the promotor 
region of the gene which causes decreased expression of cystatin B. This 
expansion can be repeated up to 75 times. The gene also usually carries one 
of these mutations: G4R, Q17P, three splice site mutations which alter the 
positions of introns and exons, a stop codon at position 68, or a frameshift at 
position 72 followed by a stop codon at position 75 (Lafreniere et al. 1997, 
Virtaneva et al. 1997).  
 
Cystatin B is now also thought to play a far more important physiological role. 
As well as a protease inhibitor, it is has now been linked to indirect regulation 
of the cell cycle through binding to histones and inhibiting cathepsin L in the 
nucleus (Ceru et al. 2010). Its important role in cell homeostasis has been 
further highlighted by studies showing it binds Aβ (Skerget et al. 2009), 
reduces oxidative stress through binding to SOD1 (Ulbrich et al. 2013) and 
prevents apoptosis. Cystatin B has also been linked to induction of 
autophagy, an intracellular quality control mechanism that disposes of protein 
aggregates and damaged organelles (Poljanar & Zerovnik, 2011).  Further 
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evidence for these multiple functions have come from studies showing its 
involvement in cancer, immunity, inflammation and neurodegenerative 
amyloid diseases. Indeed, cystatins A, B and C are found in the plaques of 
Alzheimer’s and Parkinson’s disease patients (Li et al. 1993). 	  
 
Cystatin B is a useful model for looking at amyloid as it forms fibres readily in 
vitro over about 2 weeks (pH 4.7, 100mM NaCl, 37°C). (Zerovnik et al, 2002). 
Cystatin B can also form domain swapped dimers (figure 1.4) and higher 
order oligomers.  
 
 
 
 
 
It is interesting to note that the ability of a polypeptide to form amyloid fibres is 
not restricted to those associated with disease. It is now clear that this is a 
generic feature of all proteins given the correct conditions in vitro. Myoglobin 
can form amyloid fibres in 50mM sodium borate, pH 9.0 at 65⁰C (Fändrich et 
al. 2001). This has led many researchers to the conclusion that amyloid 
formation is a natural alternative conformation for proteins and that strategies 
such as chaperones are important evolutionary adaptions to suppress amyloid 
formation in vivo (Fändrich et al. 2001).  
 
 	  	  
Figure 1.4: Cystatins form domain swapped dimers. Cystatin b monomer (a) and 
dimer (b). A non-covalent interaction within the monomer is broken and the 
corresponding region on another monomer takes its place (Sanders et al, 2004).  
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1.3 Structure of Amyloid Fibrils 	  
Although each amyloid is formed by the misfolding of a specific protein, the 
fibrillar aggregates they form are remarkably similar. They all form highly 
ordered fibrils which have a diameter of 7-10nm and are rich in β-sheet 
structure.  The β-sheet strands run perpendicular to the axis of the fibril 
(Sunde & Blake, 1997).  
 
One of the major research challenges in the amyloid field is to move beyond 
these initial observations and develop a high-resolution structure of the 
amyloid fibrils and indeed other aggregated states (Wetzel, 2002). Due to the 
insoluble nature of amyloid fibrils, traditional methods of structural 
determination such as x-ray crystallography and solution state NMR cannot 
be used. It has therefore been necessary to exploit and develop other 
techniques such as solid state NMR, circular dichroism, x-ray fibre diffraction, 
electron microscopy and fourier transform infrared spectroscopy to examine 
amyloid fibre structure (Serpell et al. 1999).   
Figure 1.5: The structure of amyloid fibrils formed from an 11-residue fragment of 
transthyretin. A combination of cryo-electron microscopy (a) with solid-state NMR has 
enabled a detailed atomic-level structure to be detrmined (b). A more detailed view (c) shows 
the three filaments that form the mature fibril formed by pairs of cross-β protofilaments, which 
are composed of pairs of β-sheets.The fibril surfaces are shown as electron density maps, and 
β-sheet areas as ribbons; Oxygen (red), carbon (grey) and nitrogen (blue) atoms are also 
shown. Figure taken with permission from Knowles et al. 2014.  
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1.3.1 Amyloid β Fibrils 	  
One of the most useful techniques by which Aβ fibrils have been studied is by 
electron microsopy. When viewed by negative stain transmission EM, Aβ 
filbrils are shown as smooth, regularly twisting fibres (Figure 1.6 A). EM 
analysis of Aβ fibrils has also highlighted the importance of the fibril assembly 
conditions. pH and the presence of other additives such as cholesterol and 
liposomes have been shown to affect fibril morphology (Stromer & Serpell, 
2005).  
 
Direct visualization of β-strands is now possible by Cryo-EM. The Serpell 
group have visualized fibrils of a synthetic Aβ peptide (residues 11-25 of Aβ1-
42). They showed that the fibrils are composed of in register β-sheets that form 
a tube (Serpell & Makin, 2002).  
 
Cryo EM along with mass-per-length (MPL) measurements and 3D image 
reconstruction has revealed even more about the exact morphology of Aβ 
fibrils-they are composed of smaller protofilaments. Aβ1–42 fibrils are 
composed of only one protofilament. However, Aβ1–40 fibrils are composed of 
two protofilaments (Figure 1.7). A fibril structure was resolved at 8 Å 
resolution and it showed pairs of β-sheets within the two protofilaments. 
Comparison of Aβ 1–42 and Aβ1–40 fibril structures revealed that they have very 
similar axial twofold symmetry and similar protofilament structure. The MPL 
data showed that the protofilaments of Aβ1–40 and Aβ1–42 fibrils have the same 
number of Aβ molecules per cross-β repeat. They also observed two different 
Aβ1–40 morphologies; fibrils with a 20nm distance between protofilament 
cross-overs and fibrils where this distance was 30nm. However, MPL data 
showed that these fibrils are structurally very similar and the difference 
observed could be due to the packing of the protofilaments, or different 
packing of the Aβ peptide within them (Schmidt et al. 2009). 
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Figure 1.6:  Cryo-EM of Aβ11-25  fibrils. A: Unstained fibrils in vitreous ice. B: A 
single fibril showing striations across the fibril with a distance between them of 
4.7 Å. Box below is an enhanced image which shows striations more clearly. C: 
A Fourier transform from fibril shown in B shows a strong central reflection at 
4.7 Å (from Stromer & Serpel, 2005).  
 
A	   B	   C	  
	  
Figure 1.7: STEM images and density maps of Aβ  fibrils. 1: STEM images of Aβ1–42, 20-nm 
Aβ1–40 and 13-nm Aβ1–40 fibrils. 2: Density reconstructions of Aβ1–40 and Aβ1–42 fibrils. 2: (A) 
Side views of Aβ1–42 and Aβ1–40 fibrils. (B) Mapped densities of Aβ1–42 fibril cross-sections 
(cross-sectional area is ≈44 nm2) (C) Cross-section through the 20-nm Aβ1–40 fibril density map 
(left)15 Å and (center) 8 Å resolution (The cross-sectional area is ≈90 nm2). (D) Cross-section 
through the 13-nm Aβ1–40 fibril density map. The cross-sectional area is ≈77 nm2 (Schmidt et 
al. 2009).  
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However, it is solid state NMR which has so far been the most powerful tool 
for determining the structure of Aβ fibrils. The Tycko group recently published 
an important structural model of Aβ1-40 fibrils seeded from Alzheimer’s brain 
extract. In vitro studies have shown that Aβ fibrils grown from seeds 
(sonicated, short fragments of mature fibrils) keep the structure of their seeds. 
This enabled them to study the fibril structures from the brains of two 
Alzheimer’s disease patients as shown in Figure 1.8 (Lu et al. 2013).  
 
Solid state NMR and EM of the seeded fibrils showed that each patient had a 
single predominant fibril structure and that the morphologies were different for 
each patient.  This structural specificity of the brain seeded fibrils has exciting 
possible implications for the disease process; fibrils could spread from a 
single nucleation site and different clearance mechanisms in patients’ brains 
may promote different nucleation events.  
 
From one of the patients they were able to build a full molecular structure of 
the fibrils. From the chemical shift data it appears that the whole Aβ sequence 
is part of the highly ordered, rigid fibril structure.  
 
Importantly, they compared their structure to previous in vitro work done by 
themselves and others. Their fibres had a three fold symmetry consistent with 
some in vitro fibril structures with twisted morphologies. However, other in 
vitro studies have shown fibrils with a 2-fold symmetry (Perkova, 2005). There 
were also novel conformation features in fibrils seeded from the Alzheimer’s 
brain. These included a twist in residues 19-23 that allows the burying of 
sidechains F20 or E22, a kink at G33 and bend at G37-38. In vitro fibrils have 
not shown such complexity (Lu et al. 2013).  
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Figure 1.8: Molecular structure of Aβ40 fibrils from an AD patient A) Structural model with the 
lowest total experimental restraint energy in Xplor-NIH calculations. The three-fold-symmetric repeat 
unit can be seen, including the backbone (grey) and sidechain (green) carbon. (B) A model structure 
created from the superposition of structures which fit within experimental restraints (PDB 2M4J). The 
sidechains of three Aβ1-40  molecules are shown in yellow, green, or orange. (C, D) Two views of a 
fibril structure, created by repeating the three molecule Aβ1-40 unit 18 times with 0.48 nm spacing 
along the fibril axis. (E) Possible structural polymorph of Aβ1-40 fibrils with three-fold and (F) two-fold 
symmetry, developed from SSNMR and EM of fibrils grown in vitro (Lu et al. 2013).  
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Whilst the structure of Aβ1-40 fibrils has been well studied by the Tycko group 
and others, the structure of Aβ1-42 fibrils has proved more elusive. This is 
largely to do with difficulties in the production of a large homogeneous sample 
of Aβ1-42 fibrils.  
 
Some recent interesting EM data along with previous H/D data has now 
furthered our understanding of the molecular architecture of these fibrils.  
 
3D reconstructions of Cryo-images have shown that the layers within the fibril 
are formed from dimers of the Aβ1-42. The two peptides, which form the dimer, 
have identical conformations; the C-terminal has β-sheet structure, whereas 
the N-terminal has a much more flexible structure (Schmidt et al. 2015). A 
density map reconstruction (figure 1.9) showed a central core domain along 
the main axis of the fibre with two peripheral domains. The Grigorieff group 
were able to image fibrils decorated with fragments antigen binding (Fab) from 
the 2H4 antibody. 2H4 recognises the N-terminal of Aβ1-42, indicating the N-
terminal of the Aβ1-42 peptides form the peripheral domains. The C-terminal 
segments, therefore, form the β-sheet core structural domain of the fibrils 
(Schmidt et al. 2015). This agrees with previous H/D exchange data, which 
showed that the Aβ1-42 N-terminal residues 18-42 exchanged very slowly, 
meaning they must be part of the core structure (Lührs et al, 2005) 
 
However, how exactly the C-terminal domains of the Aβ peptides stack to 
form this extended β-sheet is still not entirely clear. Some groups have 
assumed a U-shaped conformation in the fibril core (Lührs et al, 2005). This is 
similar to what has been proposed for Aβ1-40. EM density map data, however, 
suggests packing of the dimer units by back-to-back interactions along the 
longest uncharged β-sheet face of the Aβ1-42 peptide-like a zip.   
 
In reality, all these models could exist since small differences in fibril 
production protocols could result in different fibril morphologies being 
enhanced under different conditions.  
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Figure 1.9: Two models for the 3D structure of an Aβ1-42 fibril. 1: (A and B) Ribbon models of the 
structural core formed by residues 17–42 showing intermolecular interactions between β-strands. (B) Salt 
bridge between residues D23 and K28 (dotted lines) and two other important salt bridges formed by the 
central Aβ1–42 molecule (boxed) are shown. (C) Diagram of the odd end of 35MoxAβ1–42. Hydrophobic 
(yellow), polar (green), negatively charged (red), and positively charged (blue) side chains are shown. (D) 
Simulation of a 35MoxAβ1–42 fibril that consists of four protofilaments. Lower diagram is a noisy gray-scale 
image of the fibrils which has been blurred to give a resolution of 2 nm. A ×5-magnified cross section 
perpendicular to the fibril axis is also shown. The twist angle is 0.45° per molecule. (E) Cryo EM of single 
35MoxAβ1–42 fibrils (Scale bar: 50 nm.) (Figure from L Lührs et al, 2005) 
2: (A) Models of fibrils by this group overlayed (B) Aβ1–42 diagram showing two Aβ1–42 peptides with zipper-
like region (boxed). Positively charged (blue) and negatively charged residues (red) are shown. (C) Side 
view of the fibril superimposed with a backbone model of the fibril core. (D) Cross-section through the fibril 
showing dimer arrangement (E) Cros section through a stack of seven dimers. (F and G) A space filled 
model showing arrangement of charged (purple) and uncharged (yellow) residues (figure from Schmidt et. 
al 2015).  
 
 
1	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1.3.2 Cystatin B Fibrils 	  
As mentioned in section 1.2, cystatin B can form fibrils in vitro and due to its 
structural homology to other amyloid proteins e.g. cystatin c it is a useful 
model when studying amyloid fibril structure. In conditions favourable to 
fibrillisation, like the other cystatins, cystatin B initially forms a 3D domain 
swapped dimer using the central 2 and 3 β-strands. It has been hypothesized 
that this type of dimerization could be the mechanism for fibril propagation, i.e. 
molecule 1 domain swaps with molecule 2, molecule 2 swaps with molecule 3 
and so on. The extended β-strand is, therefore, formed from interactions 
within adjacent dimers (strand 1 forms an interface with strands 5 of the next 
dimer in cystatins). This propagated 3D domain swapped model of 
amyloidogenesis would explain why amyloid fibrils of mixed proteins or even 
protein isomers do not exist.  
 
Conservation of this central β-strand in mature fibrils of cystatin B was shown 
by hydrogen deuterium exchange. It was also discovered that that N-terminal 
region of the protein, an α-helix in the monomer, becomes unstructured 
during fibril assembly (Morgan et al. 2008).  
 
The evidence, however, for whether cystatin B forms fibrils through 
propagated domain swapping is unclear. For such domain swapping to occur 
over a whole fibril length, not just two molecules, a degree of conformational 
freedom is required in the hinge loop which exchanges with the rest of the 
structure.  However, the domain which exchanges in cystatin B is not a 
flexible loop; it instead forms part of the hydrogen bonded β-sheet in the dimer 
and fibril.  A different fibril model has therefore been proposed by our group 
with evidential data from limited proteolysis. This model shows that 3D 
domain swapping is maintained between dimers in the fibril chain but is not 
propagated. Protection of β-sheet strand five suggests that this forms part of 
the extended fibril β-sheet, not an edge strand as in the original model.  This 
model, therefore, proposes that dimers are stacked on top of each other to 
create an interface between strand 5 of one molecule and strands 2 of the 
next (Davis et al. 2016).  
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Figure 1.10: Two different structural models of cystatin B fibrils. A and B are proposed 
models for the propagated 3D domain swapped fibril. The N terminal strand and α-helix are 
removed from the models as data shows these domains are disordered in the fibril. B 
shows how the swapping interface or loop could be shortened by having four molecules of 
cystatin B, in plane, side by side. However, the loop would still have to be flexible and 
electron microscopy dimensions do not match up to this model. C is a model based on H/D 
exchange NMR data. The dimer units stack on top of each other forming contacts between 
strand 5 and 2 (blue and orange). The removal of the helix from the β-sheet surface 
creates a hydrophobic surface for another protofilament to form a hydrophobic sandwich so 
the hydrophobic side chains are shielded from the solvent (yellow). D shows the current 
working model taking into account limited proteolysis data. Strand 5 needs to be accessible 
to proteases without large scale structural remodeling. Both models C and D fit EM size 
restrictions (indicated by the dotted line).  
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1.3.3 α-synuclein Fibrils 	  
Like other amyloid proteins, fibrils of α-synuclein are composed of several 
protofilaments which contain a cross β-structure in which the individual 
strands run perpendicular to the fibre axis. EPR, limited proteolysis and 
SSNMR have shown that residues 31-109 are folded in the fibril. The N-
terminus can have a number of different conformations, whilst the C-terminus 
remains unstructured.  
 
Clever hydrogen/deuterium studies have been used to determine secondary 
structure elements of the fibrils. Del Mar et al. proposed a model whereby the 
main chain bends back on itself in order to fulfill the width constraint of ≤10nm 
observed by EM.  Their model showed tight hairpin bends running 
perpendicular to the fibril axis so that side chain amides could H-bond with β-
sheet amides (Del Mar et al. 2005).  
 
A more recent study (figures 1.11 and 1.12), which combined H/D exchange 
data together with the SSNMR data, showed five possible β-sheets in the fibril 
core. The first three β-strands are 6-8 amino acids long, whereas the other 
two are 9-13 amino acids in length. These strands stack to form a 5-layer β-
sandwich with β1 next to β2, β2 adjacent to β3 and so on with hairpin loops 
between each β-strand (Vilar et al. 2008).  
 
In straight α-synuclein fibrils, two protofilaments align with one another to form 
a fibril. Twisted fibrils also consist of two protofilaments but they are twisted 
around one another. The packing of straight and twisted fibrils requires 
different protofilament interactions. β4 and β5 interact in straight filaments, 
whereas in the twisted fibrils residues 22-30, which are not in the fibril core, 
are thought to interact.  
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Figure 1.11: Cryo-EM images of straight and twisted α -synclein fibrils.  In 
both cases two dense lines 2nm wide form a thicker filament. Scale bars: A 
and B, 20nm; C and D, 10nm (from Vilar et al. 2008) 
 
Figure 1.12: Structural model of α -synuclein fibrils from all published 
data.  Center: Model of folding in a molecule of α-synuclein within a 
protofilament. Left: The packing of a straight protofilament. Right: Packing in a 
twisted filament. (from Vilar et al. 2008)  
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1.4 Structure of Intermediate Species 
  
Although it has been known for many years that there is a close relationship 
between the appearance of amyloid deposits and pathology in protein 
misfolding diseases, there is still much to be understood about how this 
aggregation causes these pathological events.   
 
In the case of systemic amyloidoses it is thought that simply the presence of 
large amounts, in some cases kilograms, of amyloid deposits in vital tissues 
and organs is the cause of disease (Knowles et al. 2014).  
 
However, the mechanism of disease in the case of neurodegenerative 
disorders is obviously much more complicated. In many patients there is no 
detectable correlation between the quantity of fibrillogenic aggregates 
(amyloid plaques) in post mortem brain sections and the extent of cognitive 
decline pre-mortem (Haas & Selkoe, 2007).  
 
There is now substantial evidence that soluble pre-fibrillar (oligomeric and 
protofibrillar) species are the primary toxic agents in neurodegenerative 
disease (Härd, 2011).  The study of these fibrillar precursors and early 
oligomeric assemblies is challenging due to their transient, heterogeneous 
and unstable nature. However, new experimental approaches have started to 
provide useful information about these structures and their mechanism of 
toxicity (Stefani, 2012).  
 
It is important to note here that the large insoluble aggregates are often 
surrounded by the smaller, soluble species both in vitro and in vivo.  It is, 
therefore, difficult to say which species is directly inducing neuronal loss and 
dysfunction. Caughey and Lansbery warned researchers “not to throw the 
baby out with the bathwater” in their 2003 review. It is now considered more 
likely that there is continuous exchange between the fibrils and oligomeric 
species (Haas & Selkoe, 2007).  
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1.4.1 Amyloid β Oligomers 	  
There is now a plethora of confusing literature describing the many small 
intermediate assemblies of Aβ. These different classes include protofibrils, 
annular assemblies, Aβ derived diffusible ligands (ADDLs) and globulomers 
(Haas & Selkoe, 2007).  It also unclear which of these intermediates are on or 
off pathway to amyloid fibril production.  
 
Protofibrillar Aβ was the first of these intermediates to be studied as they are 
directly observed during the fibrillisation of Aβ in vitro. Typically, protofibrils 
can be up to 200nm long and 5-6nm wide (mature amyloid fibrils are usually 
∼10nm). They can continue to polymerise in vitro to form amyloid fibrils and 
can also dissociate to form smaller aggregates (Figure 1.13). Electron 
microscopy and Atomic Force Microscopy have shown that they are more 
flexible than mature fibrils as they exist as both curved and straight 
assemblies (Härd, 2011). Aβ protofibrils interact weakly with the amyloid 
staining dyes Congo red and Thioflavin T indicating that they contain high 
levels of the β-sheet structure observed in mature fibrils. Circular dichroism, 
infrared spectroscopy, x-ray diffraction and SSNMR have been used to reveal 
a secondary structure of two β-strands (Fändrich, 2012). 
 
Figure 1.13: Structure of Aβ1-40 oligomers, protofibrils and mature fibrils. 
Negative stain EM images from Fändrich, 2012.  
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Annular assemblies of Aβ in vitro are doughnut shaped structures with an 
outer diameter of 8-12nm. They are believed to enclose a water filled channel 
and have some structural similarity to pore forming toxins (Lashuel et al. 
2002). Little is known about their molecular structure due to the heterogeneity 
of preparations but it has been hypothesized that their pore forming nature 
enables them to perturb the cell membrane, ultimately causing cell death.  
 
There have been smaller oligomeric species (4-6nm in diameter) observed in 
preparations of Aβ in vitro. These are termed Aβ-derived diffusible ligands or 
ADDLs.  Ultracentrifugation has been used to identify ADDL-like assemblies 
from post mortem AD brains. How structurally analogous these species are is 
still unclear. There is evidence that both synthetic Aβ ADDLs and natural 
soluble ADDL-like oligomers can inhibit hippocampal long-term potentiation 
(Walsh & Selkoe, 2007, Haas & Selkoe, 2007).  
 
Globulomers of Aβ have also been well characterized using protein 
engineering. Globulomers are the spherical oligomers seen in SDS or fatty 
acid containing preparations. Solution NMR was initially used to identify 
dimeric Aβ units within globulomers of Aβ1-42. These dimers were created by 
residues 18-23 and 28-33 forming a two stranded anti-parallel β-sheet 
connected by a hairpin at residues 24-27. Intramolecular interactions between 
the two 34-39 fragments formed the final dimer structure in a two stranded 
parallel β-sheet. By introducing a Cysteine at position 17 and 34 they were 
able to stabilize the hairpin with a disulphide bond. This β hairpin structure is 
similar to the cross β conformation of Aβ observed in mature fibrils. However, 
the hydrogen bonding in these hairpins is intramolecular resulting in 
antiparallel β-strands. In mature fibrils the β-strands are parallel due to 
intermolecular hydrogen bonds (Yu et al. 2009, Hard, 2011).  
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1.4.2 Cystatin B Oligomers 	  
There are two important reasons for studying cystatin B oligomers: 
1) Cell metabolism and viability assays have shown that oligomers show 
similar effects on cells even if the oligomers are prepared from a 
protein not implicated in an amyloid disease.  This suggests that there 
is a generic mechanism by which oligomers are causing cellular 
dysfunction (Fandrich, 2012). Due to the difficulties in working with Aβ 
oligomers it is useful to be able to produce “model oligomers” of an 
alternative, well characterized protein which can still be used to study 
toxicity.  
2) As mentioned earlier, mutants of cystatin B are responsible for a form 
of progressive myoclonus epilepsy called Unvericht-lundborg disease 
or EPM1. Loss of function of cystatin B is observed in most patients as 
EPM1 mutations usually result in lower expression of cystatin B. 
However, gain of toxic function of some EPM1 cystatin B mutants may 
also play a role in the disease, since cystatin B can behave as an 
amyloidogenic protein (see 1.3.2). Indeed, intracellular inclusions have 
been found in the brain of an EPM1 patient (Polajnar et al. 2014). Wild 
type and mutant cystatin B have been shown to aggregate upon 
overexpression in cells (Cipollini et al. 2007). It has also been shown 
that the small aggregates are toxic to cells and increase oxidative 
stress. It has, therefore, been hypothesized that these oligomers are 
responsible for some of the pathology seen in EPM1 including loss of 
the Purkinje layer of the cerebellum, cerebral atrophy, reduced cortical 
thickness and white mass loss throughout the brain (Polajnar et al. 
2014).  
 
Purifying large quantities of overexpressed wild type cystatin B oligomers from 
E. coli had not yet been achieved prior to this project. However, oligomers of 
the G4R mutant cystatin B have been purified from E. coli, in previous work by 
our group and visualized by EM (figure 1.14). Whilst, the yield of these 
oligomers was low (less than 1.5mg/L of LB) the oligomers are stable for 
months at 4°C, meaning further structural analysis could take place.  
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G4R cystatin B produces oligomers of at least 5 different classes. The 
diameter of these oligomers ranges from 8-88nm as determined by electron 
microscopy. The G4R cystatin B oligomers do not bind Thioflavin T indicating 
that they do not share the large extended β-sheet structure observed in the 
amyloid fibrils. The oligomers are also resistant to denaturants such as 
guanidine hydrochloride and SDS. They are also resistant to digestion by the 
strong proteinase K enzyme indicating a strong, dense and compact structure 
(Davis, 2016). 
 
 
Figure 1.14 TEM of purified cystatin B G4R oligomeric species (taken with 
permission from Davis, 2013.  
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1.4.3 α-synuclein oligomers 	  
Similar to Aβ, during in vitro fibrilisation of α-synuclein, a number of spherical 
oligomers and protofibrils are observed prior to production of mature fibrils 
(Figure 1.15). A number of genetic mutations linked to Parkinson’s disease, 
e.g. the A30P mutation, promote the production of spherical oligomers and 
slow their conversion to fibrils. The protofibrillar form is also able to create 
pores in synthetic vesicles (Lashuel et al. 2002).  
 
 
Single molecule FRET (intermolecular fluorescence resonance energy 
transfer) data has been used to characterize two distinct species of α-
synuclein oligomer-small oligomer (A) with medium FRET values and large 
oligomers (B) with higher FRET values. Some structural insight of these 
oligomers was gained by measuring susceptibility to proteinase K digestion 
compared to monomer and fibrillar forms. The type A oligomers were as 
sensitive to proteinase K digestion as monomers, whereas the type B 
Figure 1.15: TEM analysis of oligomeric samples of α-synuclein (a) before 
incubation (b) after incubation for 3 days. Notice the appearance of small 
straight fibrils and worm like structures. (c) after 1 week (Paslawski et al. 2014)  
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oligomers were substantially more resistant to digestion. This indicates that 
the larger oligomers are more strongly structured and contain more β-sheet 
structure, reminiscent of the mature amyloid fibrils. Kinetic data showed that 
the smaller type A oligomer could grow through monomer addition into mature 
fibrils. The type B oligomers, however, are formed though conversion of type 
A oligomers or the disaggregation of fibrils. The larger oligomers are also able 
to convert into the smaller oligomers (Cremades et al. 2012). 
 
A further H/D exchange study further refined this oligomerisation model 
(Paslawski et al. 2014).  Oligomer type A was the most protected. The 
population of Oligomer type A also decreased with prolonged labeling. This 
type of exchange kinetics is related to slow refolding or dissociation during 
labeling. Oligomer type B was stable over the labeling timescale (100min). EM 
analysis revealed that if the oligomer preparation is incubated at 37°C for 3 
days two distinct structures appear-worm like clusters and straight fibrils 
(Figure 1.16). This data all leads to a model whereby Type A oligomers are on 
pathway aggregates to fibril formation and due to their equilibrium with 
monomers, they can form fibrils that are elongated by monomers.  Oligomer 
type B is more abundant and appears to cluster to form worm like structures. 
This makes oligomer type B the likely cytotoxic, membrane permeabilising 
species.  
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1.5 Kinetics of Amyloid Formation 	  
Understanding the kinetic factors involved in the conversion of soluble 
proteins into amyloid assemblies is of high importance if one is to understand 
the circumstances which cause this conversion in amyloid disease in humans.  
However, researching this self-assembly of soluble proteins into ordered 
insoluble aggregates is extremely challenging. Most agree that proteins need 
to unfold from their native structure in order to form amyloid fibrils in vitro and 
in vivo. Delineating the mechanisms of folding and aggregation requires the 
identification of the key species involved in the aggregation pathway by 
detailed kinetic analysis (Jahn et al. 2006).  
 
Producing reproducible aggregation data is often difficult and the non-linear 
nature of this aggregation makes the theoretical mathematics difficult to 
elucidate. However, analysis of the typical sigmoidal Thioflavin T reaction time 
course has revealed that aggregation is a nucleated polymerization reaction.  
An initial lag phase is normally observed before an exponential growth phase 
until a plateau is reached as all soluble species have been converted into 
fibrils. When pre-formed aggregates are added to a solution of soluble protein 
the lag phase can be completely removed and rapid flibril formation can take 
place due to seeding (Knowles et al. 2014).  
 
However, the relationship between the duration of the lag phase and 
processes taking place at the molecular level is in reality very complex (as 
shown in Figure 1.17).  Primary nucleation is thought to be responsible for the 
initial formation of aggregates from soluble species but in the case of amyloid 
formation, especially the well studied examples such as Aβ1-42, secondary 
processes are thought to be more important in the production of new fibrils. 
Whilst initially, in the absence of fibrils, early aggregates and oligomers are 
formed by primary nucleation, once a critical aggregate concentration has 
been reached secondary processes will be the major source of fibril 
production (Cohen et al. 2012 and Xue, 2015). Fragmentation is thought to be 
the most critical secondary process as each fragmentation event increases 
the number of fibril ends to which soluble species can attach. Secondary 
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nucleation, where the fibrils themselves act as surfaces for nucleation may 
also contribute to the observed lag phase and exponential growth processes 
(Knowles et al. 2014).  
 
 
 
Figure 1.16 Kinetics of amyloid formation. (a) Amyloid formation occurs via the  
monomer (green) through primary nucleation or from existing fibrils through both 
monomeric and aggregated species by secondary nucleation. (b) Integrated rate 
laws from filament growth show that they have sigmoidal functions which are 
characterized by a lag time (τlag) and a maximal growth rate (rmax; red line). (c) 
Comparison of these integrated rate laws with experimental measurements. From 
Knowles et al. 2014.  
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1.6 Other types of oligomers or inclusions 
 
In chapter 4 of this thesis I present a study of the polymerization of cystatin B 
into “oligomers” in vitro. However, the pathological nature of these cystatin B 
oligomers is unclear and, indeed, others such as the Melli group have found 
them to be “physiological and functional” in vivo (Rispoli et al, 2013).  I have, 
therefore, presented here a review of other protein inclusions which show 
similar characteristics to those of cystatin B.  
1.6.1 Marinesco Bodies 	  
Marinesco bodies (MBs) are eosin positive, ubiquitinated, intranuclear 
inclusion bodies and were first described by Georges Marinesco in 1902. 
They are found in the substantia nigra and locus coeruleus of the human 
brain. The bodies are small (2-10µm) homogeneous, droplet shaped 
structures (Figure 1.17). Their formation is thought to be a response to cell 
stress and ageing as they are found more frequently in adult cells but whether 
they have a role in neurodegenerative disease is unclear. Work on MBs in the 
1960s showed that they were found as frequently in patients killed in 
accidents as those suffering from terminal illness. They also found that there 
are no more or larger MBs in PD patients than those found in patients of a 
comparable age not suffering from the disease (Yuen & Baxter, 1963).  
 
However, later studies on intranuclear ubiquitin inclusions in trinucleotide 
repeat diseases such as Huntington’s disease (Alves-Rodrigues et al. 1998) 
and the discovery of higher numbers of MBs in those suffering from myotonic 
dystrophy has led to research into a possible pathogenic role for these bodies. 
More recent work has shown an increase in the number of MBs in dementia 
with Lewy body patients and that MB frequency correlates inversely with 
markers of striatal dopamine in healthy elderly people. It has, therefore, been 
hypothesised that MBs are involved in the age-related loss of nigral 
dopaminergic neurons (Beach et al. 2004).  
 
There are other intranuclear inclusions such as intranuclear rodlets (INRs) 
which are thought to be both structurally and functionally related to MBs. They 
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are both formed from amorphous granular material, interspersed with regular 
parallel or lattice-like fibrillar arrangements. INRs and MBs have also both 
been shown to contain pro-myelocytic leukemia (PML) protein (Kumada et al. 
2002; Woulfe et al. 2004). PML nuclear bodies (another type of inclusion body 
which are scattered throughout cell nuclei) are thought to have a number of 
functions including protein storage, degradation, and sequestration, and 
regulation of transcription. However, it is still not clear whether all these 
bodies, which are all found in healthy brains, are part of normal brain 
functionality or are abnormal structures, detrimental to neurons. However, 
their ubiquitination and the fact that they are analogous structures to those 
seen in trinucleotide repeat diseases indicates that they are an important 
regulatory mechanism for controlling the concentration of nuclear proteins 
(Woulfe et al. 2004). 
 
 
Figure 1.17: Marinesco Bodies in the nucleus of substantia nigra cells. They are 
small droplet like structures 2µm-10µm in diameter (from Yuen & Baxter, 1963).   
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1.6.2 Bunina Bodies 	  
Bunina bodies (BBs) are small eosinophilic intraneuronal cystoplasmic 
inclusions. They are one of the pathological hallmarks of amyotrophic lateral 
sclerosis (ALS) and are found in the remaining lower motor neurons (LMNs) 
of the spinal chord and brain stem of ALS patients. They were first described 
by Bunina in 1962 in two familial cases of ALS. Since then their morphology 
has been well studied. Electron microscopy shows that they consist of 
amorphous, electron dense material, showing clear areas in the centre which 
contain filaments and vesicles (Figure 1.18). They often form chain-like 
clusters and do not have a limiting membrane (Okamoto et al. 2007).  
 
However, their exact function still remains unclear. There have been many 
immunohistochemical studies on BBs using a huge number of antibodies 
against a variety of proteins e.g. tau, APP, α-synuclein, actin, myosin, 
neurofilament, α/β-tubulins and microtubule associated proteins (Sasaki et al, 
2006). However, only two proteins have been found in BBs: cystatin C 
(Okamoto et al. 1993) and transferrin (an iron binding protein which transports 
ferric iron into tissues) (Mizuno et al. 2006).  
 
Interestingly, cystatin C immunoreactivity is significantly lower in the LMNs of 
ALS patients and the formation of TDP-43 inclusions (another hallmark of 
ALS) may be linked to this. There is a positive correlation between the 
occurrence of BBs and TDP-43 inclusions in spinal and brainstem LMNs (Mori 
et al. 2009, 2010, 2014). However, a recent case report (Kimura et al. 2014) 
showed that BBs can be present elsewhere in the brain such as in the 
cerebellar dentate nucleus where TDP-43 inclusions are rarely found 
indicating that the mechanism of BB formation is separate from that of TDP-
43 inclusions.  
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Figure 1.18: Electron microscopy of Bunina Bodies. One can see two main 
features-amorphous material and other tubular and vesicular structures.  Typically 
Bunina bodies consist of densely packed amorphous material surrounded by some 
tubular and vesicular structures, sometimes with a central clear are containing 
10 filaments of about 10nm (from Okamoto et al. 2007).  
 
 
1.6.3 Cystatin B 	  
As mentioned in section 1.4.2 of this introduction, cystatin B is able to form 
oligomers. The Melli group have studied whether such polymerisation occurs 
in vivo and what functions these oligomers or inclusions may have. They 
showed that cystatin B does indeed form oligomeric structures in human and 
rat cells when overexpressed. They hypothesise that this may be an important 
regulatory mechanism as regulation and expression of protease inhibitors 
such as cystatin B must be tightly controlled in order to prevent neural 
degeneration (Cipollini et al. 2007). Further discussion of the importance of 
such cystatin B inclusions can be found in chapter 4.  
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1.7 Chaperones and Amyloid Disease 	  
1.7.1 Chaperones: An Introduction 	  
A chaperone protein assists proteins to obtain their correct three-dimensional, 
functional conformation. In English, a human chaperone is “a person, usually 
a married or elderly woman who, for the sake of propriety, accompanies a 
young unmarried lady in public as guide and protector”. Chaperone is 
therefore an apt name in biochemistry for these important proteins which 
inhibit incorrect interactions between molecules but do not give steric 
information or form part of final protein functional structures (Ellis, 1991).  
 
Chaperones have evolved for a number of important reasons, stemming from 
the fact that proteins are stabilized by many non-covalent, and therefore 
weak, interactions. These include ionic interactions, hydrogen bonding, van 
der Waals forces and hydrophobic effects. In the cellular environment, where 
overall protein concentration can be over 200mg/ml in eukaryotes, there is 
potential for these weak interactions to form non-specifically, leading to 
incorrect protein interactions, protein misfolding and, therefore, aggregation. 
Cell stresses such as heat stress and reactive oxygen species can also 
increase the propensity for proteins to misfold and aggregate, and indeed 
chaperone expression levels are increased during these events. Chaperones 
are also required during normal cellular events including the emergence of 
proteins from the ribosome. The N-terminus of proteins is synthesized before 
the C-terminus, meaning the partially synthesized protein, when still attached 
to the ribosome, is exposed in a partially unfolded and aggregation prone 
state.  Chaperones, especially those from the Hsp70 family, have also been 
linked to protein transport across membranes. Proteins have to unfold in order 
to pass across membranes and so are particularly vulnerable to inappropriate 
interactions and aggregation during this process (Zimmermann, 1998). It 
should also be noted that many proteins are multimeric and/or need further 
components in order to be fully functional. Chaperones are required for 
different polypeptide chains to meet and form complete, stable complexes. 
They also allow the correct addition of post-translational modifications such as 
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glycosylation and phosphorylation and the binding of other components such 
as DNA and haem groups.  
 
There are four large families of ATP-dependent molecular chaperones: 
Hsp100 proteins (also called Clps), Hsp90 proteins, Hsp70 proteins and 
Hsp60 proteins. There are also ATP-independent chaperones including small 
Hsps (sHsps). Enzymatically active chaperones such as peptidyl proline 
isomerases and protein disulphide isomerases are important in the correct 
remodeling of peptide bonds and disulphide bridges (Doyle et al. 2013).  
 
How chaperones actually work is an area of huge scientific interest and many 
of the mechanisms are still to be fully established. One of the most 
characterised chaperone systems are those involving Hsp70 also know as 
DnaK in E. coli. Hsp70 proteins are essential, highly conserved and are 
involved in many cellular processes including nascent protein folding and the 
remodeling of protein complexes. Hsp70 proteins have an N-terminal binding 
domain (NBD) and a substrate-binding domain (SBD) (Meimaridou et al, 
2009).  The SBD has two sub-domains; a β-sheet substrate binding pocket 
and an α-helical lid domain. NMR has been used to show the structure of the 
ADP-bound closed form of DnaK. The SBD and NBD are joined by a short 
flexible linker region, meaning conformational changes can occur during the 
chaperone cycle.  A triple mutant of DnaK (E47C, T199A and F529C) was 
used to mimic the ATP-bound open conformation. The crystal structure 
showed interactions between the lid and β-sheets of the SBD with the NBD.  
 
The nucleotide present at the NBD is known to allosterically regulate binding 
at the SBD of DnaK. When ADP is present, DnaK has high affinity for 
substrates. The ATP-bound state has low affinity for substrates. This 
substrate binding and ATP hydrolysis by Hsp70 proteins is regulated by two 
co-chaperones, Hsp40 (DnaJ) and NEF (GrpE).  
 
Hsp60s have also been well studied due their “unfoldase” activity. For 
proteins which fold slowly, Hsp60s bind to hydrophobic regions in the 
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misfolded state and induce local unfolding that helps overcome the kinetic 
barrier to correct protein folding. The bacterial Hsp60, GroEL, is the best-
characterised example of this type of chaperone. It is composed of 14 
subunits of 60 kDa which are arranged into 2 rings, making it 840 kDa in total 
(Zahn et al. 1996). Like Hsp70, nucleotide binding and a co-chaperone called 
Hsp10 (GroES in bacteria) are required for its activity. 
 
The Hsp100s are members of the AAA+ superfamily of ATPases.  Most 
members of the family bind a substrate protein and use energy from ATP to 
unfold and translocate the protein to an associated protease to be degraded. 
However, the bacterial Hsp100, ClpB, and its yeast (Hsp104) and 
mitochondrial (Hsp78) homologues are able to resolubilise protein aggregates 
without the need for an associated protease. This disaggregation activity is 
mediated by interaction between ClpB (and its homologues) with the Hsp70 
chaperone system (Glover & Lindquist, 1998, Hodson et al. 2012).  
 
Hsp104 is one of the most well studied of this type of chaperone due to its 
role in yeast prion propagation. Yeast prions can adopt a β-sheet rich amyloid 
fibril conformation similar to the mammalian prions. It has been shown that 
Hsp104 is involved in Sup35p fibril formation as deletion of Hsp104 results in 
a loss of the yeast prion phenotype (Chernoff et al. 1995). This is thought to 
be because Hsp104 is not acting to break up the amyloid fibrils. This results in 
less fibril seeds, meaning the process of seeding further amyloidosis cannot 
take place (Wegrzyn etl. 2001).  
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1.7.2 Hsp70/DnaK and amyloid disease 
 
There is a strong link between chaperone regulation and the onset of 
amyloidogenic diseases (Dobson, 2003). Hsp70 has been shown to have a 
broad range of anti-aggregation functions. Indeed, as mentioned earlier 
Hsp70 works alongside Hsp104 and ClpB to dissolve large aggregates.   
 
However, Hsp70/DnaK itself has also been shown to be important in a 
number of neurodegenerative diseases and has been studied for its 
therapeutic potential, particularly in Parkinsons disease. Hsp70 is found in AD 
plaques, polyglutamine aggregates in HD patients and in Lewy bodies of PD 
patients (Muchowski & Wacker, 2005). There has been much in vivo work 
showing the effect of Hsp70 on α-syn aggregation. Over-expression of Hsp70 
along with WT α-syn rescued PD flies from neuronal loss. Interestingly, Lewy 
bodies were still present when the neurons were examined under the 
microscope. This indicates that Hsp70 protects neurons from soluble toxic 
forms of α-syn and may even stabilize the fibrils present in Lewy bodies 
(Auluck et al. 2002, Witt, 2009).  
 
There are also some interesting in vitro experiments showing the anti-amyloid 
activity of Hsp70. Hsp70 has been shown to be one of the key proteins 
involved in chaperone mediated autophagy (CMA). Along with co-chaperones 
(Hsp40, Hsp90, Hip and Hop) it is believed to associate with proteins such as 
α-synuclein on the cytosolic side of lysosome membrane. The exact details of 
how this chaperone machinery unfolds the protein substrate before 
translocation into the lysosome are unknown. However, by keeping α-
synuclein soluble and shunting it into this lysosomal sink it is unable to form 
toxic aggregates (Agarraberes & Dice, 2001).  
 
Thioflavin T experiments have shown that Hsp70 inhibits α-synuclein amyloid 
formation in vitro without the need for co-chaperones or ATP. However, 
Hsp70 is only able to influence aggregation at the “early stages” of the 
process and has no effect on the fibrils. Addition of Hsp70 at time points 
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during the course of an aggregation reaction resulted in a premature levelling 
off of the fluorescence intensity. However, Hsp70 did not alter the ThT 
fluorescence in a reaction that has already reached its maximum. This 
indicates that Hsp70 does not cause the dissociation of α-synuclein fibrils, 
and is not acting as a disaggregase chaperone like Hsp104. NMR showed 
that Hsp70 does not bind to monomeric α-synuclein but instead binds to a 
range of prefibrillar species, including very early aggregates or even non-
native monomeric species. It is thought that Hsp70 is “capping” these 
hydrophobic species, therefore, halting their maturation into amyloid fibrils and 
keeping them in a more soluble state so that they can be degraded (Dedmon 
et al. 2005).  Figure 1.19 shows binding of prefibrillar α-synuclein to Hsp70 by 
gel filtration.  
 
 
 
 
Figure 1.29: Gel filtration 
chromatrography data showing 
Hsp70 binds prefibrillar α-
synuclein. Binding is shown by 
an increase in the area of the void 
volume peak by nearly 25% 
accompanied by a 5% decrease in 
the area of the Hsp70 peak when 
pre-fibrillar α-synuclein and Hsp70 
are co-incubated. (Dedmon et al. 
2005).  
 
Very recent work by the Radford group has shown a further role for Hsp70. 
They observed that Hsp70 inhibits β-2-microglobulin fibril mediated cellular 
dysfunction by preventing molecular shedding. Using ThT fluorescence, they 
showed that Hsp70 enhances the kinetic stability of the fibrils and that no 
depolymerisation of the fibrils occurs after 3hrs in conditions when this 
normally occurs (pH 6.4). Hsp70 also reduced membrane disruption by β2m 
fibrils and rescued SH-SY5Y cells from fibril-mediated inhibition of MTT 
reduction (Tipping et al, 2015).  
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1.7.3 DnaK and Cystatin B 	  
As further detailed in Chapter 4, DnaK (along with copper) has been shown to 
be the “polymerizing factor” responsible for cystatin B oligomerisation in E. 
coli. When DnaK is added to CysB in stoichiometric amounts no ATP or co-
chaperones are required for these oligomers to form. Even at sub-
stoichiometric amounts only Magnesium and ATP are required.  
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1.8 Amyloid disease therapeutics 
 
Therapeutics for amyloid diseases such as Alzheimer’s and Parkinsons 
remain elusive. Researchers are still searching for  “wonder neuroprotective 
drugs” that would both delay the onset of disease and slow their progression. 
There have been many unsuccessful clinical trials which have highlighted the 
many obstacles in the way of developing therapies for neurodegenerative 
diseases. There are still vast gaps in our knowledge of the complex molecular 
mechanisms underlying neurodegenerative disease and it is thought that any 
successful treatment would have to work on multiple targets. The lack of a 
good biomarker for these neurodegenerative diseases also makes recruiting 
patients for clinical trials difficult. However, the in vitro and in vivo studies 
discussed in the first half of this introduction have provided researchers with 
some key therapeutic strategies: inhibition of amyloid protein production, 
inhibition of protein aggregation and clearance of aggregated protein. Anti-
inflammatories and anti-oxidative therapies may also play their part as 
potential therapeutics for amyloid disease.  
 
There are a huge range of therapeutics being researched. Discussed below 
are a few examples of promising approaches.  
 
1.8.1 Inhibition of amyloidogenic protein production 	  
As mentioned in 1.2, Aβ is produced from the cleavage of APP by β and γ 
secretase. Inhibitors of these two enzymes are therefore thought to be 
promising targets for an AD therapeutic. Indeed, protease inhibitors have 
proved effective therapies for other diseases such as HIV and hypertension 
(Wolfe, 2006).  
 
β-Secretase has been well studied; its cleavage mechanism and the inhibitory 
pathways which could reduce Aβ production are well characterised. Structural 
studies of β-secretase suggest that a large inhibitor molecule would be 
needed to fit into its relatively large active site (Ghosh et al. 2012). However, 
such molecules with large molecular weights do not have good blood brain 
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barrier (BBB) permeability, making these types of β-secretase inhibitors poor 
drugs for AD (Gravitz, 2011). One β-secretase inhibitor which has been trialed 
is LY2886721. This drug was initially promising as it could be taken orally, 
reduced Aβ production and rescued transgenic AD mice from cognitive 
decline. Unfortunately, a phase II trial of this promising β-secretase inhibitor 
was suspended in June 2013 by Eli Lilly and Co. due to liver toxicity in 
patients (Lahiri et al. 2014).  
 
γ-secretase, the second enzyme involved in APP cleavage, is a membrane 
embedded protease complex which has a heterogeneous site preference for 
APP and therefore cleaves APP at multiple sites. This is the reason for the 
variable lengths of Aβ peptide, with the Aβ1-42 isoform being the most 
aggregation prone. Modifiers of γ-secretase activity such as some non-
steroidal anti-inflammatory drugs (NSAIDs) and their analogs do not stop γ-
secretase cleavage of APP but shift its cleavage site from residue 42 to 38 
meaning the Aβ variant produced is less likely to aggregate. Secretase 
inhibitors would also decrease oligomer formation (Haas & Selkoe, 2007).  
 
Eli Lilly had to halt the Phase III clinical trial of their γ-secretase inhibitor, 
Semegacestat, as it was found to be accelerating disease progression. The 
reasons for this are unclear but could be due to an as yet unknown activity of 
γ-secretase in the brain. γ-secretase is known to have several other 
physiological substrates, including Notch which is involved in cell fate 
decisions, hence a degree of caution in the use of such inhibitors as they may 
lead to very serious side effects.  
1.8.2 Immunotherapy 	  
There are several types of immunotherapy which could be used in Amyloid 
disease. Direct active immunotherapy with synthetic intact Aβ1-42 provided the 
first vaccine against Alzheimer’s disease, called AN-1792. However, the 
Phase IIa trial had to be halted due to 18 out of 298 (6%) of patients 
developing meningoencephalitis. The reason for this pathogenicity has not 
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been fully established, although most evidence points to Aβ specific T-cells 
(Delrieu et al. 2012).  
 
The second type of immunotherapy which has been trialed is passive 
immunisation using monoclonal anti Aβ antibodies. However, the efficacy of 
such a vaccine has also been called into question. A Phase II clinical trial for 
the passive vaccine containing the monoclonal anti Aβ antibody 
Bapineuzumab showed the effects of the vaccine were almost non-existent 
and 12 out of 124 patients developed vasogenic cerebral edema.  
 
The reasons for the failure of these vaccines are unclear but some theories 
suggest that the vaccine only concentrates on Aβ and not tau. It is also likely 
that the antibodies do not clear the oligomeric species of aggregated Aβ. 
However, it is thought that vaccines would work in patients who have less 
advanced forms of the disease or are presymptomatic as the vaccine would 
keep amyloid β aggregates within manageable levels (Schnabel, 2011).  
 
1.8.3 Natural compounds 	  
Epidemiological studies have moved attention away from traditional drug 
discovery techniques towards therapeutic approaches stemming from diet and 
natural remedies. Much epidemiological evidence points to a lower risk of 
Alzheimer’s disease in populations with diets rich in polyphenols. Polyphenols 
are naturally occurring small molecules, found in fruits, vegetables and plants. 
More than 8,000 natural polyphenols have been identified. These range from 
simple small molecules to highly polymerized compounds. The number of 
phenol rings and the types of chemical groups attached to these rings is used 
to classify such compounds. Generally, they consist of two aromatic rings with 
hydroxyl groups which are joined by a three-carbon bridge. The two main 
groups are the flavonoids and the non-flavanoids (Beecher, 2003). 
Importantly, for their therapeutic use, they absorbed efficiently in the small 
intestine and do not usually show adverse side effects (Thapa & Chi, 2015).  
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It should be noted here that there are huge challenges involved in conducting 
these types of epidemiological studies. In order to analyse the independent 
effects of any dietary supplement there is a long list of other lifestyle variants 
linked to amyloid disease which must be accounted for including: gender, age, 
history of hypertension, diabetes, hyperlipidemia, formal education, ApoE 
status, smoking, alcohol consumption and physical activity (Yamada et al. 
2015).  
 
The Mediterranean diet has garnered much attention due to its already strong 
associations with a reduced risk of cardiovascular diseases, type II diabetes 
and cancer (Diez-Espino et al. 2011). The Mediterranean diet is characterised 
by high intake of extra virgin olive oil, plant-based foods and fish, low intake of 
meat, moderate intake of dairy products and regular but moderate intake of 
red wine. There have been a number of trials which have reported that such a 
diet is associated with a reduction in risk of dementia, mild cognitive 
impairment (MCI) and AD.  
 
A recent randomized trial with the PREDIMED (PREvención DIeta 
MEDiterránea)- Navarra cohort showed that intervention with a Mediterranean 
diet high in extra virgin olive oil (1L/week) improved cognitive performances in 
fluency and memory tasks and reduced MCI compared to controls. This 
cohort of 268 subjects (74.1 ± 5.7 years old, 44.8% men with no 
cardiovascular disease but at high risk of cardiovascular disease due to type II 
diabetes or other vascular risk factors) were randomly put into three groups 
for a period of 6.5 years.  Each received either a low fat diet, a typical 
Mediterranean diet containing 1L per week of extra virgin olive oil or the same 
diet but with mixed nuts (30g/day). The trial confirmed that it was the phenolic 
content of the olive oil and not the unsaturated lipid content which was 
responsible for the beneficial effect. Those on the Mediterranean diet high in 
extra virgin olive oil had significantly better performances on both visual and 
verbal memory tasks than those who received the nut supplementation 
(Jacomelli et al. 2010; Valls-Pedret et al. 2012).  
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Whilst olive oil is mainly composed of glycerides (98%), the remaining 2% 
consists of several phenolic compounds including phenolic acids (caffeic, 
vanillic, syringic), phenolic alcohols (tyrosol and hyrdroxytyrosol), lignans 
(acetoxypinoresinol and pinoresinol), flavones (apigenin and luteolin) and 
secoiridoids (oleuropein, aglycone, oleohcantal). Total phenols in olive oil 
usually range from 130-350mg/kg.  
 
One of the most widely studied polyphenols present in extra virgin olive oil is 
oleuropein aglycone (OLE) (figure 1.20). Like many of the polyphenols I will 
cover in this thesis it has been shown to have many beneficial effects: anti-
cancer, anti-hypertensive, anti-mircobial and anti-inflammatory. Recently, 
however, it has been studied due to promising anti-amyloid and 
neuroprotective activity (Rigacci et al 2010).  
 
 
Figure 1.20: Oleuropein (left) and oleuropein aglycone (OLE) (right) structures 
(from Stefani & Rigacci, 2013).   
 
Preliminary mass spectrometry and NMR work showed that OLE associates 
with monomeric Aβ1-40 (Bazoti et al. 2008, Galanakis et al. 2011, Kallberg et 
al. 2001). Interestingly, the OLE-binding region overlaps with the Aβ peptide 
sequence critical for fibrillisation indicating that binding of OLE interferes with 
aggregation. Further evidence for this was demonstrated with Aβ1-42 and 
human islet amyloid polypeptide (hIAPP). Thioflavin T (ThT), ANS binding, 
circular diochromism, AFM and TEM showed that OLE redirects the 
aggregation pathway away from toxic oligomers and fibrils towards non-toxic 
amorphous aggregates (Rigacci et al. 2010). In vivo work also corroborated 
the idea that OLE inhibits toxic amyloid aggregation. When OLE was 
administered to CL2600 Caenorhabditis elegans (C. elegans strain 
constitutively expressing Aβ3-42) it resulted in a significantly lower number of 
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plaques and toxic oligomers meaning a reduction in worm paralysis and an 
increase in survival (Diomede et al. 2013). The anti-amyloid activity of OLE 
has been most recently studied by using the TgCRND8 transgenic AD mouse 
model (encodes a double-mutant form of APP and shows amyloid plaque 
deposition and cognitive decline from the age of 3 months). Mice fed with an 
OLE supplemented diet for 8 weeks had a significantly lower Aβ plaque load 
and performed much better on memory tasks than control mice (Grossi et al. 
2013).   
 
Traditional Asian diets have also been associated with a reduction in risk of 
amyloid disease. Indeed, frequency of AD in India is about one quarter of that 
in the USA (0.7% in India compared to 3.1% in the USA among 70-79 year 
olds) (Ganguli et al. 2000). The curry spice turmeric has been linked to this 
trend and has long history as a traditional medicine in Asia. Curcumin (figure 
1.21) is thought to be the main active ingredient in turmeric. Curcumin has 
been reported to be a potent antioxidant and anti-inflammatory. Some of the 
highest profile research and clinical trials have been studying the anti-cancer 
properties of Curcumin (Hatcher et al. 2008; Aggarwal et al. 2007; Jobin et 
al.1999; Chan et al. 1998).  It is for its anti-amyloid properties, however, that 
Curcumin has come to the forefront of much recent therapeutic work.  
 
 
 
Figure 1.21: Curcumin Structure (from Stefani & Rigacci, 2013). 
 
The Yamada and Cole groups have shown that Curcumin inhibits aggregation 
of Aβ1-40 and Aβ1-42   as well as disaggregating preformed fibrils. Curcumin 
also prevented the formation of Aβ oligomers shown using an antibody 
specific to Aβ oligomers. It should also be noted that the Cole group found 
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Curcumin to be the strongest inhibitor of fibril formation out of a library of 214 
compounds. Curcumin, due to its slight structural similarity to Congo red, can 
stain amyloid plaques in hippocampus sections from the Tg2576 mouse brain 
(a mouse model expressing a 695 residue splice from human APP with the 
Swedish double mutation-K670N/M671L). Using the same mouse model they 
were also able to show that Curcumin is able to cross the BBB and stain 
plaques after oral feeding (Yang et al. 2004, Ono et al. 2004).  
 
Green tea, which is the unfermented (non-oxidised) form of black tea, is also 
a large part of the Asian diet, being mainly consumed in China, Japan and 
India (Caruana and Vessallo, 2015).  Green teas contain many simple 
flavonoids (catechins or flavon-3-ols). The most abundant of these is 
epigallocatechin-3-gallate (EGCG) (figure 1.22); 10% of the dry weight of tea 
leaves is EGCG (Graham, 1992).  
 
 
Figure 1.22 EGCG structure (from Palhano et al. 2013). 
 
EGCG is one of the most widely studied polyphenols in terms of its 
neuroprotective properties having been studied for use on 14 amyloidogenic 
proteins (Andrich & Bieschke, 2015).  The earliest studies with EGCG 
identified that it reduced cytotoxicity of Aβ in cellular models (Choi et al. 2001, 
Levites et al, 2003), reduced amyloid deposition in APP-transgenic mice 
(Rezai-Zadeh et al, 2005) and reduced aggregate formation in Drosophila and 
yeast models of Huntingtin aggregation (Ehrnhoefer et al. 2006).  
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There are many hypotheses for the mechanism of EGCG neuroprotection in 
amyloid disease. Much early work pointed to its antioxidant and iron-chelating 
activity (Mandel et al. 2008). EGCG has a 3’, 4’-dyhdroxyl group on the B-ring 
as well as a gallate group which can reduce Fe2+ to form redox inactive iron 
and, therefore, protect cells against oxidative damage.  The OH groups mean 
that it is a potent chelator of transition metals such as copper.  In terms of 
amyloid disease, the anti oxidant and metal chelating properties of EGCG are 
significant since oxidative stress and the accumulation of transition metals 
have been clearly linked to neurodegeneration (Zecca et al. 2004).  
 
However, the radical scavenging and metal chelating properties of EGCG are 
only part of the story. Much evidence suggests that EGCG prevents the 
formation of fibrils and other toxic aggregates by binding to amyloidogenic 
proteins. NMR of EGCG with monomeric α-synuclein showed that 30% of 
amino acid resonances were lost suggesting hydrophobic interactions or 
hydrogen bonding of EGCG with the peptide backbone or hydrophobic 
residues within the polypeptide chain (Ehrnhoefer et al, 2008). EGCG has 
also been shown to interact with Aβ at hydrophobic sequences important for 
β-sheet formation (residues 14-24, 27-37) (Lopez del Amo et al. 2012; Grelle 
et al. 2011)  
 
Aggregation of amyloid proteins in the presence of EGCG has demonstrated 
that EGCG inhibits the formation of Thioflavin T and Congo red positive fibrils. 
In the case of Huntingtin (Ehrnhoefer et al. 2006), Aβ (Ehrnhorfer et al. 2008; 
Lopez del Amo et al. 2012) α-syn (Bieschke et al. 2010), IAPP (Meng et al. 
2010) and Insulin (Wang et al. 2012) EGCG redirects the fibril formation 
pathway to the production of spherical aggregates-named amorphous 
aggregates. These amorphous aggregates are considered off-pathway to 
amyloid formation as they do not act as fibril seeds when added to monomeric 
Aβ or α-syn, they do not contain much β-sheet content compared to fibrils and 
they are not cytotoxic (Ehrnhorfer et al. 2008; Lopez del Amo et al. 2012).  
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Figure 1.23: AFM showing EGCG remodeling Aβ42 fibrils and oligomers into 
amorphous aggregates. Fibrillar Aβ42 (15 µM) was incubated with EGCG (15 µM) 
for 24 h in PBS at 37  °C (from Bieschke et al. 2010).  
 
Even more interestingly, EGCG has also been shown to remodel preformed 
amyloid fibrils into amorphous aggregates (Figure 1.23). EGCG was added to 
preformed α-syn and Aβ fibrils and after incubation for 24hrs amorphous 
aggregates, instead of the long fibrils, are detected by EM and AFM. CD and 
seeding experiments confirmed that these amorphous aggregates have 
similar properties to those formed with monomeric α-syn and Aβ in the 
presence of EGCG-a lack of β sheet structure and off pathway to amyloid fibril 
formation. Neuronal cell models (SYSY5Y and PC12) were used to show that 
these remodeled amorphous aggregates are not cytotoxic (Bieschke et al. 
2010).  
 
The mechanism of this remodeling has also been studied using red (Cy5) and 
green (Alexa 488) fluorescently labeled α-syn fibrils. The labeled fibrils were 
mixed and incubated with EGCG. Immunofluorescence (IF) microscopy was 
then used to visualize the fibrils. It was hypothesized that the fibrils are 
dissociated by EGCG, which allows for re-aggregation into amorphous 
aggregates, meaning the aggregates would be a mix of red and green 
fluorescence (yellow). However, the amorphous aggregates seen by IF in this 
experiment were uniformly red or green. This result confirmed a different 
hypothesis whereby EGCG directly converts the fibrils into amorphous 
aggregates without the need for fibril dissociation into monomers or small 
oligomers (Bieschke et al. 2009). The Kelly group has elucidated the nature of 
EGCG binding to amyloid fibrils and how this may remodel the fibrils. They 
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propose that oxidized EGCG (EGCG based quinones) are able to covalently 
modify amyloid fibrils through Schiff base formation using free amines or thiols 
present at the EGCG hydrophobic binding sites. This covalent modification of 
the fibrils causes cross-linking meaning that they cannot dissociate or 
fragment to form toxic oligomers (Palhano et al. 2013).  
 
As one can see from the example of small molecule therapeutics in this 
chapter, the exact molecular detail of how these molecules may be acting on 
the amyloid are still to be fully understood.  
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1.9 Overview of Thesis 
 
The title of this thesis “Amyloid Disease: Are the oligomeric species a good 
therapeutic target?” was chosen because of the two original aims of this 
thesis; to isolate and characterise oligomers of cystatin B and to identify small 
molecule therapeutics that could be used to detoxify such species.  
 
In Chapter 3 and 4, the preparation and characterisation of cystatin B 
oligomers is presented. This project investigated the role of DnaK and copper 
in this process.  
 
Chapter 5 presents work on identifying a novel therapeutic for amyloid 
disease from Salvia sclareoides (a species of Sage plant) using NMR and 
mass spectrometry.  
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Chapter 2: Materials and Methods 
2.1 Buffers and Reagents 	  
All reagents were analar grade and obtained from Fisher Scientific (UK) or 
Sigma-Aldrich, except where indicated. Deionised water (18.2Ω) from an Elga 
Purelab 611 Classic UVF was used in all experiments. Buffers were filtered 
through a 0.2 µm filter and 1 mM sodium azide (NaN3) was added to all 
buffers, except bacterial growth media.  
2.1.1 Luria-Bertani Media: 
  
 For 1l: 10 g bacto-tryptone (Oxoid ltd, UK) 
                5 g yeast extract (Oxoid) 
                10 g NaCl (Melford) 
 
The solution was made up in deionised water and sterilised by autoclaving. 
Antibiotic was added after cooling.  LB-agar was made by adding 2.8 g 
Nutrient agar in 100ml of deionised water and autoclaved. Around 20ml is 
used to pour 1 plate.  
2.1.2 M9 Minimal Media 	  
This is used for growing labeled protein for NMR experiments.  
For 1l: 6 g Na2HPO4  
          3 g KH2PO4  
          0.5 g NaCl  
 
The solution was made up in deionized water. The pH was adjusted to 7.4 
before autoclaving. The following were added to the media after autoclaving:  
For 1l: 650 µl trace elements (autoclaved)-see below 
           1.5 g glucose  
           1 ml 1 mg/ml thiamine  
           2 ml 0.5 g/ml (15NH4)2SO4  
           1 ml 1 M MgSO4  
           0.1 ml 1 M CaCl2 
 
	   61	  
 
Trace elements  
Per 100 ml dH2O:  
550 mg CaCl2.2H2O  
140 mg MnSO4.H2O  
40 mg CuSO4.5H2O 
220 mg ZnSO4.H2O  
45 mg CoCl2.6H2O  
26 mg Na2MoO4.2H2O  
40 mg H3BO4  
26 mg KI  
 
The above were added to 70ml of water and the pH adjusted to 8 before 500 
mg EDTA was added. The pH was readjusted to 8.0 and then 375 mg 
FeSO4.7H2O was added. The solution was made up to 100ml and autoclaved.  
2.1.3 SDS-PAGE gels and buffer 	  
4 x Upper Buffer:  0.5 M Tris/HCl pH 6.8, 0.4% w/v SDS 
4 x Lower Buffer:  1.5 M Tris/HCl pH 8.8, 0.4% w/v SDS 
 
Running Gel (16% acrylamide, tris-HCl pH 8.8):        
4 ml 40% acrylamide (37.5 : 1 acrylamide : bis-acrylamide; Bio-Rad), 2.5ml 
lower buffer, 3.5 ml H2O, 100 µl 10% w/v ammonium persulphate and 10 µl 
N,N,N’N-tetramethylethylenediamine (TEMED). 
 
Stacking Gel (4.5% acylamide tris-HCl pH 6.8): 
1.1 ml 40% acrylamide (37.5 : 1 acrylamide : bis-acrylamide Bio-Rad), 2.5 ml 
Upper Buffer, 6.4 ml water, 110µl 10% w/v ammonium persulphate and 11 µl 
TEMED. 
 
Running Buffer:  25 mM Tris/HCl pH 8.3, 190 mM glycine, 0.1% w/v SDS 
2 x Loading Buffer: 100 mM Tris/HCl pH 6.8, 200 mM DTT, 4% w/v SDS, 0.2 
% w/v bromophenol blue, 30 % v/v glycerol. 200µl aliquots were stored at  
-20°C and defrosted as required. 
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Stain: 450 ml methanol, 450 ml d.H2O, 100 ml glacial acetic acid, 2.5 g 
coomassie brilliant blue R250. 
 
Destain: 450 ml methanol, 450 ml d.H2O, 100 ml glacial acetic acid. 
2.1.4 Sodium Phosphate Buffers 	  
Two 1l stock solutions of the following were made: 
1) 0.1 M Di-sodium hydrogen orthophosphate (Na2HPO4) 
2) 0.1 M Sodium dihydrogen orthophosphate (NaH2PO4) 
 
These stocks were combined to the relevant final concentrations to make the 
required buffer. For example, for 1l of 10mM sodium phosphate buffer pH 6.0, 
12ml Na2HPO4 and 88ml NaH2PO4 were added together and made up to 1L 
with dH2O.  
2.1.5 Buffers for making competent cells 	  
RF1: 30mM KCH3CO2, 100mM RbCl, 10mM CaCl2, 50mM MnCl4, 15% 
glycerol 
RF2: 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% glycerol  
  
2.1.6 IPTG 	  
A 0.5M stock solution of isopropyl-β-D-galactosidase was prepared. The 
solution was added to growth media to a final concentration of 0.5 mM to 
induce protein over-expression.  
 
2.1.7 Antibiotics 	  
Ampicillin: A stock solution of 100 mg/ml ampicillin sodium salt (Melford) was 
made up in sterile water. Aliquots were stored at –20°C and thawed on ice 
before being added to growth media at a final concentration of 100µg/ml.  
 
Kanamycin: A stock solution of 15mg/ml was made up in sterile water. This 
was added to growth media to a final concentration of 15µg/ml.  
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Chloramphenicol: A stock solution of 25mg/ml was made up in absolute 
ethanol. This was added to growth media to give a final concentration of 
25µg/ml.  
2.1.8 Cystatin B Fibrillisation Buffer 	  
For fibrillisation of Cystatin B, 15mM sodium acetate 150mM NaCl buffer 
pH4.7 was used. 10% TFE was added to trigger the reaction. 
 
2.2 Protein production 
 
2.2.1 Expression and Purification of Cystatin B 
 
Making competent cell stocks 
The E. coli strain BL21 Gold (DE3) was used for protein expression. XL10 
Blue cells were used for production of plasmid stocks.  
 
LB Agar plates were streaked using non-competent frozen glycerol cell stocks 
of the desired strains. The plates were incubated overnight at 37⁰C. A single 
colony from the plate was used to inoculate 5ml of LB growth media. This 5ml 
culture was grown overnight at 37⁰C in a shaking incubator (200rpm). 200µl 
was taken from this starter culture and used to inoculate 10ml of LB. This was 
grown at 37⁰C, 200rpm until the OD600 was ~0.6. The cells were then 
incubated on ice for 5 minutes. The cells were centrifuged for 10 minutes at 
3500 xg4000 rpm and the cell pellet re-suspended in 3.3ml of RF1 buffer. The 
cells were incubated on ice for 30 minutes. After centrifuging again the pellet 
was re-suspended in 1ml RF2 buffer and incubated on ice for 30 minutes. The 
cells were aliquoted into 200µl fractions and stored at -80⁰C.  
 
Plasmid preparation 
Plasmid pET11a DNA containing the cystatin B construct was provided by 
Peter Davis. The plasmid DNA was extracted and purified from 5 ml overnight 
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cultures of competent E. coli XL1-Blue using the QIAprep Spin Miniprep Kit 
(Qiagen), following the manufacturer’s instructions.  
 
Transformations 
A 200µl aliquot of competent cells was thawed on ice. 180µl was placed in a 
thin walled falcon tube and the remaining 20µl left in the cryo-tube to be used 
as a no plasmid control. 1µl of plasmid DNA was added to the 180µl aliquot 
and incubated on ice for 30 minutes. The cells were heat shocked at 42⁰C for 
90 seconds and then incubated on ice for 2 minutes. 800µl of LB media was 
added to the falcon tube and 80µl of LB media was added to the cryo-tube. 
The cells were incubated at 37⁰C, 200 rpm for an hour. The cells from the 
falcon tube were serially diluted in fresh LB (undiluted, 10x and 100x) and 
100µl was plated onto selective LB agar (containing 100mg/ml Ampicillin). 
100µl of the no plasmid control cells were also plated. The plates were grown 
overnight at 37⁰C.  
 
Expression of Cystatin B 
A single colony was selected from a suitable plate and used to inoculate 50ml 
of LB or M9 media (containing 100 mg/ml ampicillin). This starter culture was 
incubated overnight at 37⁰C, 200rpm. 10ml of this starter culture was used to 
inoculate 1l of LB media containing 100mg/ml ampicillin. 4l of culture were 
grown as this generally gives a good yield of protein. Flasks were incubated at 
37⁰C, 200rpm until the OD600 reached 0.6. Isopropyl-β-D-
thiogalactopyranoside (IPTG) was then added to each flask at a final a 
concentration of 0.5mM to induce the cells. The cells were then grown for a 
further four hours at 37⁰C, 200rpm. The cells were centrifuged at 17700 
xg10,000rpm for 15 minutes at 4⁰C. The cell pellets were re-suspended in 
~50ml of 10mM Sodium phosphate buffer (pH6) and frozen at -80⁰C.  
 
Cell Lysis 
Cells were thawed on ice and transferred to a 200ml beaker. The following 
were added to the cell suspension: EDTA-free protease inhibitor (1 tablet per 
50ml; Roche Life Science, UK), 0.1 mg/ml DNase1 and 20 mM MgCl2. The 
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cell suspension was sonicated on ice for 6 cycles (30 seconds of sonication, 1 
minute cooling) at 12 microns using a Soniprep 1500. The suspension was 
then centrifuged at 28174 xg15000 rpm for 10 minutes at 4⁰C to pellet the cell 
debris.  The supernatant was retained and filtered using a 0.45µm filter. This 
solution was then dialysed overnight against 1l of 10mM sodium phosphate 
pH6 at 4⁰C.  
 
Ion-Exchange Chromatography 
The dialysed solution was loaded onto a 50ml SP-sepharose fast-flow column 
(GE Healthcare) which had been equilibrated with 10mM sodium phosphate 
buffer, pH6. The column was washed with the same buffer until the OD280 was 
reduced to the baseline value. The protein was then eluted over a 160ml 0-
500mM NaCl gradient in 10mM sodium phosphate buffer. 4ml fractions of 
eluent were collected and the presence of cystatin B checked by SDS-PAGE. 
All fractions containing cystatin B were pooled and concentrated to a volume 
of ~10ml using an Amicon ultrafiltration cell (Millipore, UK). The solution was 
filtered using a 0.2µm filter.  
 
Gel Filtration Chromatography 
The 10ml protein solution was loaded onto a 350ml preparative Superdex-75 
gel filtration column which had been equilibrated with 10mM phosphate buffer, 
pH6, 100mM NaCl (filtered and degassed). The protein was then eluted with 
the same buffer and 6ml fractions collected. The OD280 of the fractions was 
monitored and fractions containing cystatin B were pooled and stored at 4⁰C. 
4l of bacterial growth yielded 100 mgs of cystatin B.  
 
2.2.2 Expression and Purification of α-synuclein 	  
The α-synuclein plasmid construct was kindly provided by Dr Diane Hanger 
from Kings College, London. The WT α-synuclein insert was cloned into the 
NdeI/HindIII sites of pRK172 (AmpR). This plasmid was amplified in XL-10 
Blue cells, transformed into BL21 Gold (DE3) and cell cultures were grown as 
detailed for cystatin B (2.2.1). The bacterial cell pellets were re-suspended in 
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100ml high salt buffer (50mM Tris, 0.75M NaCl, 1mM EDTA, pH 7.4) 
containing 2 protease inhibitor tablets (Roche Life Sciences, UK). The 
suspension was incubated at 100ºC for 10 minutes and then centrifuged at 
17700 xg10,000 rpm for 20 minutes. The supernatant was dialysed against a 
salt free buffer (10mM Tris, pH.7.5) and then applied on to a 50ml Q-
sepharose fast-flow column and eluted using a 160ml 0-0.5M NaCl gradient. 
Fractions containing the protein were pooled, concentrated to 10ml and run 
down a preparative Superdex 75 SEC column (GE Healthcare).  A 4L growth 
yielded about 70mg of purified α-synuclein protein. An extinction coefficient at 
280nm of 5800 cm-1 M-1 was used to calculate protein concentration.  
 
2.2.3 Aβ preparation 	  
Lyophilised HFIP treated Aβ1-42 or 1-40 was purchased from rPeptide (Georgia, 
USA) as 1mg aliquots. Before re-suspension the aliquot was allowed to 
equilibrate to room temperature for 10 minutes.  1ml of cold HFIP was added 
to the vial to produce a 1mg/ml solution of Aβ peptide. The vial was sonicated 
in a sonicator bath (DECON Ultrasonics, Sussex UK) for 10 minutes at room 
temperature to allow for complete dissolution. 0.1mg aliquots of the resulting 
peptide solution were transferred to sterile eppendorfs. The HFIP was 
removed by evaporation under a stream of N2 and any further traces were 
removed by lyophilisation of the aliquots. The eppendorfs were stored at -
20ºC.  
 
2.3 Protein Analysis 
 
2.3.1 Gel Electrophoresis 	  
Tris-glycine SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) was used 
to determine presence of protein during protein purifications.  The BioRad 
Protean 3 apparatus was used. A running gel was first cast (16%acrylamide) 
and a stacking gel (4.5% acrylamide) cast above this. The gel was run in tris-
glycine buffer, 0.1%SDS, pH8.6.  10µl of each protein sample was added to 
10µl of loading buffer and 10µl of this was loaded into a well.  5µl of Precision 
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Plus Protein Dual Xtra Standards (Bio-Rad) were loaded into one well on the 
gel. The gel was run at 180kV for around 45 minutes or until the dye front 
neared the bottom of the gel. After removing the gel from its casing, it was 
stained using Coomassie Blue on a gel shaker for 1 hour. The gel was then 
destained overnight. Pictures of gels were taken using a Hewlett Packard 
scanner. 
 
2.3.2 Protein concentration 	  
Protein concentration was determined using the UV absorption of the protein 
at 280nm. The absorption spectra of the proteins from 250-350nm was 
recorded using a Cary 50 spectrophotometer. The concentration of protein 
can then be determined using the Beer-Lambert Law:  
Concentration = 
!!" 
where A is the absorbance, ε is the extinction coefficient and t is the path 
length. The extinction coefficients for the proteins used in this thesis were 
4470 M-1cm-1 for cystatin B, 5120 M-1cm-1 for α-synuclein and 1490 M-1cm-1 
for amyloid β samples. 
 
2.4 Amyloid Fibrils 
 
2.4.1 Cystatin B Fibril production 	  
The cystatin B protein sample was concentrated to 30µM using a rinsed 
vivaspin (Sartorius, UK) with a 3500MW cut off. The protein sample was then 
buffer exchanged also using a vivaspin (with a difiltration cup) into the 
fibrilisation buffer (15mM sodium acetate). The protein concentration was 
checked by UV absorbance. 10% Trifluoroethanol (TFE) was added to the 
solution last. The solution was incubated at 37⁰C for 2 weeks, over which time 
fibrils formed.  
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2.4.2 Aβ1-40 fibrils production 	  
A 0.1mg aliquot of HFIP treated Aβ was allowed to equilibrate to room 
temperature before addition of 20µl DMSO (giving a peptide concentration of 
10mM). The sample was sonicated for 10 minutes before the addition of 1 ml 
of fibrillisation buffer (50mM sodium phosphate, 150mM NaCl, pH 7.4). The 
sample was left at 37ºC for 48hrs.  
2.4.3 α-synuclein fibril production 	  
Soluble α-synuclein protein was buffer exchanged into a fibrilsation buffer (20 
mM Tris, 150 mM NaCl, pH 7.2) and concentrated to 100µM using a 10 KDa 
MWCO vivaspin. To produce fibrils, the protein solution was transferred to 
microcentrifuge tubes and placed in a rotating mixer (20 rpm) for 7 days at 37 
°C. Each tube contained a small glass bead (approximately 2 mm diameter) 
to increase agitation. Production of fibrils was checked using EM.  
 
2.5 Electron Microscopy 	  
2µl of sample was applied to a carbon coated copper grid which had been 
glow discharged at low pressure using a Cressington 208 glow-discharge unit. 
The sample was left to adsorb onto the grid for 1 minute and then blotted. The 
grid was then washed in two drops of water and blotted before being stained 
in 0.75% uranyl formate (a negative stain). Excess stain is blotted and the grid 
dried using vacuum suction. Grids were viewed using a Philips CM-100 
microscope at 100kV. Micrographs were recorded using a 1024x1024 pixel 
Gatan CCD camera.  
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Chapter 3: Cystatin B Mutation and Characterisation 
3.1 Introduction 	  
Previous studies on cystatin B by the Staniforth group have been completed 
using a cystatin B variant originally used for crystallographic studies. This 
meant it did not contain the cysteine residue present at position 3 in the true 
wild type protein. This had been mutated to a serine to prevent potential 
disulphide bridges forming so that the protein would produce good crystals. 
Recent studies, however, have shown that this cysteine residue is important 
in the oligomerisation of cystatin B (Rispoli et al., 2013). 
 
The serine was therefore mutated back to a cysteine in both the WT and G4R 
variants of cystatin B. As mentioned in Chapter 1, G4R is an EPM1-
associated mutation. Although overexpression of the cystatin B (S3C) WT 
should produce oligomers, it is believed that the G4R (S3C) mutation will 
promote increased oligomerisation as previous work in our lab has shown that 
the G4R mutant can oligomerise even without a cysteine residue at position 3 
(Davis, 2013).  
 
To avoid confusion, in this thesis cystatin B used previously will be called 
cystatin B C3S so other references to cystatin B will be to the true WT or G4R 
construct with a cysteine in position 3.  
 
3.2 Materials and Methods 	  
3.2.1 Mutagenesis 	  
Mutant constructs were produced using the pet11a plasmid which already 
contained the cystatin B C3S sequence. The following primers were used to 
mutate the serine to a cysteine at position 3:  
WT Forward: 5’ – GATATACATATGATGTGTGGTGCTCCGTCTGCTACTC – 3’ 
WT Reverse:  5’ – GAGTAGCAGACGGAGCACCACACATCATATGTATATC – 3’ 
G4R Forward: 5 ’– GATATACATATGATGTGTCGTGCTCCGTCTGCTACTC – 3’ 
WT Reverse: 5’ – GAGTAGCAGACGGAGCACGACACATCATATGTATATC – 3’ 
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Primers were diluted to a concentration of 125 ng/µl with distilled water. A 
QuikChange Site-Directed Mutagenesis Kit (Qiagen, UK) was used along with 
the diluted primers to produce the desired mutation.  
 
The PCR reaction mixture was set up as follows:  
 
1 µl pET11a plasmid template 
1 µl Forward primer 
1 µl Reverse primer 
1 µl dNTPs 
5 µl 10x reaction buffer 
41 µl dH2O 
1 µl PfuTurbo DNA polymerase 
 
PCR was carried out using the following cycling parameters:  
 
After PCR, the reaction was placed on ice for 2 minutes, after which 1 µl of 
Dpn1 restriction enzyme was added. This degrades methylated (non-mutant 
DNA) but leaves the unmethylated newly mutated DNA intact. 
The mutant plasmid was amplified using transformation into XL-10 Blue cells. 
The plasmid was then transformed into BL21 GOLD (DE3) cells as described 
in Chapter 2.  
 
The mutant proteins were purified as described in Chapter 2.  
3.2.2 ThT fibrillisation  
100µl samples of 30 µM cystatin B (prepared as in 2.4.1) in 15mM sodium 
acetate, 150 mM NaCl, 10% TFE, pH 4.7 containing 10 µM Thioflavin T were 
added to 96 black half-well plates (Corning). These were incubated in a 
Segment No. Cycles Temp /°C Time 
1 1 95 30 seconds 
2 18 95 30 seconds 
55 1 minute 
68  1 minute per kb of 
plasmid (pET11a 
plasmid = 6 mins) plus 
an extra 2 mins, 
therefore 8 mins 
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Biotech Omega Fluorescence plate reader (BMG Labtech, UK) at 37°C with 
double orbital shaking at 100 r.p.m. for 10 seconds before each reading. 
There were 5 replicates for each mutant and the mean of these replicates was 
plotted along with the standard error of the mean. The excitation wavelength 
was 440 nm and the fluorescence emission was measured at 485 nm every 5 
minutes.  
3.3 Results 	  
3.3.1 Cystatin B mutants were successfully purified 	  
The results of the final stage of the cystatin B purification involving size-
exclusion can be seen in Figure 3.1. SDS-PAGE analysis shows clear bands 
at ~ 11 KDa suggesting that cystatin B was purified successfully. This purified 
cystatin B was pooled and kept at 4°C. The gels only show monomeric 
cystatin B and there are no larger species or oligomers due to the presence of 
SDS, a denaturant, and DTT, a reducing agent. A clue to the oligomeric 
nature of the cystatin B species can be gathered from the elution time from a 
superdex 75 preparative size-exclusion column. 
 
As can be seen in Figure 3.1, WT cystatin B shows a tetramer peak (A) and 
an unresolved dimer and monomer peak (B). The cystatin B G4R size-
exclusion chromatogram showed an additional peak between fractions 16 and 
18. The fractions were pooled separately and analysed on the discontinuous 
SDS- PAGE gel to check for potential oligomers. No band corresponding to 
11 kDa cystatin B can be seen which suggests little if any monomeric cystatin 
B is in those fractions. This may suggest that the protein present in those 
samples is of a large molecular weight which cannot enter the 16% gel; if 
similar to oligomers produced by Davis (2013), these species may be 
resistant to dissolution in a variety of solvents including SDS. These fractions 
were analysed further using an analytical Superdex 200 HR 10/30 (bottom 
panel of Fig 3.1). There is no peak for monomer or dimer cystatin B (elute at 
32 and 30 minutes respectively). Instead, peaks can be seen at 15 and 50 
minutes, which could be oligomeric species since 15 minutes is the void 
volume and 50 minutes would correspond to a very retarded peak, typical of 
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hydrophobic species.  
 
The oligomer fractions shown in Figure 3.1 were also examined by electron 
microscopy (EM). No oligomers were seen by EM from the WT preparation, 
however, oligomers were seen in the G4R preparation (Figure 3.2). Both WT 
and G4R oligomers were visualized by EM when cystatin B was purified from 
E. coli grown in minimal media as described in chapter 4.  
  
Figure 3.3 shows chromatograms for cystatin B C3S and G4R/C3S from 
previous constructs with serine in position 3 for comparison to the 
chromatograms in Figure 3.1. 
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Figure 3.1: Cystatin B  WT and G4R 
purification. Top left: SDS-PAGE gel of 
fractions from SEC of Cystatin B (S3C) 
WT. Top Right: Chromatogram from SEC 
of Cystatin B (S3C) WT. The peaks are 
labelled (A) tetramer, (B) dimer/monomer 
peak. Monomer can be seen as a shoulder 
on this peak. Middle left: SDS-PAGE gel of 
fractions from SEC of Cystatin B (S3C) 
G4R. Protein containing fractions were 24-
41. Middle right: Chromatogram from SEC 
of Cystatin B (S3C) G4R. (A) is an 
oligomer peak corresponding to fractions 
16-18 which were pooled seperately. (B) is 
a tetramer peak, (C) is dimer and (D) is 
monomer. Bottom right: SEC-HPLC 
analysis of fractions 16-18. Small peaks at 
15 and 50 mins could correspond to 
oligomers.  	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Figure 3.2:  Electron microscopy images of cystatin B G4R oligomers observed in the 
oligomer fraction from purification by the SEC shown in figure 3.1.  
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Figure 3.3:  SEC profiles of the original (C3S) Cystatin B constructs. Top: Cystatin B C3S. 
The tetramer and dimer peak and monomer peaks are labelled. Bottom: Cystatin B C3S/G4R . 
There is a small oligomer peak covering fractions 16-19. The amount of dimer exceeds the 
amount of monomer significantly in both proteins. 
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Samples of the mutated proteins after gel filtration were analysed by 
electrospray ionisation (ESI) mass spectrometry. Figure 3.4 shows the mass 
spectrometry data for a sample of cystatin B WT. The mass peak at 11110.25 
Da corresponds to cystatin B WT monomer. The mass peak at 22,277 Da 
corresponds to cystatin B WT dimer. ExPASy Protparam (Gasteiger et al. 
2005) was used to calculate the expected molecular weight and this was 
11,139.5 Da. This difference of 29.25 Da on the purified monomer could 
correspond to a common mass lost associated with de-amidation (Keller et al. 
2008). The dimer peak has no adducts.  
 
Figure 3.5 shows the analysis of cystatin B G4R. The mass peak at 11,239.34 
Da corresponds to the cystatin B G4R monomer. A mass peak at 22476.74 
Da corresponds to cystatin B G4R dimer. These masses are both within error 
of the ESI mass spectrometry method (S. Thorpe personal communication) as 
ExPASy Protparam calculated the molecular weight of the cystatin B G4R 
monomer to be 11,238.7 Da.   
 
The masses corresponding to the dimer for both proteins are very close to the 
masses calculated by ExPASy and are within error of the ESI-MS equipment 
available (0.5 Da for WT, 1.3 Da for G4R). In an instance where disulphide 
bonding was occurring there would be a concurrent loss of 2 protons (2 Da). 
This was not observed in this experiment but the accuracy of this technique is 
not sufficient to be entirely conclusive.  
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Figure 3.4: Mass spectrometry of purified cystatin B WT. The cystatin B peak eluted between 
6.055-6.228 minutes. The raw detected ion masses are shown at the top. The de-convoluted 
spectrum is shown below. A peak at 11110.25 corresponds to a monomer or Cystatin B WT. The 
peak at 22218.38 corresponds to Cystatin B dimer. 
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Figure 3.5: Mass spectrometry of purified cystatin B G4R. The cystatin B peak eluted between 
6.005-6.254 minutes. The raw detected ion masses are shown at the top. The de-convoluted 
spectrum is shown below. A peak at 11239.34 corresponds to a monomer or cystatin B G4R. The 
peak at 22476.74 corresponds to cystatin B G4R dimer. 
	   79	  
3.3.2 Distribution of species in the WT and G4R (S3C) cystatin B 
 
It is interesting that compared with the C3S constructs, the monomer species 
was promoted in the purification of cystatin B, particularly the G4R construct, 
as can be seen in Figure 3.1. This leads one to assume that the presence of a 
cysteine in the protein and the resulting potential for disulphide bonding is not 
leading to oligomerisation per se.  
 
Purifications of cystatin B C3S yielded more dimer (Figure 3.3) and indeed the 
protein reverts to dimer from monomer or tetramer species in the usual buffer 
conditions of pH 6 and no salt.  
 
3.3.3 Fibrillisation Kinetics of Cystatin B Mutants 	  
To identify any differences in the aggregation properties of cystatin B proteins 
with cysteine in position 3, a ThT fibrillisation experiment was carried out 
(Figure 3.6). One can see that the C3S cystatin B (previous “WT” construct) 
takes far longer to form fibrils than the other three cystatin B proteins and 
exhibits a lag phase of 900 minutes. Cystatin B C3S/G4R has a lag phase of 
500 minutes as previously characterised by Paramore (2010). The WT and 
G4R with the cysteine re-instated have a further shortened lag phase of 
around 400 minutes.  
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This potentially lends further support to the idea that the N-terminus of 
cystatin B, despite being unstructured in both the native and fibrillary forms of 
the protein, makes an important contribution to the polymerisation of cystatin 
B. Indeed, a truncation introduced to remove two N-terminal methionines in 
positions 1 and 2 also resulted in a protein with a signicantly decreased 
fibrillisation lag time with respect to the C3S construct (Sharma, 2009). While 
it may seem counter-intuitive that mutations in unstructured regions of a 
protein may lead to increased polymerization behaviour, this is not without 
precedent. Disordered regions of proteins may in fact contribute to the 
assembly reaction as suggested by the above results. 
 
3.4 Conclusion 
 
Cysteine was successfully re-instated at position 3 of the B constructs for WT 
and G4R. Basic characterization in this chapter showed that the protein was 
successfully purified under the same protocol as the C3S variant. As with 
previously characterised mutations at the N-terminal of the molecule, the 
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Figure 3.6: Fibrillisation curves of 4 different cystatin B mutants. Blue and red are cystatin B 
C3S and C3S/G4R prior to reinstating cysteine at position 3. Green and purple are WT and G4R, 
both with cysteine at position 3. Each fibrillisation was replicated 5 times.  The time course 
truncates at 260,000 rfu as this is the maximum fluorescence that the plate reader can detect.  
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presence of cysteine leads to an increased tendency to assemble into 
amyloid. Intriguingly, the presence of cysteine favours the monomeric form 
over the dimer (albeit marginally). Mass spectrometry reinforces this view and 
shows no evidence of disulphide formation in our recombinant protein 
preparations. 	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Chapter 4: Cystatin B Oligomer Production 
4.1 Introduction 	  
As discussed in the introduction to this thesis, the oligomeric species of 
amyloid proteins are thought to be toxic and are, therefore, of the utmost 
interest to those looking at amyloid disease therapeutics. The Zerovnik group 
have been able to produce cystatin B oligomers composed of 6-, 8-, 12- and 
16-mers (Ceru et al. 2008). However, oligomeric species are transient in 
nature and difficult to isolate in large quantities from protein preparations. 
Whilst our group has had some success producing oligomers using the G4R 
EPM1 related mutant (figure 1.14), WT oligomers have proved far more 
elusive. The reasons for this may well be physiological: while amyloidogenic 
proteins associated with pathology form oligomers very readily, non-
pathological amyloidogenic proteins (functional amyloids) or synthetic 
peptides rarely form stable “oligomeric” species (Fowler et al, 2007).  
 
Another reason could be the use of the C3S variant of WT cystatin B by our 
group. Work to date in the Staniforth group on cystatin B has been conducted 
solely using the C3S variant of both WT and G4R cystatin B because this was 
the original construct designed for protein crystallization. This was not thought 
to have a major impact on amyloid formation because the mutation is within 
an unstructured region of the protein. However a paper published by the Melli 
group in 2013 highlighted the importance of a cysteine residue at position 3 
for cystatin B oligomerisation (Rispoli et al. 2013). This paper showed that 
cystatin B oligomerisation occurred in a similar way in a number of cell types 
including human and bacterial cell lines. They went on to isolate the E.coli 
Hsp70, DnaK, as the “polymerising factor” responsible for cystatin B 
oligomerisation in vivo. Given the ubiquitous nature of this chaperone, the 
implication is that similar processes are likely to be occurring in human cells.  
 
In their polymerisation experiments, Rispoli et al. (2013) used cystatin B 
monomers electro-eluted from SDS-PAGE gels. However, they found that 
DnaK alone was not enough to produce oligomers; copper is also required in 
vivo unless the cysatin B is destabilised by another method. In section 1.7.1 of 
	   83	  
this thesis, there is a full account of DnaK and its interaction with co-
chaperones DnaJ and GrpE, and Mg-ATP. Rispoli et al. showed that Mg-ATP 
is only required for cystatin B oligomerisation by DnaK at molar ratios below 
1:6. Co-chaperones are not required for this oligomerisation even at sub-
stoichiometric concentrations of DnaK and cystatin B.  
 
It was, therefore, hypothesized in this project that large quantities of WT 
cystatin B oligomers could be produced by adding DnaK and Cu2+ to purified 
monomeric WT and G4R cystatin B containing a cysteine at position 3. The 
aim of this chapter was therefore to investigate this and characterise the 
resulting oligomers in solution, beyond the SDS-PAGE analysis proposed by 
the Melli group. The novelty of this work lies in characterizing the involvement 
of chaperones in the formation rather than dissolution of non-native oligomeric 
forms of proteins. 
 
Unlike amyloid fibrils for which there are well characterised fluorescent dyes 
such as Thioflavin T and Congo red, there are no specific probes for looking 
at oligomers. Therefore, those working in this area are limited to working with 
the following techniques, all of which have serious limitations when dealing 
with large, disordered and highly heterogeneous aggregate samples. Light 
scattering and sedimentation analysis is dominated by very large aggregates 
which populate oligomer preparations making it hard to detect and quantify 
the full range of oligomeric species. Gel filtration has often been used in this 
field but the solid phase of chromatography columns can interfere with the 
process of oligomer formation and certain species can be lost due to 
adherence to the column. EM has proved useful for visualising structural 
elements of these species but is not sufficiently quantitative for kinetic work. 
Furthermore, EM can only view species above 100 kDa. A few groups have 
attempted fluorescent tagging to detect the coming together of two monomers 
(Lee et al, 2011; Garai and Frieden, 2013) but the tags are bulky and likely 
interfere with the assembly reaction. Since cystatin B is mainly dimer under 
the experimental conditions used in this project, the use of this technique 
would be very limited in this study and indeed in all studies attempting to look 
at something bigger than dimer. Finally, SDS-PAGE along with western 
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blotting analysis can provide evidence for protein assembly but cannot give an 
accurate report on the size or structure of the species formed.  
 
The strategy here was, therefore, to purify oligomers of cystatin B using size 
exclusion chromatography in order to further analyse their structure using a 
combination of techniques which could include EM, limited proteolysis and 
hydrogen-deuterium exchange in combination with either mass spectrometry 
or NMR. In addition, kinetic time courses for the reaction were planned in the 
presence of different chaperone/ATP combinations. As evident from the 
above discussion, oligomeric aggregates are notoriously difficult to handle 
which explains the lack of biophysical characterisation in the literature. In a 
similar way, the plan here may have been over ambitious. However, the 
qualitative characterization detailed in this chapter does describe the 
morphology of cystatin B oligomers which resemble inclusions or bodies such 
as the Bunina or Marinesco bodies discussed in section 1.6. The role of 
chaperones in the formation of such species has never been identified 
previously and the qualitative description of their activity presented here is of 
great interest to an emerging field (Jain et al, 2016; Rabouille & Alberti, 2017). 
The parallels between the species observed here and that isolated in cell 
culture by Rispoli et al make this of particular interest as such “bodies” have 
not previously been prepared in vitro. 
 
It should also be noted that the “oligomers” or “bodies” described in this 
chapter could be distinct from the oligomers associated with amyloid 
formation. There is now a growing interest in the area of phase separated 
bodies or granules. Such granules are also linked to neurodegenerative 
disease; for example, mRNP stress granules which are formed when protein 
translation is limited. Whilst their link to neurodegenerative disease has been 
established (e.g. mutations which cause ALS can increase stress granule 
formation) little is known about their structure or physical properties (Jain et al. 
2016, Li et al. 2013). Much research has been undertaken to observe such 
granules in vivo but they have not been prepared in vitro (Jain et al. 2016).  
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4.2 Materials and Methods 
4.2.1 DnaK Purification 	  
The DnaK plasmid was kindly provided by Dr Steven Burston from the School 
of Biochemistry, University of Bristol.   
 
2 µl of TOPO pET151-D plasmid expressing the DnaK protein construct was 
added to E.coli XL-10 blue cells (see chapter 2). Single colonies were picked 
and used to inoculate 100 ml LB-broth with 100 µg/ml ampicillin. 4 x 25 ml 
cultures were incubated in a shaking incubator for approximately 16 hours at 
37oC and 220 r.p.m. Overnight cultures were used to inoculate 4 x 2 L flasks, 
each containing 1 L LB-Broth and 100 µg/ml ampicillin and shaken at 37oC.  
When the cultures had reached an OD of 0.6, expression was induced with 1 
mM IPTG. 3 hours after induction, the cells were pelleted at 4 oC, 4000 r.p.m. 
for 20 min, before re-suspending in 60 ml of 50 mM Tris-HCl pH 7.5, 100 mM 
KCl, 20 mM Imidazole and 10% glycerol. The cell paste was freeze thawed at 
-20oC prior to sonication. The cell debris were then removed by centrifugation 
at 20,000 r.p.m, 4oC for 30 minutes.  
 
The cytosolic supernatant fraction was passed down a Ni-Sepharose column 
pre-equilibrated in 50 mM Tris, pH 7.5, 20 mM Imidazole, 10 % Glycerol and 
100 mM KCl. The N-terminally His-tagged DnaK protein that bound to the 
column was eluted after extensive washing using an imidazole gradient of 20 
mM to 300 mM (50 mM Tris, pH 7.5, 10 % Glycerol and 100 mM KCl). The 
peak fractions at 280 nm were pooled and dialysed against 50 mM Tris, pH 
7.5, 10 % Glycerol and 150 mM KCl, 20 mM MgCl2 for storage and to remove 
the imidazole.  
 
A typical purification protocol yields 200-300 mg from 4 litres, which is then 
aliquoted and frozen in liquid nitrogen at ~150 µM for storage at -80 oC. To 
calculate the concentration of DnaK, an extinction coefficient at 280nm of 
14,500 cm-1 M-1 was used. 
 
DnaJ and GrpE were supplied as purified proteins by the same group.  
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4.2.2 Oligomer formation 	  
Before addition of DnaK to cystatin B, both the cystatin B and DnaK samples 
were buffer exchanged into 50 mM Tris, 150 mM KCl and 20 mM MgCl pH 6 
using a 20 ml 10 KDa MWCO Vivaspin at 4000 r.p.m. If copper was used, 50 
µM CuCl2  was added to the cystatin B 10 minutes before the addition of other 
components. The final reaction volume was always 1 ml. When Mg-ATP was 
used it was used at a concentration of 5 mM. 
4.2.3 Analytical size exclusion chromatography 	  
Protein samples were tested for the presence of oligomers at specific time 
points using size exclusion high-pressure liquid chromatography (SEC-
HPLC).  Either a Shodex KW803 (with a KW-G guard column) (Shodex, 
Japan) or an analytical Superdex 200 HR 10/30 column (GE Healthcare) were 
used attached to a Perkin Elmer 200 HPLC system equipped with UV-visible 
absorbance detector. The column was run in the same buffer used for 
oligomer formation and absorbance was measured at 280 nm.  
4.2.4 Circular Dichroism 	  
Circular Dichroism (CD) was performed using a Jasco-J810 
spectropolarimeter. The pathlength was 0.1cm and a wavelength range of 
190-300 nm was used. Spectra were acquired at room temperature with a 
data pitch of 1nm and a rate of 20-50 nm/min. 10 spectra were acquired for 
each sample and averaged. Mean residue ellipticity ([θ]), measured in 
deg·cm2 dmol-1, was calculated using the following equation: 
 
[Θ] = !∗!""∗!"!∗!∗!!  
 
Where Θ is the measured ellipticity in degrees, Mr is molecular weight in KDa, 
c is the protein concentration in mg/ml, d is the pathlength in cm and NA is the 
number of amino acids in the protein.  
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4.2.5 Limited proteolysis and Mass Spectrometry 	  
A protocol for limited proteolysis of oligomers using proteinase K (Sigma 
Aldrich) was obtained from Davis et al (2015). The protease:cystatin B mass 
ratio used was 1:50. The reaction was carried out at pH 8 and 1 mM CaCl2 
was added to the sample. After addition of the protease, a time 0 sample was 
removed immediately and then quenched using a final 
phenymethanesulfonylfluoride (PMSF) concentration of 5 mM and frozen at -
20°C. Further time point samples were removed from the reaction solution 
and treated in the same way.  
 
The samples were defrosted and centrifuged at 14,000 r.p.m. for 10 minutes 
before analysis by mass spectrometry (MS). The supernatant was retained 
and the pellet was washed with 40% acetonitrile, 1% β-mercaptoethanol. 
Samples were run on a Grace Vydac Everest C18 reverse-phase column 
using a Waters Alliance 2695 HPLC machine over a linear 5-50% acetonitrile 
gradient for 40 minutes and 50-95% acetonitrile gradient for 5 minutes at 2 
ml/min. Micromass LCT electrospray-ionisation time-of-flight (Waters 
Corporation, Manchester) was used for mass determination.  
4.2.6 Ultracentrifugation 	  
A 10-30% glycerol gradient was produced using a gradient mixer and 
dispensed into a 12 ml centrifuge tube using a fine capillary tube. 500 µl of 
protein sample was then applied to the top of this tube with a pipette. An 
SW41 rotor (Beckman) was used in a Beckman Optima LE 80K 
Ultracentrifuge and samples were spun at 36K rpm at 4ºC for 24 hrs. Layered 
samples were removed in 18 x 0.7 ml aliquots from each tube and the 
contents analysed by western blot. 
4.2.7 SDS-PAGE 	  
Oligomer protein samples were either run on a 10% gel (stacking gel as in 
2.6.3) or a RunBlue precast 4-20% gradient gel (Expedeon, UK). The gels 
were stained with Instant Blue (Expedeon, UK).  
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4.2.8 Western Blotting 	  
Gels were transferred to a nitrocellulose membrane using a BioRad Trans-
Blot Turbo machine. The membrane was blotted with blotting buffer (5% milk, 
0.1% Tween-20 in PBS) for 2 hrs. Blotting buffer was removed and the 
membrane was incubated in the primary antibody overnight at 4 °C. The 
membrane was washed 3 times with 0.1% Tween-20 in PBS for 5 minutes 
each time then incubated in the secondary antibody for 1 hour at room 
temperature. To visualise the blot, the membrane was incubated in clarity 
western ECL blotting substrate (BioRad, UK) and viewed using a ChemDoc 
MP Docking System (BioRad, UK).  
 
Primary antibodies were goat anti-cystatin B C-16 and goat anti-cystatin B A-
12 (Santa Cruz Biotechnology, Germany). Both primary antibodies were 
diluted 1:250 in buffer. The secondary antibody used was donkey anti-goat-
HRP IgG diluted 1:4000 in buffer. 
4.2.9 Expression and Purification of α-synculein 	  
α-synuclein was expressed and purified as described as in section 2.1.2. 
ε280nm for α-synuclein is 5120 cm-1 M-1.  
 
4.3 Results 
4.3.1 Cystatin B oligomer formation by DnaK does not require Mg-ATP 
or co-chaperones 	  
The purification of different forms of WT and G4R cystatin B including 
oligomers from E. coli presented in Chapter 3 suggests that size exclusion 
chromatography would be a useful tool to separate and quantify the 
oligomeric species produced in the presence of cystatin B and chaperone. 
The first part of this study involved screening for the presence of oligomers in 
the presence of different ratios of chaperone to cystatin B and in the presence 
of Mg-ATP and / or co-chaperones.	  	  	  
Figure 4.1 A shows a SEC-HPLC elution profile of 50 µM cystatin B incubated 
1:1 with DnaK in the presence of Mg-ATP and copper. The buffer conditions 
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were kept at pH 6.0 in Tris buffer so as to favour the monomeric form of 
cystatin B, which is suggested by Rispoli et al (2013) to be the form of cystatin 
B necessary for assembly. Samples were injected at the intervals shown to 
observe any assembly reaction as a function of time. “Time 0” corresponds to 
injection immediately after mix. An analytical superdex-200 column was used 
in this experiment meaning the total elution time is 60 minutes. Control runs 
(Figure 4.1 B-D) were used to assign elution times for DnaK (25 min), cystatin 
B monomer (35 min), dimer (32 min) and tetramer (28 min). These 
correspond to peaks B, D and C in figure 4.1 A and occur at the expected 
retention times from our calibration (Figure 4.1D). 
 
Figure 4.1 A shows that cystatin B elutes in this mixture principally as dimer 
(C) with only a small peak for the monomer (D). One can see a small peak at 
about 17 minutes which corresponds to a very large species (A). This is very 
close to the void volume of the column, meaning these oligomers have a high 
molecular weight (greater than 600KDa). The large peak at 38 minutes is the 
Mg-ATP which elutes with the sample solvent. 
 
Figure 4.1 can be used to estimate the ratio in peak height between the DnaK 
peak (B) and the total cystatin B dimer and monomer peaks (C+D 
respectively) before any oligomerisation occurs, which is expected to be 3.2 
(ε280 (DnaK) / ε280 (CysB) = 14,500 / 4470) even though they are at equimolar 
concentrations (50µM), due to their differing aromatic content. However in 
control runs with pure DnaK or cystatin B, the ratio is 2.45 ±	 0.2. It is 
therefore likely that some DnaK is lost either through aggregation or through 
adsorption to the column matrix. This ratio is independent of concentration 
and the presence of Mg-ATP. The time course presented in figure 4.1. shows 
that this ratio remains unchanged for the duration of the experiment (4 hours). 
 
To look at oligomer production, it is useful to look at the reduction of monomer 
(since this is converted to the oligomers). The monomer peak (D) has been 
enlarged in Figure 4.2. One can see that the monomer peak starts at about 
0.03 but is reduced to about 0.015 by the end of the first hour of the 
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experiment (a reduction of about half). There does not seem to be any further 
reduction in the height of the monomer peak even after 24 hours (data not 
shown). This result suggests a significant population of the monomeric 
cystatin B is lost. 
 
Figure 4.3 is an enlarged view of the void volume peak (A). One can see that 
oligomers have been produced by the end of the first run (0 hrs) while they 
are absent from the control runs containing cystatin B or DnaK alone (Figure 
4.1.B & C). Any potential increase in the height of this peak is within the noise 
of the experiment. It is likely that some species are not resolved by the 
column; perhaps with time the oligomers increase further in size to that of a 
species that is filtered out by the online filters. It also became clear after 
further experimentation that the population of oligomers is heterogeneous and 
so their elution on SEC may occur at different times and be difficult to detect.  
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Figure 4.1:  Time course of Cystatin B incubated with DnaK and Mg-ATP. A: Time 
dependent elution profile of 50 µM Cystatin B WT incubated 1:1 with DnaK and 5mM Mg-ATP. 
50 µM CuCl2 was also present in the sample. Peak A is the void volume peak, B is DnaK, C is 
Cystatin B dimer, D is cystatin B monomer and E is ATP. B: Elution profile of 15 µM DnaK. C: 
Elution profile of 15 µM Cystatin B. D: Calibration curve of proteins run on the HPLC superdex-
200 column for comparison with different species of cystatin B and DnaK.   
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Figure 4.2: Cystatin B monomer peak (D) from SEC-HPLC profile shown in 
Figure 4.1 as a function of incubation time with DnaK and Mg-ATP	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To examine the concentration dependence of the oligomerisation of cystatin 
B, and to remove nucleotides from the data, the experiment was repeated 
with 2 µM cystatin B and DnaK without Mg-ATP present. A Shodex SEC 
column was also used as this has a shorter elution time (20 minutes) which 
would allow for better resolution of the first hour of the experiment. It was also 
thought that the different chemistry of the column could allow for better 
resolution of the oligomers. Both wild-type (Figure 4.4) and the G4R mutant 
(Figure 4.5) were tested. In addition to the DnaK (9.8 min) peak, dimeric (11.2 
min) and monomeric (11.9 min) cystatin B peaks, a clear peak can be seen at 
15 minutes which cannot be seen in the cystatin B and DnaK only controls. 
This was therefore assumed to be oligomers. When using the Shodex 
column, cystatin B oligomers seem to be eluted after the non-aggregated 
species, even though they are at a higher molecular weight. This is consistent 
with previous findings of the Staniforth lab (Davis, 2013). It may also be that at 
these concentrations of cystatin B, 25-fold less than in the previous 
experiment, the oligomers formed stick to the column suggesting a more 
hydrophobic exterior. It is symptomatic of aggregates and misfolded proteins 
that elution times on size exclusion are disturbed due to interactions with the 
column. 
 
In all of these 2 µM elution profiles, as well as the formation of a 15 minute 
peak, there is a striking increase in the apparent DnaK peak (9.8 min) height 
over time (Figure 4.7 A). This could indicate that the oligomer peak is 
overlapped with that of the DnaK under these experimental conditions or that 
the conformation of the DnaK structure is changing significantly. This seems 
less likely as there is no nucleotide (Mg-ATP) in this reaction. 
 
The experiment was repeated with wild type cystatin B at 20 µM to see if 
more oligomers could be produced (Figure 4.6). Samples were run every 5 
minutes to allow for even better time resolution at the start of the experiment. 
As with the 2µM samples, very little is observed in the void volume but instead 
changes can be seen at both 9.8 and 15 minutes. Compared with the 2 µM 
data, the 9.8 min DnaK peak is better resolved and a clear shoulder appears 
on the DnaK peak at 9.1min. This suggests the presence of a significantly 
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different molecular weight species, likely to be larger than a simple complex of 
DnaK and cystatin B monomer. 
 
The 15 min peak remains fairly stable throughout the experiment (Figure 4.7 
B). Therefore these oligomers are formed before the HPLC equipment can 
make its first reading (time 0). However, it should also be noted that it is only 
small fraction of the total cystatin B which is converted into this oligomeric 
form.  
 
Figure 4.7 C & D compare the populations of monomeric and dimeric cystatin 
B in these time courses. Whilst not completely clear from the data, it seems 
that the dimeric species is converted more readily to oligomers because as 
the concentration of cystatin B is increased, the proportion of monomeric 
cystatin B that is converted decreases more than that of the dimer. This 
agrees with Melli and co-worker’s hypothesis  (Cipollini et al, 2008). 
 
 
 
 
Figure 4.4: SEC-HPLC profile of 2 µM cystatin B (S3C) WT incubated 1:1 with 
DnaK over 4 hrs. CuCl2 was also present in the sample 
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Figure 4.5:  SEC HPLC profile of 2 µM cystatin B (S3C) G4R incubated 1:1 with 
DnaK over 4 hours. CuCl2 was also present in the sample 	  	  	  
 
Figure 4.6: SEC HPLC elution profile of 20 µM cystatin B (S3C WT) incubated 
with DnaK over 4 hrs. Control profiles of both cystatin B and DnaK can be seen in 
orange and grey. CuCl2 was also present in the sample 
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 15min Oligomers 
 
Cystatin B monomer 
 
Cystatin B dimer 
 
Figure 4.7: Change in protein peak heights over 4hrs. (A) change in DnaK peak 
height, (B) change in the 15 minute cystatin B oligomer peak height, (C) change in 
11.9 min (cystatin B (S3C) WT monomer) peak height and (D) change in cystatin B 
11.2 min (dimer) peak height over time. Green is an experiment in which DnaK and 
cystatin B were both 2 µM, purple is for the experiment in which both proteins were 
20 µM and blue is a control sample in which cystatin B was not present. 
 
Oligomers formed at low ratios of DnaK to cystatin B 
 
To ascertain whether these oligomers could be made in vivo, where the 
availability of DnaK may be limiting, different ratios of DnaK to cystatin B were 
tested in the presence of 5 mM Mg-ATP (Figure 4.8). A constant 
concentration of 10µm cystatin B was used in this experiment. The following 
ratios of cystatin B:Dnak were used; 1:1, 1:10, 1:100, and 1:1000. Potential 
oligomer peaks can be seen before 20 minutes for the 1:1 sample. However, 
potential oligomer peaks for the 1:10, 1:100, 1:1000 experiments were not 
clear.  
 
(A) (B) 
(C) (D) 
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Figure 4.8: SEC-HPLC elution profile of Cystatin B (S3C) WT incubated at 
different ratios with DnaK. CuCl2 and Mg-ATP were also present in the sample 
 
 
In conclusion, the HPLC results in this section suggest that the monomeric 
form of cystatin B is crucial to the assembly of oligomers, in agreement with 
Melli and co-workers. The elution behaviour of the oligomers makes these 
species difficult to quantify because they appear to have different retention 
times. The increase in a peak at 9.1 min on the Shodex column, which 
overlaps with the elution time for DnaK seems the most likely candidate. The 
lower ratio of absorbance observed on SEC between DnaK and cystatin B is 
not resolved here, but is addressed in section 4.3.2, which describes further 
analysis using electron microscopy. This validates the idea that the oligomeric 
species observed in the presence of cystatin B do not occur in DnaK only 
controls. The next step, therefore, was to validate the presence of oligomers 
in these samples using electron microscopy. This is a well used technique in 
the literature for the visualization of oligomers and allows for comparison of 
the oligomers studied in this project with others found in the literature.  
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4.3.2 Morphology and Validation of Cystatin B Oligomers by TEM 
 
It should be noted here that oligomers of cystatin B have never been seen in 
any fibrillar preparations of the protein by our group and is, therefore, not 
naturally pathological. On the other hand, cystatin C preparations are always 
full of oligomeric species when examined by EM. EM is therefore a very 
powerful technique for validating the presence of oligomeric species as well 
as characterizing them.  
 
We examined the morphology of the cystatin B oligomers formed in the 
presence of DnaK without Mg-ATP (Figure 4.9), with the co-chaperones 
DnaJ, GrpE and Mg-ATP (Figure 4.10) and with DnaK and just Mg-ATP 
(Figure 4.11). Oligomers varied in size and morphology but were generally 
observed to be circular species which could be described as spherical rather 
than annular in appearance. While most of the observed species were 
droplet-like in the absence of Mg-ATP (Figure 4.9), in the presence of Mg-
ATP, the oligomers looked more consistently granular and similar in size 
(Figure 4.11). In the presence of co-chaperones or in the absence of 
nucleotide, the oligomers took on a “beads on a string” appearance, 
sometimes appearing like bracelets. The size of these beads varied more on 
the grids prepared with co-chaperones. Very large spherical structures, a little 
like imploded vesicles, can be seen (Figure 4.10) None of these structures 
could be seen on the control grids with only the chaperones (Figure 4.12) 
where only the odd amorphous aggregate is observed. 
 
Remarkably, all these structures resembled oligomeric structures co-purified 
along with G4R C3S cystatin B from E. coli over-expressing this protein 
(Davis, 2013). Control grids of the cystatin B preparation in the absence of 
chaperones show no oligomeric structures (data not shown): indeed, our lab 
has been trying to isolate such structures for many years with very little 
success! 
 
Prior work by Davis (2013) and work presented in 4.3.7 shows that such 
oligomers are resistant to being broken down by a number of solvents and 
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proteases. They are also resistant to lipase degradation indicating that they 
are not lipid and are, therefore, protein inclusions. Whilst Davis’s oligomers 
were purified from E. Coli, the oligomers presented here were produced using 
purified protein, meaning the only other protein these oligomeric species could 
contain is DnaK. However, whilst it cannot be ruled out that these are 
oligomers of DnaK, given the chaperoning nature of DnaK and the unknown 
chaperoning activity of cystatin B it would seem unlikely that cystatin B is 
creating aggregates of DnaK. However, the presence of DnaK in the 
aggregates is plausible. This could be probed directly using an antibody to the 
DnaK His-tag followed by gold labeling under the TEM. This could also add 
detail to inferences made about the difference in morphology observed when 
Mg-ATP is present in the sample. Indeed Mg-ATP lowers the affinity of the 
chaperone for its substrate (1.7).  The data presented here indicates that the 
presence of Mg-ATP yields a more regular and ordered oligomeric species 
(Figures 4.10- 4.13).  
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Figure 4.9: Electron micrographs of cystatin B (S3C) WT Oligomers formed 
with DnaK but without ATP or co-chaperones. The cystatin B and DnaK 
concentration was 10µm. CuCl2 was also present in the sample. Micrographs are at 
21000x magnification. 
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Figure 4.10: Electron micrographs of cystatin B (S3C) WT oligomers formed in 
the presence of ATP and co-chaperones. The cystatin B and DnaK concentration 
was 10µM. CuCl2 was also present in the sample Micrographs are at 21000x 
magnification.   
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Figure 4.11: Electron micrographs of cystatin B (S3C) WT oligomers formed in 
the presence of ATP. The cystatin B and DnaK concentration was 10µm. CuCl2 was 
also present in the sample. Micrographs were taken at 21000x magnification.   
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Figure 4.12: Electron micrographs of DnaK without Cystatin B. The DnaK 
concentration was 10µm. CuCl2 was also present in the sample. Micrographs were 
taken at 21000x magnification.   
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An analysis of the size distribution of these species is shown in figure 4.13. 
While the range of particle sizes varies hugely in the absence of nucleotide or 
in the presence of co-chaperones (where potentially the Mg-ATP is 
hydrolysed faster), the species observed in the presence of Mg-ATP is more 
regular and is 33.7 ± 5.1 nm. In the absence of the nucleotide, rather than 
discrete species, a continuum of sizes is observed where it is difficult to pick 
out particular species. For this reason, and because the species observed are 
not seen in isolation but instead are clumped together with each other, further 
analysis by image averaging was not attempted. 
 
 
 	  
Conditions Average Width 
(nm) 
Maximum Width 
(nm) 
Minimum Width 
(nm) 
DnaK 53.02 ± 21.5 171.3 25 
DnaK + ATP + 
co-chaperones 
44.6 ± 23.3 131.1 20.17 
DnaK + ATP 33.7 ± 5.1 48.4 21.7 
 
Figure 4.13: Size distribution analysis of Cystatin B oligomers prepared under 
the conditions in Figures 4.9-4.11. Oligomers were measured using Digital 
Micrograph 3 (Gatan). 100 oligomers were measured under each condition. The 
average width is shown with the standard deviation.  
 
DnaK DnaK+ATP
+co-chaps 
DnaK+ATP 
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Western blotting 
The initial work (Cipollini et al., 2007) on the oligomerisation of cystatin B in 
cell lines used western blots of SDS-PAGE gels as a method for measuring 
the formation of oligomers. Once they had verified that the oligomers were 
only produced as a result of the addition of specific cellular components and 
were not an artifact of their experiment, the authors could use the pattern of 
bands observed to compare different cellular conditions.  
 
In this work, western blotting was used to validate that oligomers produced 
were similar to those reported by the Melli group. Figure 4.14A shows western 
blots of gels run with various oligomer experiment samples using the C16 
antibody to the C-terminus (top) or the A12 antibody to the N-terminus 
(bottom) of cystatin B. All oligomer samples were produced without Mg-ATP. 
Figure 4.14B shows a positive control using the C16 and A12 antibody to 
soluble cystatin B. The SDS-PAGE gels used in these western blots were 
10% gels. This meant that the monomeric cystatin B band at around 11 KDa 
cannot be seen as the gel was run until the dye front had run off the gel in 
order to visualise the oligomer bands at the top of the gel. While the antibody 
to the C-terminus (C-16) was able to detect oligomers in the preparations 
done at higher concentrations (50µM and 20µM proteins), the antibody to the 
N-terminus proved very poor suggesting that the N-terminus may be hidden 
from the antibody even on the blot. It is clear that the oligomers maintain 
some structure or they would not be running as high molecular weight 
assemblies on this gel. The position of the DnaK chaperone is visible on the 
top gel as a white band with no background staining. No band(s) can be seen 
for 2 µM WT or G4R cystatin B oligomers in lanes 5 and 6 respectively; 
suggesting the concentration of oligomers in these protein preparations is too 
low for detection by this method.  
 
If it is true that the N-terminus is hidden from accessing the antibody in the 
larger aggregates, it suggests that this part of the protein is somehow buried. 
Furthermore, if the N-terminus behaves as in the cystatin amyloid structure 
and remains unstructured, it could be that these oligomers are forming 
micelle-like structures with the unfolded N-terminus on the inside and the 
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potentially more ordered C-terminus on the outside. Such N-terminal driven 
formation of “aggregate compartments” has recently been shown by 
Franzmann et al. (2018). Their research indicates that the intrinsically 
disordered N-terminal prion like domain of Sup-35 (a yeast translation 
terminating factor) provides the interactions needed for phase separation and 
the formation of stress-induced membrane-less compartments, which they 
term “bimolecular condensates”.  Such formation of “compartments” or 
“bodies” by phase separation is discussed further in the conclusion (4.3.9) to 
this chapter.  
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Figure 4.14A: Western Blots of cystatin B oligomer samples run on 10% SDS 
PAGE gels.  Western blots incubated with C16 (top) and A12 (bottom) antibody. Lanes: 
1=Cystatin B (S3C) WT, 2=Cystatin B (S3C) G4R, 3=DnaK, 4= 2µM WT oligomers 5= 
2µM G4R oligomers, 6=50 µM WT oligomers, 7=50 µM G4R oligomers, 8=20 µM WT 
oligomers, 9=20 µM G4R oligomers, 10=10 µM WT oligomers, 11=10 µM G4R oligomers, 
12=1:10 WT oligomers, 13: 1:100 WT oligomers, 14: 1:1000 WT oligomers. 
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Figure 4.14B:  Control western blots of cystatin B WT samples run on 
10% SDS PAGE gels.  Western blots were incubated with C16 (top) and 
A12 (bottom) antibody. 50 µM cystatin B was loaded into each lane. .  	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4.3.2 The importance of copper in the formation of cystatin B oligomers 
 
Ultracentrifugation and western blotting 
Oligomer samples containing either copper or EDTA were produced as in 
table 4.1. These samples were then purified by gradient ultracentrifugation to 
separate the cystatin B oligomer species from the rest of the soluble protein 
species, and indeed the DnaK. After centrifugation, the total gradient was 
carefully aliquoted, fraction 1 coming from the top of the centrifuge tube and 
fraction 17 or 18 coming from the bottom of the tube. Larger protein species 
with larger molecular weights (i.e. oligomers) should be in the fractions near 
the bottom of the centrifuge tube. These fractions were analysed by SDS-
PAGE using a gradient gel (RunBlue precast 4-20%) and then western blotted 
using the C-16 antibody to cystatin B. The results of this can be seen in 
Figures 4.15 and 4.16.  
  
Sample Conditions 
1 10µM Cystatin B, Cu2+, 10 µM DnaK, ATP 
2 10µM Cystatin B, Cu2+, 10 µM DnaK, 
3 10 µM Cystatin B + 10 µM DnaK + EDTA + ATP 
4 10 µM Cystatin B+10 µM DnaK + EDTA 
Table 4.1: Sample conditions for ultracentrifugation 
 
Sample 1 (Figure 4.15A), which contains copper and ATP, does not show 
much protein in fractions 1-9. These are fractions from the top of the 
centrifuge tube so should contain protein which has not been converted to a 
higher molecular weight species. There are some small bands in these 
fractions at around 11 KDa and 22 KDa showing monomer and dimer species 
of cystatin B. The lack of protein in these fractions could indicate that protein 
in this sample has been converted to oligomer. However, sample 1 does not 
appear to have any bands on the western blot for fractions near the bottom of 
the ultracentrifuge tube (10-17). This could be because the oligomers were 
too big to make their way into the gel and or are spread out of a wide range of 
molecular weights (see EM data presented in figure 4.13). It could also be 
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because the concentration of oligomers is too low, as 500 µl of each 10 µM 
sample is dissolved in a 12ml glycerol gradient for ultracentrifugation.  
 
Sample 2 (Figure 4.15B) which contained copper but no ATP has a few bands 
corresponding to monomer/dimer cystatin B from fractions at the top of the 
ultracentrifuge tube (1-5). There are no detectable bands on the western for 
fractions 6-8. However, there are large bands in the lanes corresponding to 
fractions 9-10 and 15-18. This could indicate that some oligomers of cystatin 
B had formed but were broken down in the denaturing conditions of the gel 
and loading buffer.  Some smudged, unresolved oligomers can be seen 
higher on the gel. This poor resolution is due to low concentrations and the 
range of molecular weights.  
 
Samples 3 and 4 (Figure 4.16) which contain EDTA and no copper have 
much larger bands in the fractions from the top of the ultracentrifuge tube. 
There are no bands seen in fractions taken from the bottom of the 
ultracentrifuge tube (fractions 14-17). This indicates that much of the cystatin 
B remained as monomer and dimer and did not form oligomeric species.  This 
confirms the importance of copper in the formation of cystatin B oligomers.  
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Figure 4.15: Western Blots of ultracentrifuge oligomer samples. (A) Sample 1 
fractions (B) Sample 2 fractions.   
A 
B 
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Figure 4.16: Western Blots of ultracentrifuge oligomer samples. (A) Sample 3 
fractions. (B) Sample 4 fractions  
 
A 
B 
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TEM of ultracentrifuged samples 
The purified oligomers were also analysed by TEM. However, images in 
Figure 4.17 do not show any visible oligomers. This could be because, under 
the conditions of this experiment, the oligomers are at such a low 
concentration after dilution in the 12 ml of gradient buffer needed for 
ultracentrifugation (see 4.2.6).  
 
 
Figure 4.17: Micrographs of ultracentrifuged samples 1-4. Samples for EM were 
taken from fraction 17 of the ultracentrifuged samples.  
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4.3.3 Separation of oligomers from DnaK 	  
From the EM and HPLC experiments, DnaK appears to form some sort of 
transitory complex with the oligomers formed. In order to view the oligomers 
by TEM without DnaK present and for further analysis of the oligomers by 
mass spectrometry, a vivaspin (Sartorius, UK) with a molecular weight cutoff 
of 1 million Daltons was used to filter the chaperones from the sample. The 
flow-through and retentate were kept and analysed by EM. The flow-through 
was analysed by TEM and this showed that no oligomers were present.  
However, the retentate after successive washes with buffer only yielded 
amorphous aggregates which can be seen in the TEM images in Figure 
4.18.There are two possible reasons for this. Firstly, it could imply that DnaK 
is somehow involved in the maintenance of the oligomer structures viewed. Its 
removal from the complex by purification results in a loss of oligomeric 
structure and the formation of large amorphous aggregates. Secondly, the 
vivaspins could be causing the formation of the amorphous aggregates due to 
the “sticky” membrane surface – something which has been reported in the 
Staniforth lab previously when working with oligomeric species. This particular 
separation technique was unsuccessful since the flow-through contained no 
protein according to the absorbance at 280nm.  
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Figure 4.18: Samples of oligomer from vivaspin filtering devices (Sartorius, UK). 
Washes 1, 2 and 3 are labeled. 
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4.3.4 Is oligomer formation by DnaK specific to Cystatin B? 	  
To test whether DnaK was able to chaperone oligomer formation from other 
proteins, another human protein, α-synuclein, was used. As mentioned in 
chapter 1 of this thesis, α-synuclein is also an amyloidogenic protein and is 
able to form oligomers in vivo (section 1.4.3). The same conditions were used 
as for the Cystatin B experiments. Figure 4.19 shows the analysis of different 
α-synuclein species during the time course of the experiment. Four peaks 
were identified on the HLPC traces as originating solely from α-synuclein (A-
D). To observe possible aggregation over time, changes in these peak heights 
were measured over 4 hours.  
 
 
 
Figure 4.19: SEC-HPLC of 50µM α-synuclein incubated with Mg-ATP and DnaK. The 
peaks corresponding solely to α-synuclein species are labelled in the elution profile as A-
D. Control elution profiles for α-synuclein (black) and DnaK (brown) alone are also shown. 
The change in peak height is plotted below for each of these peaks. The error on species 
“A” is highest as the signal is lowest. This error is about 10% for peak A as estimated from 
the signal to noise. The large peak at 25 minutes is from DnaK and the large peak at 38 
minutes is from Mg-ATP.  
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No changes in the population of soluble α-synuclein are detectable here and 
together with the TEM data in figure 4.20, where only the odd patch of stain 
could be seen, it seems that the observed cystatin B oligomeric species are 
indeed likely to be specific to this protein.  
 
Figure 4.20: TEM of 50µM α-synuclein incubated 1:1 with DnaK in the presence 
of Mg-ATP. Due to the presence of large patches of stain it was difficult to establish 
whether the above features represent true proteinaceous species rather than 
artefactual stain. The species most likely to be protein are shown here.  
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4.3.5 Cystatin B oligomers can be purified from E. coli 	  
When the WTS3C or G4RS3C cystatin B constructs were expressed in BL21 
DE3 E. coli cells grown in minimal media (section 2.5.2), purification of these 
proteins by size exclusion chromatography revealed a peak corresponding to 
oligomeric forms of the proteins. Figure 4.21 (A) shows a slight peak and 
shoulder (labeled oligomer) which includes fraction 18-23. This corresponds 
to high molecular weight species larger than the tetramer. This was of great 
interest since oligomers of WT cystatin B have never been purified straight 
from an E. coli growth by the Staniforth group.  
 
The same proteins purified from LB broth by size exclusion chromatography 
can be seen in figure 3.1. In the chromatograms in Figure 3.1 there is no 
evidence for oligomers in the WT cystatin B and only a small peak covering 
fractions 16-18 is observed for oligomer species in the G4R.  The tetramer 
peak is also small compared to the monomer and dimer peaks. Some 
oligomers of G4R cystatin B purified from E.coli grown in LB broth were 
observed by EM but no WT oligomers were observed (Figure 3.2).  The E.coli 
grown in minimal media produced more high molecular weight species of 
cystatin B (Figure 4.21). The tetramer and dimer species seem to be 
promoted in minimal media as their peaks are much larger for the WT and 
G4R than that in figure 3.1. There is also an oligomer peak in both the WT 
and G4R chromatograms. Further evidence of the presence of oligomers in 
the fractions was collected using EM (Figure 4.22 and 4.23) 
 
Figure 4.21 B shows a chromatogram for purified Cystatin B G4R grown in 
minimal media. Similar to figure 4.21A there is a peak (A) corresponding to 
oligomeric species of G4R. Whilst oligomers of cystatin B have been 
successfully purified from E. coli in past  work (Davis, 2013) and in chapter 3 
of this thesis , in those conditions the observed peak is very small. An 
estimate of the fraction of cystatin B which is oligomeric grown in minimal 
media condition is ≈ 5% for the WT and ≈ 15% for G4R in these S3C 
constructs, while the proportion purified by Peter Davis for G4R in the S3 
construct had been closer to 3%. 
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It is notable that these oligomers were made by the E. coli when grown in 
minimal media. Under these conditions the E.coli will be producing more heat 
shock proteins, including DnaK. It is possible, therefore, that the same 
process is going on in vivo that I had been trying to replicate in vitro.  
 
The oligomeric fractions from SEC were then analysed by TEM. As can be 
seen in figures 4.22 (G4R) and 4.23 (WT), these look very similar to the 
oligomers in figure 1.15 by Peter Davis using the C3S construct. Further to 
this, one can also see the similarity to the morphologies observed in Figure 
4.10 which are cystatin B oligomers prepared in vitro (in the presence of 
DnaK, ATP and co-chaperones) where there are no potential cell membrane 
or content contaminations. One could therefore determine that an therefore 
confirm that these could beare oligomers of Cystatin B. Previous work by the 
Staniforth group (Davis. 2016) on G4R oligomers (see chapter 1) showed that 
they were lipase resistant indicating that they are indeed protein oligomers 
and not anything cell membrane related. In addition, when E. coli express WT 
Cystatin B very few oligomeric species are observed eluting from the gel 
filtration column; whereas purification of G4R cystatin B does yield an 
observed peak corresponding to oligomeric species. This indicates that these 
oligomers are either of the protein itself or are something which is a result of 
the protein being expressed. Gold labeling by TEM could also validate this. 
Either cystatin B is chaperoning the formation of these inclusions or as 
previously stated above the more likely explanation is that a chaperone is 
causing the cystatin B to become inclusions.  
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Figure 4.21: Chromatograms for the last step in the purification of cystatin B 
from E. coli extracts. Top: Cystatin B WT, Bottom: Cystatin B G4R. 
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Figure 4.22: TEM of cystatin B S3C G4R oligomers purified from E. coli 
(Fraction 19). All images were taken using a magnification of 21,000.  
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Figure 4.23: TEM of WT S3C oligomers (Fractions 18-23) purified from E. coli. 
All images were taken using a magnification of 21,000. 
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4.3.6. Defining the size of the oligomers by HPLC 	  
The oligomers (fraction 19 from SEC in Figure 4.21) purified from E. coli were 
analysed further using analytical SEC-HPLC to estimate their molecular 
weight (Figure 4.24). Although the concentration (3.35 µm) and absorbance of 
this oligomer fraction is low the figure suggests that oligomers remain stable 
and elute at the void volume of the analytical superdex 200 HR10-30 column. 
The WT oligomers were too dilute to detect using this method. As can be 
seen from the data presented in Figure 4.24, the oligomers elute at the void 
volume of the column at around 15 minutes. It is, therefore, impossible to 
determine their exact size using this method.  
 
 
Figure 4.24: Characterisation of oligomers purified from E. coli by SEC-HPLC. 
The y-scale on the left is for the oligomers while the y-scale on the right is for the 
G4R monomer fraction. 
 
4.3.7. Stability of the oligomers  	  
The stability of the G4R oligomers was also explored using acetonitrile 
solvents. If a suitable diluent could be found, then we would be able to use 
this to characterise the components using mass spectrometry. As shown in 
figure 4.25, 40% acetonitrile was the optimal condition for this. Unfortunately, 
even under optimized conditions, the protein concentration is very low due to 
either incomplete dissolution or low initial protein mass. Thus, no mass 
spectrometry data were obtained from this sample. In future, the purification of 
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greater quantities of this species would allow not only verification of its identity 
by mass spectrometry but also potentially a limited proteolysis experiment in 
which we would have added proteases to the oligomers then compared their 
breakdown products at different times after the addition of protease. This 
would then allow direct structural comparison with cystatin B amyloid fibrils. 
 
The absence of a monomeric peak in the apparently dissolved sample in 40% 
acetonitrile suggests that dissolution may not have been successful and this 
would also explain the lack of mass spectrometry data. 
 
 
 
 
Figure 4.25: Stability of G4R oligomers purified from E. coli. Above is the SEC-
HPLC of the protein dissolved in PBS (black), 70%acetonitrile (0.1% TFA) – pink - 
and 40% acetonitrile (0.1 % TFA) - green. Below is the SEC-HPLC of the protein 
dissolved in 1% TFA. Monomeric cystatin B should elute at 30 minutes. 
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4.3.8. Structural analysis of Cystatin B oligomers 	  
Figure 4.26 shows the far-UV CD spectrum of the G4R oligomers (Fraction 19 
from the fractions collected by SEC shown in Figure 4.21) compared with the 
monomeric fractions (34-38). Not only does the resulting spectrum show the 
sample to be protein, but one can see that the oligomer peak has shifted to 
the left compared to the monomer peak. This shape change indicates a 
change in protein secondary structure from mostly β-sheet (as is the case in 
monomeric Cystatin B) to a less structured or more α-helical structure. 
Analysis of the peaks showed that the oligomers are only 5% β-sheet and are 
28% α-helical. While the presence of fraction 19 depends on the 
overexpression of G4R cystatin B and is most likely therefore this protein, 
given the work of Melli and co-workers, it is plausible that G4R cystatin B 
induces the formation of inclusions that are heterogeneous in protein content. 
This represents an alternative explanation to the CD data. 
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Figure 4.26: Far-UV CD of cystatin B oligomers purified from E. coli. 
 
Despite the failure to dissolve oligomers using acetonitrile, in order to further 
analyse the structure of the oligomers by mass spectrometry, a sample of the 
G4R oligomers was digested using Proteinase K at a ratio of 1:50 Cystatin B 
to DnaK. It was hoped that the addition of protease would render the resulting 
species less stable and allow their analysis. Aliquots were removed from the 
whole sample at 0mins, 30 mins, 1hr, 4hrs and 24hrs. These were 
immediately frozen to halt the reaction. The resulting digested samples were 
dissolved in 40% acetonitrile (1% β-mercaptoethanol) due to earlier data on 
the stability of the oligomers under different conditions (see 4.3.7). However, 
after the samples were run, first down a reverse column and then electrospray 
mass spectrometry-no masses were found. This could be due to a very low 
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concentration of protein or imperfect dissolution of the oligomers meaning the 
mass is still too big for mass spectrometry resolution.  
 
4.3.9 Conclusion 	  
It is important here to put the potential oligomers produced in the work 
described in this chapter into the context of the wider research literature in this 
area. Since these potential oligomers were either produced from purified 
protein or in E.coli, it is essential to address whether they are comparable to 
other such structures found in human cells, and, therefore, of physiological 
significance. In the introduction to this thesis (section 1.6), I looked at other 
examples of proteins which form “oligomers” or inclusions which are not 
always pathogenic e.g. Marinesco bodies. It is possible that the potential 
oligomers observed in this chapter are not true amyloidogenic “oligomers” but 
could be more homologous to the bodies, granules or compartments 
discussed below.  
 
Work by Alberti group (Alberti & Hyman, 2016) refers to membrane-less 
compartmentalization in the cytoplasm of cells by a process called phase 
separation. These compartments are thought to be liquid-liquid phase 
separate from the cytoplasm, leading to the formation of liquid droplets in the 
cytoplasm. There has been much work on the molecular mechanisms of 
phase separation. Intrinsically disordered proteins (IDPs) have been the most 
studied drivers of phase separation. One example is the RNA-containing 
compartments found in ALS patients. It is thought that two IDPs, TDP-43 and 
FUS, are responsible for their formation (Patel et al. 2015). In ALS, these 
proteins form pathological inclusions later in the disease.  
 
Such cellular compartments are associated with ageing and disease and 
therefore, this phase separation must be sensitive to changes in the cellular 
environment such as heat shock, changes in macro-molecular concentration 
of the phase-separating proteins and changes in the concentration of ions.  
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These liquid compartments can convert into more solid-like structures with 
different physical properties and morphologies. It is thought that there may be 
a “hydrogel” type intermediate state between liquid and solid compartments 
and that the solid compartments may contain highly ordered fibrils. The 
proteins FUS (Patel et al. 2015, Han et al. 2012, Kato et al. 2012) and 
hnRNPA1 (Molliex et al. 2015, Kim et al. 2013) have been shown to do this.  
 
There seems to be a driving force for proteins in liquid-like compartments to 
form solids with time (Alberti & Hyman, 2016). One reason why proteins may 
form solid structures is that these solid-like structures have important 
physiological functions. For example thr human mitochondrial antiviral 
signaling (MAVS) protein can change into a fibrous state on the surface of 
mitochondria. In its fibrous form MAVS interacts with tumor necrosis factor 
(TNF) receptor-associated factors (TRAFs) and propagates a signal that 
results in the induction of type I interferons and other antiviral molecules (Hou 
et al. 2011).  
 
Figure 4.27: A model of phase separation. A protein (red) undergoes a phase 
transition into a liquid droplet by liquid–liquid demixing. The droplet changes 
structure over time. The above images on the top show purified FUS protein 
forming liquid droplets, a gel, and fibrous aggregate (from Alberti & Hyman, 2016).  
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Figure 4.28:  A Model of MAVS Activation Involving a Prion-like Conformational 
Switch. Binding of RIG-I to viral RNA and ubiquitin allows the CARD domains of RIG-I to 
interact with the CARD domain of MAVS. This interaction induces a conformational change 
of the MAVS on the mitochondrial outer membrane into prion-like aggregates (from Hou et 
al. 2011). 
 
The liquid-like compartments could also allow for concentrated bio-chemical 
reactions, and then the solid-like compartments could be used to inactivate or 
store macromolecules. In the case of cystatin B, this phase separation could 
be occurring and perhaps these “oligomers” should be referred to as 
compartments or inclusions.  
 
In order to assess the most likely “granule” type we can assign to the cystatin 
B assemblies observed here, it is useful to consider the physical properties of 
the different granules reported in the literature. 
 
Size: the range of sizes of granules reported in the literature varies 
significantly and may be a distinguishing feature of the different assembly 
type. For example, membrane-less compartments reported by Alberti and 
others are 1-10 µm, RNA containing stress granules in both human and yeast 
cells have dimensions of 250nm while synthetic haemoglobin S droplets 
produced by concentrating the protein to >3 mM are 1-10 µM in size. The 
Marinesco bodies presented in the introduction are also of similar size (Yuen 
& Baxter, 1963) 
 
	   131	  
Density: the density of intracellular inclusions is one of the key characteristics 
reported on in the literature. Methods of choice include STORM where the 
rate of diffusion of fluorescently tagged protein is observed to change over 
time in liquid droplets as they undergo a phase separation often associated 
with pathology (Jain et al. 2016). Another method which does not require 
tagging includes light scattering (combination of static and dynamic).  
 
Shape: While liquid droplets are amorphous spheres, stress granules have a 
more granular, cluster-like morphology with a range of shapes (Buchan & 
Parker, 2009; Jain et al. 2016). Bunina bodies are roughly spherical, clear in 
the centre and contain filaments (Figure 1.19). They are often seen to form 
chain-like structures (Figure 1.19).   
 
Content: While some intracellular inclusions are relatively pure, as methods to 
characterise them become more sophisticated, it is apparent that a number of 
these are heterogeneous. Stress granules contain RNA and RNA binding 
proteins which include a wide range of species associated with translation and 
its control, as well as ribosomal units and factors involved in cell signaling 
(Buchan & Parker, 2009). 
 
While the size of the granules observed here is consistent with those 
observed in the literature, the presence of liquid compartments, hydrogel-like 
compartments and solid-like compartments could account for the variation in 
morphologies seen by EM (Figures 4.9-13).  It is interesting that copper is 
required for their formation since this has been highlighted as important in 
other amyloid studies and an increase in copper concentration is associated 
with ageing (Matheou et al. 2015). It could also be that these Cystatin B 
inclusions are copper storage compartments which act as a useful sink when 
copper is in excess but equally acts as a source for physiological functions 
when it is scarce.  
 
While the density of the granules is currently unknown, the remarkable 
change in morphology in the presence of Mg-ATP suggests that the absence 
of this co-factor leads to a change in the ordering of the protein within the 
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inclusions. This is particularly interesting in the light of the recent discovery of 
the role of Mg-ATP in stress granule formation in vivo (Jain et al. 2016). 
Levels of Mg-ATP are also known to decrease with age, suggesting that this 
may contribute to an increase in stress granule formation. It may be that we 
have discovered a route to the formation of such species in the brain, 
something which has not been reported on previously. Indeed, cystatin B is 
known to localise to the nucleus in human cell lines (Riccio et al. 2001) and 
plays a key role in neurogenesis (Polajnar et al. 2014). Cystatin B containing 
inclusions have been reported in one EPM1 patient, lack of further research 
makes it unclear whether this is a general feature of the disease (Cohen et al 
2011 and Polajnar et al. 2012).  
 
4.3.10 Future work 
 
Ongoing work in the Staniforth laboratory includes the use of asymmetric field 
flow fractionation (AF4), a new state-of-the-art fractionation technique allowing 
for the separation of a range of oligomer sizes and characterisation of 
different species quantitatively using online UV and MALS. This would 
contribute greatly to our understanding of the yield of cystatin B assemblies 
produced using DnaK. While current analysis is far from perfect, the phase 
separation that occurs in solutions of the enzyme lumasine synthase yields a 
% mass of 10-4 to 10-6 (Gliko et al, 2007).  This indicates that a low yield is 
potentially a result of an existing equilibrium between different phases, with 
the transition catalyzed, in this case, by DnaK. 
 
Given the importance of RNA in stress granules, the role of RNA in the 
production of cystatin B granules may be a missing piece in the puzzle. 
Adding RNA to our purified cystatin B and/or DnaK mixtures would be a 
logical next step in this study, which may impact on the observed equilibrium 
and allow more in depth characterization of the granules. 
 
It would be useful to test these cystatin B oligomers/compartments/inclusions 
for their pathogenicity. While small molecular weight species have been 
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tested by Zerovnik and co-workers, these larger inclusions may represent 
non-pathogenic assemblies. It would be particularly significant to understand 
the difference between Mg-ATP and Mg-ATP free assemblies in this context. 
This could be done firstly using a dye leakage assay as in section 5.3.4.  
 
Single molecule analysis, perhaps using Cryo-EM would be useful to gain 
further structural information. Cryo-EM could also report on density which 
could give insight into the molecular dynamics of the compartments or 
inclusions. 
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Chapter 5: A Novel therapeutic from Salvia sclareoides 
5.1 Introduction 	  
As discussed in section 1.8 of this thesis, the development of novel 
therapeutics to treat amyloid diseases is a research priority. Salvia (sage) 
plant species have been studied to this end due to their reported medicinal 
properties, having been regularly used in European and Chinese folk 
medicine. As natural products, compounds from Salvia plant species are 
excellent candidates in the search for a safe and effective treatment for 
amyloid-related diseases.  
Salvia sclareoides is an aromatic herb related to common sage that is native 
to Portugal. Preliminary studies on Salvia sclareoides n-butanol extract (SD) 
showed interactions with human prion protein (huPrP91-231) (Rauter et al. 
2012). In a 1H 15N HSQC-NMR experiment, amide resonances corresponding 
to residues 93-112, 130-187 and 205-225 were attenuated. These residues 
are in the unstructured N-terminal region, two strands of the β-sheet and the 
three α-helices indicating a potential for extensive binding across the prion 
protein. Attenuation of resonances is typically associated with ligand 
exchange dynamics, and is usually seen when ligands have dissociation 
constants in the µM range (Rauter et al. 2012).   
Preliminary work on Salvia extracts also included testing in an in vivo model 
(Fig 5.1.). Screening was carried out on SMB cells, mouse brain cells of non-
neuronal origin persistently infected with Scrapie (an infectious form of prion 
protein and commonly designated PrPsc) so they consistently produce PrPSc 
(Reddy et al, 2006 and Rudy et al, 2000). Cells were dosed for 5 days with 
different extracts and then analysed using a dot blot protocol optimised for 
blotting PrPSc.  Cell viability and total protein concentration were also 
established after cell lysis using MTT and Bradford assays respectively (data 
provided by Jenny Louth and Beining Chen, Chemistry Dept., University of 
Sheffield). Data was analysed using labworks software to determine the 
density of each dot. This is presented as ‘% control’. The signal from cells 
dosed with DMSO was used to represent the signal from untreated cells; 
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anything around 70% of the average blank value was classed as non-active. 
The MTT data is also presented in this format, with anything above 70% of the 
average blank	   classed as non-toxic. Good activity is represented by low 
results showing reduced levels of PrPSc.  
 
The Salvia water extract (SE) was the most effective at reducing the 
concentration of PrPSC. As this extract represents a practical form of the plant, 
which could be manufactured as a dietary supplement, and it contains water 
soluble components, it became the main therapeutic focus of this project. 
Another key point of investigation in this project was the use of Salvia as a 
general anti-amyloid agent. In the studies reported in this chapter, the use of 
Salvia extracts was therefore investigated for use against cystatin B, amyloid 
β and α-synuclein.  
 
Figure 5.1: SE extract attenuates PrPsc concentration in scrapie mouse SMB cells. 
Method: Cells (Birkett et al. 2001) were plated out in 96 well plates at 12,000 cells per well and 
left overnight to attach. The extracts were diluted to the correct concentration in DMSO, diluted 
1:10 in HBSS (Hank’s balanced salt solution, Gibco) and then diluted 1:20 into the culture 
medium. After 5 days the cells were lysed with lysis buffer and benzonase, and an MTT 
viability assay was used to determine toxicity. A Bradford assay was also carried out to 
determine total protein concentration. Dot blots were carried out the day after lysing to 
determine the presence of PrPsc. 8H4 (Liu et al, 2001) was used as the primary antibody and a 
HRP-tagged IgG was the secondary antibody. Images were detected via chemiluminescence. 
Each graph is a different batch of SE extract. Results: All batches except 21.5 showed activity 
in the µg/mL range. Extracts are not homogenous and as such it is difficult to get repeatable 
results from them. The 21.5 stock solution was a lighter colour than the other samples. The 
extracts were also very hard to solubilise so experiments were done with the soluble fraction. 
As samples were only partly dissolved in the cell medium, it was hard to determine exact 
concentrations. Figure provided by Jennifer Louth (dept. Chemistry, University of Sheffield). 
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5.2 Materials and Methods 
 
5.2.1 Salvia sclareoides Extracts: Extraction Procedures 	  
The Salvia sclareoides extracts used in this study were obtained from 
Professor Amelia Pilar Rauter and Professor Jorge Justino (University of 
Lisbon). Figure 5.2 illustrates the extraction processes and highlights that all 
the extracts have had the extraction solvent removed by evaporation. 10% 
DMSO buffered aqueous solvent was used to re-suspend the majority of the 
extracts and act as a general organic solvent to solvate organic active 
compounds, while infusion and water extract (SE) were suspended in 
aqueous buffer.  
 
Figure 5.2: Extraction procedure for Salvia Sclaeroides. The extraction 
procedure was devised by Catarina Dias (University of Lisbon). 
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5.2.2 ThT defibrilisation assays 	  
Cystatin B fibrils (produced as in section 2.4.1) were incubated with Salvia 
extracts at 25°C, in 15 mM sodium acetate 150 mM NaCl pH 4.7 with 
constant stirring of the samples. Defibrillisation was monitored continuously 
using thioflavin T (ThT) fluorescence. Specifically, 100 µl of DMSO was added 
to 900 µl of 30 µM cystatin B fibrils (10% DMSO) if using extracts suspended 
in DMSO (no DMSO was required for SE). Thioflavin T was added to this fibril 
solution to a final concentration of 10 µM. 1 ml of this solution was quickly 
transferred to a quartz cuvette with a path length of 1 cm and a small 
magnetic stirrer bar (5x2 mm) placed in the bottom of the cuvette. A Varian 
Cary Eclipse spectrofluorimeter was used to record the fluorescence spectra 
at different time points. An excitation wavelength (λex) of 442 nm was used 
and emission spectra were recorded from 400-600 nm. After the first few 
readings had been taken, 10 µl of 20 mg/ml Salvia extract was quickly added 
to the 1 ml sample in the cuvette (final concentration 200 µg/mL). Emission 
values at 482 nm were plotted against time to follow fibril kinetics. 
 
5.2.3 EM timecourse 
 
EM grids were prepared and visualized as in section 2.5. For the 
defibrillisation time courses, SE extract was added to fibrils at a concentration 
of 1mg/ml (to mirror the NMR experiments) and 2 µl aliquots were taken and 
placed on EM grids at specific time points.  
5.2.3 NMR 
 
For all NMR experiments, extracts were used at 1mg/ml. 
 
Preparation of Aβ1-42 ADDLs for NMR 
Aβ1-42 ADDLs were produced using an adaptation of methods from the 
literature (Klein 2002; Ryan et al. 2010). This method is designed to produce 
a homogeneous sample of small Aβ1-42 oligomers which are termed ADDLs. A 
0.1mg aliquot of freshly HFIP treated and lyophilised Aβ1-42 was first re-
suspended in 8µl of DMSO and sonicated for 10 minutes. The peptide was 
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then diluted in 333µl of cold 15 mM deuterated sodium phosphate, pH 7.5, 
0.15 M NaCl, 1 mM NaN3. The final volume was made up to 500 µl with cold 
D2O to give a final Aβ1-42 concentration of 72 µM in 10 mM phosphate buffer, 
pH 7.5, 0.1 M NaCl. The sample was incubated at 4ºC for 24 hrs. Before 
using, the sample was spun for 10 minutes at 4ºC and the supernatant 
withdrawn (no residue was observed in the bottom of eppendorf). EM was 
used to confirm the presence of ADDLs.  
 
Preparation of Aβ1-42 oligomers for NMR 
Aβ1-42 was also prepared for NMR using the method of Airoldi et al. (2013). 
Lyophilized Aβ1-42 was dissolved in 10 mM NaOD in D2O at a concentration of 
160 µM and then diluted 1:1 with 10 mM phosphate buffer (pH 7.4 and made 
in D2O) containing 100 mM NaCl (PBS) and SE extract of Salvia sclareoides 
or rosmarinic acid. The final concentrations or quantities of Aβ1-42, rosmarinic 
Acid and the SE extract of Salvia sclareoides in the samples were 80 µM, 1 
mM and 1 mg/ml respectively. The final concentration of the buffer 
components was therefore 5 mM phosphate buffer (pH 7.4) containing 50mM 
NaCl. The pH of each sample was adjusted to pH 7.5 with NaOD and/or DCl. 
 
STD NMR 
This type of NMR experiment is used to characterize ligand-receptor 
interactions. The experiment is based on the Nuclear Overhauser Effect 
(NOE) and the observation of the ligand resonance signals. It can be used as 
a screening technique in the identification of lead structures, but it is also a 
useful tool for identifying ligands within a mixture (such as the Salvia extracts) 
which bind to a receptor. An STD-NMR experiment relies on the fact that, for 
a weak binding ligand (KD ranging from 10-8 M to 10-3 M), there is exchange 
between the bound and the free ligand state. Briefly, an STD experiment 
involves subtracting a spectrum in which the protein was selectively saturated 
(on-resonance spectrum obtained by irradiating at a region of the spectrum 
that contains only resonances of the receptor (0 ppm to 1 ppm), from one 
recorded without protein saturation (off-resonance spectrum). The difference 
spectrum should contain only signals from the ligand(s) that receive saturation 
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transfer from the protein via spin diffusion through the Nuclear Overhauser 
Effect. Other compounds that may be present but do not bind to the receptor 
will not receive any saturation transfer. Their signals will be of equal intensity 
in the on-resonance and off-resonance spectra.  
 
Saturation transfer difference (STD) NMR experiments were completed using 
the same parameters as detailed in Airoldi et al. (2013). Briefly, the pulse 
program used was from the standard Bruker library (stddiffesgp.3). This uses 
a shaped pulse train for saturation which consists of 50ms gaussian pulses for 
2s. It also includes a spinlock to decrease signals arising from protein (Mayer 
& Meyer, 1999).  
 
NOESY NMR 
The Nuclear Overhauser Effect (NOE) in NOESY NMR is used to observe 
binding events. The NOE is a phenomenon that occurs when one proton 
resonance in an NMR spectrum is saturated or inverted and proton 
resonances which are spatially close experience a change in intensity 
(Neuhaus and Williamson, 2000). NOEs are partly determined by molecular 
correlation times which are inversely related to molecular tumbling rates. 
Molecules with a large molecular weight have a larger correlation time (and 
slower rate of tumbling). NOEs are positive for smaller molecules (< 600 Da) 
and are negative for larger molecules (> 1200 Da) (Decatur, 2007). One can 
therefore look at binding as free small molecule ligands should have positive 
NOE cross peaks, whereas bound ligands should have negative cross peaks.  
 
DOSY NMR 
Diffusion Ordered Spectroscopy (DOSY) NMR experiments can be used to 
identify molecules in a mixture based on their diffusion coefficients (D), and, 
therefore, their size and shape. Modulation of NMR signals during a pulse 
field gradient experiment (radio frequency pulses combined with magnetic 
field gradients) is used to measure diffusion. The degree of modulation is a 
function of the magnetic gradient pulse amplitude and is proportional to the 
diffusion coefficient (D) of the molecule (Johnson Jr. 1999). The 2D spectra 
plots chemical shift against logD. The logD values of a ligand or ligands can 
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be measured in the presence or absence of the protein. Each measured logD 
value is an average of the ligands' bound and free states. Ligands with NMR 
signals which show an increase in logD and, therefore, molecular weight, 
signify a bound population.  
5.3.4 Dye Leakage assays 
 
Preparation of carboxyfluorescein containing vesicles (LUVs) 
Using a glass pipette, 1 ml of 80% DOPC 20% DOPG lipid solution (in 
chloroform) was dispensed into a round bottomed flask and a stream of 
nitrogen gas was used to evaporate the chloroform and leave a film of lipid. 1 
ml of 50 mM carboxyfluorescein solution (50mM HEPES pH 7.4 with NaCl 
added to 440 µS) was then added and the round bottomed flask was vortexed 
until the lipid film was fully re-suspended. The resulting vesicle solution was 
passed through an Avanti mini-extruder with a 400 nm PC membrane and a 
200 nm PC membrane in order to ensure large unilamellar vesicles of uniform 
size (Avanti Polar Lipids, Alabama, USA). The LUVs were then filtered 
through a PD10 desalting column (GE healthcare, UK) to remove any excess 
carboxyfluorescein solution.  
 
Dye leakage assay 
The resulting vesicle solution was serially diluted to 10 µg/ml into 50 mM 
HEPES pH 7.4 (NaCl was added to 440 µS) and incubated at room 
temperature for 48 hours in quartz cuvettes in the presence of 2 µM Aβ1-42, 2 
µM Aβ1-42 and 10 µg/mL Salvia extract together, 10 µg/mL Salvia extract 
alone and in the absence of anything else. Fluorescence measurements (λex 
= 485nm and λem = 517nm) were taken every 5 minutes using a Varian Cary 
Eclipse spectrofluorimeter (Agilent, UK).  
 
5.2.5 Mass spectrometry of Fibrils and Salvia extract 	  
Figure 5.3. outlines the sample preparation method. Briefly, a sample of 25 µl 
80 µM Aβ1-42 fibrils was incubated for 1 minute with 25 µl SE extract at 20 
mg/ml and then centrifuged for 10 minutes at 14, 00124700 xg 0 rpm to 
produce a pellet. The supernatant was removed and sent for mass 
	   141	  
spectrometry analysis. The pellet was washed with water and the supernatant 
removed. This process was repeated 4 times with the wash/supernatant being 
sent for mass spec analysis. The pellet was finally solubilised in HFIP, 
lyophilised and then re-suspended in 40% acetonitrile, 0.1% TFA. This 
sample was also sent for mass spec analysis. Control samples containing 
10mg/ml SE extract in the absence of Aβ1-42 and a number of compounds 
identified by the Rauter group as being present in the extract (Catarina Dias, 
personal communication) were also sent for analysis. These included luteolin, 
luteolin-7-o-glucoside, glycoside A, glycoside B and glycoside S. 
 
Samples were applied directly into an electrospray time-of-flight mass 
spectrometer (agilent Q-TOF). Masslynx 3.5 software (Waters Corp.) was 
used to determine the masses present. 
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Figure 5.3: Outline of method for preparing samples of Aβ1-42 incubated with 
SE extract for analysis by mass spectrometry.  
Supernatant sample 
Wash 1 sample 
Wash 2 sample 
Wash 3 sample 
Wash 4 sample 
Pellet sample 
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5.2.6 Cell toxicity assays 	  
The CytoTox-ONE assay kit (Promega) was used for all cell assays. This is a 
fluorescent assay which measures the release of lactate dehydrogenase 
(LDH) from cells with a damaged membrane. LDH released into the culture 
medium is measured in the kit by supplying lactate, NAD+, and resazurin as 
substrates in the presence of diaphorase, resulting in the conversion of 
resazurin into resorufin. The generation of the fluorescent resorufin product is 
proportional to the amount of LDH released and therefore dead cells. 
 
LDH assay with SH-SY5Y cells 
Human neuroblastoma cells (SH-SY5Y) in media containing F-12 Ham’s 
nutrient mixture supplemented with 10% fetal bovine serum (FBS), 1% L-
glutamine (L-Q), 1% penicillin/streptomycin antibiotics (P/S) and 1% 
nonessential amino acids (n-aa) (Invitrogen) were grown in a 5% 
CO2 atmosphere at 37°C in a 175 cm2 flask. Confluent cells were removed 
from the flask by trypsinisation. The cells were counted and plated on a 96-
well polystyrene plate with approximately 10  000 cells per well. The plate was 
incubated overnight at 37°C to allow cells to adhere to the plastic. 
 
Cell media was removed from the wells and replaced with 100 µl of fresh 
media containing either test compounds or DMSO. The plate was then 
incubated at 37°C for 24 hrs.  
 
After incubation, the plate was equilibrated to room temperature for 30 
minutes. Some wells containing just cells in media were used as dead cell 
(positive) controls. 2 µl of lysis solution was added to these cells.  
 
100 μL of CytoTox-ONE solution was added to the wells followed by 10 min 
incubation at room temperature. 50 μL of stop solution was then added to 
each well. The fluorescence was measured at an excitation frequency of 545 
± 20 nm and an emission frequency of 620 ± 7.5 nm. It is also important to 
measure the fluorescence of the cell medium incubated with CytoTox-ONE 
solution.  There were 3 repeats for each condition.  
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Results are calculated using this equation:  %  𝒄𝒚𝒕𝒐𝒙𝒊𝒄𝒕𝒚 =    (𝒆𝒙𝒑𝒆𝒓𝒊𝒎𝒆𝒏𝒕𝒂𝒍 − 𝒄𝒆𝒍𝒍  𝒎𝒆𝒅𝒊𝒂  𝒃𝒂𝒄𝒌𝒈𝒓𝒐𝒖𝒏𝒅)(𝒅𝒆𝒂𝒅  𝒄𝒆𝒍𝒍  𝒄𝒐𝒏𝒕𝒓𝒐𝒍 − 𝒄𝒆𝒍𝒍  𝒎𝒆𝒅𝒊𝒂  𝒃𝒂𝒄𝒌𝒈𝒓𝒐𝒖𝒏𝒅) 
 
LDH assay with mouse primary neurons 
When using primary neurons, a 12 well plate with 100,000 cells per well was 
used. Cells were cultured in phenol red free neurobasal media (with B27 
supplement) (Invitrogen).  
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5.3 Results 
5.3.1 Salvia extracts do not work by simple monomer binding 
 
Cystatin B has been used in our lab as a model for the study of amyloid 
formation; indeed a study of cystatin B oligomeric inclusions is included in 
chapter 4 of this thesis. Here we used soluble cystatin B to determine the 
general propensity of salvia extracts to bind to protein. As discussed in 
chapter 3, soluble cystatin B naturally populates at least 3 different forms 
under most experimental concentrations: tetramer, dimer and monomer where 
only the latter is relevant physiologically but where dimer dominates under 
most laboratory experimental conditions (approx. 70% of samples used here, 
as established by SEC). 
 
1H 15N HSQC NMR of soluble cystatin incubated with SE Extracts 
The binding of Salvia extracts to soluble cystatin B was tested using 1H 15N 
HSQC NMR by Peter Davis. As shown in Figure 5.4, the following dimer 
peaks are greatly reduced on addition of the SE extract: V47, V49, G50, T51, 
E62, V69, and F98. Peaks S7, Q10 N52 D63 S72, E76, T81 and S83 are also 
somewhat reduced upon addition of the extract. The attenuated residues are 
also shown on the structure of both the monomer and dimer of cystatin B. The 
attenuated residues are mainly found at the dimer interface.  The 
disappearance or decrease in intensity of peaks can be interpreted in a 
number of ways. It suggests that addition of the extract has led to the 
formation of a new “bound” species or catalyzed the formation of a different 
species which is either in slow exchange with the previously observed species 
or is exchanging with a larger protein species which cannot be detected using 
solution NMR due to a slow tumbling speed. In the first instance, one would 
expect the concomitant appearance of new resonances with different 
chemical shifts whereas in the latter case, this would not occur.  
 
Our data therefore support a model where Salvia extracts destabilise cystatin 
B dimers to form a species undetectable by NMR, most likely an aggregated 
species. The specificity of this effect for the non-physiological dimer is 
	   146	  
intriguing.  It suggests that the species that the extracts bind to is in 
equilibrium with dimeric but not monomeric cystatin B. 
Figure 5.4: Top 1H 15N HSQC NMR spectra of cystatin B and SE extract. The spectrum 
of 30 µM cystatin B is shown in Black, that of 30 µM cystatin B with 1 mg/mL SE extract is 
overlaid in red. Peaks corresponding to attenuated dimer peaks are labelled. Bottom: 
cystatin B monomer and dimer with greatly attenuated residues shown in red and peaks 
which show some attenuation shown in dark blue.  
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The impact of SE extract on soluble Aβ1-42 assemblies 
We then proceeded to analyse the effect of the extracts on 80µM solubilised 
Aβ1-42 peptide, freshly prepared in PBS. According to previous work by Airoldi 
et al (2013) on the SD extract, a preparation of this sort rapidly assembles into 
a solution rich in soluble oligomers (sections 5.2.3 and 5.3.4.), however in our 
hands this solution retained a similar 1D 1H-NMR spectrum over 24 hours 
(Figure 5.5). The intensities of the NMR peaks decrease by only 20%, 
suggesting up to 80% of the sample remains monomeric or of a small 
molecular weight. Our experiment was to resuspend our Aβ1-42 prepared as in 
section 5.2.3 in either PBS alone, PBS containing SE extract or PBS 
containing the anti-amyloid compound rosmarinic acid. In the presence of SE, 
the Aβ1-42 peptide forms no fibrils (Figure 5.6), and a significant proportion 
remains soluble as evidenced by NMR. The reduction in monomer Aβ1-42 
signal over 24 hours is less when either SE extract or rosmarinic acid (a 
typical anti-amyloid agent) are present but is still significant. The ratio of 
intensity of the monomer Aβ1-42 peak is 0.79 when there is no extract present, 
0.88 when 80µM rosmarinic acid is present and 0.86 when the soluble Aβ1-42 
ADDLs are incubated with SE extract. The difference between these three 
conditions does not appear significant. 
 
The resulting solution was examined by electron microscopy (Figure 5.6). No 
evidence of fibrillary species was seen although small worm-like oligomers 
are present on some grids. Most of the visible species are very small, with 
diameters less than 10nm, suggesting a species with a small number of Aβ1-42 
molecules, in the range of 10 molecules. In comparison, the control sample 
contains small fibrils and some amorphous aggregate.  
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Figure 5. 5: The relative efficiency of the SE extract on the population of soluble Aβ1-42 as 
detected by 1D 1H NMR spectroscopy. 80 µM freshly solubilised Aβ1-42 samples incubated in 5mM 
phosphate pH 7.5, 50mM NaCl and 25ºC, on their own (top), with rosmarinic acid (middle) and with 
SE extract (bottom): initial spectra are shown in red (top and bottom) or purple (middle); at 24 hours 
the spectra are shown as blue (top and bottom) or green (middle). 
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Figure 5.6A: Initially monomeric Aβ1-42 incubated with SE extract during 24 
hour NMR experiment. 80µM Aβ1-42 was prepared freshly and incubated with SE 
extract in 10mM PO4, 100mM NaCl pH 7.4 for 24 hours at 25ºC, then the resultant 
solution visualized using TEM.. Size bars are shown 
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Figure 5.6B: A control reaction (Aβ1-42 incubated in 10mM PO4, 100mM NaCl pH 
7.4 for 24 hours at 25ºC). Size bars are shown. Images of the SE extract on its own 
are shown in Figure 5.13. 
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In conclusion, both the 1H 15N HSQC NMR of soluble cystatin B and the EM of 
soluble Aβ1-42 incubated with SE extract show that protein is not kept soluble 
by the extract. Cystatin B, which exists mainly as a dimer when in solution, 
appears to form larger protein species when incubated with SE and the 
initially soluble Aβ1-42 can be seen to form small oligomeric species. These 
results are of interest because it was originally hypothesised that the extract 
could be working by stabilising monomeric species. This is obviously not the 
case and more importantly, the role of aggregated species in the prevention of 
toxicity as well as in its causation needs to be understood further. 
Characterisation and quantification of these species would be a desirable next 
step with the impending arrival of fractionation (asymmetric field flow 
fractionation – AF4) and light scattering equipment to Sheffield. 
 
5.3.2. Toxicity of aggregate species in the presence of SE extract 
 
Dye Leakage 
 
Figure 5.7 shows the protective effect of SE extract on a lipid bilayer in the 
presence of Aβ1-42. Dye leakage from large unilamellar vesicles (LUVS) was 
similar when SE and Aβ were both present and for the SE and LUV controls. 
The rate of dye leakage is far higher when the LUVs are incubated with Aβ1-42 
alone. This indicates that membrane damage by Aβ is reduced in the 
presence of SE extract. This experiment was only completed once and further 
repeats are required to confirm this conclusion.  
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Figure 5.7: Dye leakage from LUVs in the presence of Aβ1-42 and SE 
extract. Fluorescence due to dye leakage from LUVs is shown in the 
presence of Aβ1-42 alone (red), SE extract alone (purple) and in the presence 
of both Aβ1-42 and SE extract (green). A control showing dye release from 
LUVs alone is shown in blue.  
 
 
Aβ1-42 Cell toxicity assays 
 
The SE extract was tested for its ability to inhibit the toxicity of Aβ1-42 to mouse 
primary neurons. This data is shown in Figure 5.8. Whilst the data indicates 
that cells incubated with SE extract showed increased cell death, there was in 
fact only one well (out of 3 repeats under those conditions) which showed a 
real increase in cell death. It could have been that the cells in this well were 
more “sickly” than the rest of the plate.  
 
There was also no significant difference in cell death between the DMSO 
control cells, cells incubated with Aβ and the cells co-incubated with Aβ and 
SE. This could be because the assay itself needs optimization and more 
repeats need to be done. Aβ does not always induce cell death consistently 
and batch testing of Aβ may need to take place. The cells may also need to 
be incubated with the Aβ for longer (48hrs).  
 
SE extract (as well as SD and Infusion) were also tested for their toxicity to 
SHS-5Y cells at different concentrations. As shown in Figure 5.9, SE was not 
toxic to the cells at any of the concentrations used.  
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Figure 5.8: % cytotoxicity of mouse primary neurons incubated for 24hrs 
under 4 different conditions.  
 
 
 
 
 
 
 
 
Figure 5.9: % cytotoxicity of SHS-5Y cells incubated for 24hrs with 
Salvia extracts. SD(red), SE(blue) and Infusions (green). Each experiment 
was replicated 5 times and variability between replicates is shown as error 
bars.  
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5.3.3. SE extract remodels amyloid fibrils into amorphous aggregate  
 
In order to look at the kinetics of defibrillisation by the Salvia SE extract, a 
continuous Thioflavin T (ThT) fluorescence assay was employed. This 
technique is used conventionally in this field to quantify the levels of amyloid 
fibril-like species. Cystatin B amyloid fibrils are most stable at pH 4.7 and so 
the experiments presented in figures 5.10-5.11 were done at this pH. If the 
Salvia extracts are able to destabilise the fibrils at this pH, this would support 
their application as a therapeutic.  
As shown in Figure 5.10, Thioflavin T loss (ThT) is rapid and occurs within 20 
seconds of the addition of 0.2mg/ml SE extract. Thioflavin T in the control 
sample remains constant. This rate of fluorescence loss is extremely fast, 
although not uncommon in the literature (Bieschke et al., 2010). Time courses 
were therefore done with diluted Salvia extracts to see if the time over which 
the fluorescence drop was observed could be increased in order to produce 
more highly resolved data.  
Even with a 10 fold dilution, SE extract still appears to break down the fibrils 
extremely quickly (figure 5.11A).  A time course with a 50 fold dilution of SE 
extract was also completed to see if this would produce better data (figure 
5.11B). It appears that the extract at this low concentration has no effect on 
the fibrils. This could be because the ratio of extract to fibril is very important 
and no effect is seen as soon as there are not enough molecules of active 
compound to interact with the fibril.  
Although it is tempting to interpret this data as directly reporting on the 
fibrillary state of cystatin B, a more likely interpretation is that at higher 
concentrations of extract, an active compound or compounds in the extract is 
displacing the ThT dye from the fibril. This is a well reported issue with ThT 
assays (see section 1.3.1) but does have the advantage that it does instead 
report on the affinity of the extract for amyloid fibrils, in that it competes well 
for the thioflavin T binding site at very low concentrations. The extracts are not 
directly quenching the fluorescence at these wavelengths: the extracts do not 
absorb light at the wavelengths used for excitation and emission of thioflavin T 
(420-500nm). 
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Figure 5.10: The effect of SE extract on the Thioflavin T fluorescence of 
cystatin B fibrils at pH 4.7. The extract leads to a considerable drop in fluorescence 
when added at 0.2mg/ml. Top is a time course monitored over a longer time (100 
minutes) to observe any long term effects. A control of cystatin B fibrils without 
addition of SE extract is shown in green. The bottom time course shows the rapid 
decrease in ThT fluorescence within the first few seconds when SE extract was 
added at 20 seconds to cystatin B fibrils (arrow).   
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Figure 5.11: Dilutions of SE extract show varying levels of activity. SE extracts 
remains active at 10x dilution (top) Further dilution of SE to 50x renders it ineffective 
on 30µM cystatin B fibrils. 
 
 
 
 
	   157	  
EM Time Courses of Amyloid fibrils incubated with SE extract 
Due to the potentially misleading and inconclusive data from the ThT time 
courses, it was decided that an electron microscopy time course would be a 
good alternative. A new sample of cystatin B fibrils was treated in the same 
way as for the ThT timecourse where 1mg/ml SE extract was added to a 
30µM fibril sample. 2µl aliquots of this reaction were taken at time points and 
put on a grid. Each time point is defined as the time at which the EM grid was 
placed in the stain after the extract was added.  
 
Cystatin B Fibril Time Course 
As one can see in figure 5.12, the time course does show that cystatin B fibrils 
incubated with SE Salvia extract are remodeled over time to form amorphous 
aggregates. Distinctive amyloid fibrils are still seen after 40s and indeed fibrils 
can still be seen after 1hr although many are noticeably shorter. After 2 hours, 
however, there are only small fibrils and the grid is covered in amorphous 
aggregate. After 4 hours there is almost no fibril to be seen, and almost all 
protein which can be seen on the grid is amorphous. It is noticeable that small 
droplet-like species are seen to crowd around the fibrils after 10 minutes. The 
identity of these species, whether extract or protein, is unclear. 
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Figure 5.12. EM Timecourse of WT cystatin B fibrils incubated with SE extract.  
 
 
Figure 5.13. The discrepancy between the observed drop in ThT fluorescence 
and the change in morphology of the cystatin B fibrils. 
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Figure 5.13 shows the EM time course images superimposed on a ThT 
defibrillisation experiment. This clearly shows that the ThT data does not 
match up with the EM time-course data. Whilst SE extract does remodel the 
fibrils, this happens over hours-not over 20 seconds. The ThT data suggests 
that binding to the amyloid is likely to be rapid (~20s) while re-modelling is 
slow.  
 
 
Α-synuclein Fibril Time Course 
To ascertain whether this effect on amyloid fibrils was limited to cystatin B 
fibrils, fibrils made from α-synuclein were incubated with SE extract. Figure 
5.14 shows that the SE extract also remodeled the α-synuclein fibrils into 
amorphous aggregate. Again, droplet-like species are seen surrounding the 
amyloid. In this time course, the dissolution occurs more rapidly, with clearly 
modified morphologies apparent after 10 minutes. The active compound(s) 
within the extract are clearly not protein specific and instead must bind to 
general structural features of amyloid fibrils.  
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Figure 5.14. EM Time Course of α-synuclein fibrils incubated with SE extract.  
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Aβ1-40 Fibril Time Course 
 
Finally, SE extract was tested against Aβ1-40 fibrils, prepared as detailed in 
section 2.4.2. Again, dissolution is evident and apparent very rapidly, within 
the first minute of incubation.  
 
Figure 5.15. EM Time course of Aβ1-40 fibrils incubated with SE extract  
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EM of SE extract without fibrils 
 
To investigate the nature of the droplet-like species, control grids were 
prepared with only SE extract in the absence of any protein. Figure 5.13. 
suggests these droplets are indeed a component of the extract although they 
are present only in small patches of the grids. The localization of these 
species to the amyloids on the protein containing grids suggests an affinity for 
these species. Their organization into droplets lends further support to 
existing literature on the mechanism of compounds such as EGCG – the 
current hypothesis is that this compound forms colloidal arrays surrounding 
the amyloid aggregate (Palhano et al. 2013).  
 	  	  	  
Figure 5.13. EM micrographs of 1mg/ml SE extract incubated in the absence 
of protein. 
	  	  
 
 
 
 
	   165	  
5.3.4 Exploring the mechanism of the Salvia extracts anti-amyloid 
activity 
 
 
Does SE extract stabilize Aβ ADDLs and oligomers?  
 
 
STD NMR 
STD NMR was originally proposed by Airoldi et al (2013) as a valid method for 
the identification of compounds that can bind Aβ1-42 oligomeric species. In 
their study, they identified rosmarinic acid as an active component of the SD 
or butanol extract from Salvia sclareoides. The 1D 1H NMR spectrum of the 
SE extract was compared with rosmarinic acid and shown to lack this 
compound in any significant quantity. Its active ingredient is therefore likely to 
be something else given its similar anti-amyloid activity. 
 
Due to the lack of homogeneity in “oligomeric” Aβ samples it was thought that 
ADDLs would be a better species of Aβ1-42 to use to assess binding. One of 
the difficulties of using Aβ1-42 for these sorts of studies is that Aβ1-42 is able to 
form a vast number of different species when incubated at room temperature 
in PBS. Therefore, a model for Aβ1-42 is an important requirement.  
 
Two different protocols were used to prepare ADDLs. The first was a standard 
protocol adopted by our lab and produced oligomers of similar size as probed 
by EM (Figure 5.14A). We also attempted to reproduce previous work by 
Airoldi et al (2013) on Salvia sclareoides extracts: the preparation of Aβ1-42 
species produced using their protocol (section 5.2.3) is shown in Figure 
5.14B. In their protocol whilst ADDLs are present, other oligomeric species of 
Aβ1-42 are present as well.  
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Figure 5.14. ADDLs prepared using two different protocols. In (A), methods 
adapted for NMR spectroscopy by Klein et al. (2002) and Ryan et al. (2010). In (B), 
the method adopted by the Rauter group (Airoldi et al., 2013). 
 
The principal difference between these two protocols is that, while the former 
technique involved the addition of relatively mature, stable ADDLs incubated 
for 24 hours and shown previously to remain stable at room temperature for at 
least 5 days, the latter preparation involves co-incubation of all soluble 
species, when freshly prepared from the monomeric Aβ1-42 peptide. As shown 
in section 5.3.1, under the latter conditions, the SE extract stabilizes 
oligomeric species: here we aimed to identify the compounds responsible. 
  
The 1D 1H NMR spectra of ADDLs in the presence and absence of SE extract 
are dominated by the presence of soluble Aβ1-42 species. It was envisaged 
that these species would not disturb the interaction of oligomeric “ADDL” Aβ1-
42 species with the small molecular weight compounds present in the SE 
extract. However, upon selective saturation of upfield frequencies (on-
resonance and off-resonance), a difference spectrum showed very little 
signal, suggesting few if any compound(s) within SE were binding Aβ ADDLs, 
or rather that the STD experiment performed here was not sensitive enough 
(Figure 5.15).  
 
 
 
A	  	   B	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Trouble-shooting 
A problem further compounding this experiment was the presence of relatively 
large molecular weight species in the SE extract. This would add to the lack of 
specificity in the experiment as compounds binding to these species would 
also be identified. A control STD experiment was performed to rule out the 
possibility of saturation transfer within the extract constituents (Figure 5.16). 
The STD revealed no signals outside the noise. 
 
The SE extract was ultracentrifuged to remove insoluble plant matter and the 
resulting NMR spectrum revealed a considerable loss in signals (Figure 5.17). 
This clarified SE extract was just as effective as judged by EM defibrillisation 
assays but had fewer components to complicate STD. 
 
 
	   168	  
 
Figure 5.15. STD experiment of Aβ1-42 ADDLs incubated with SE extract. The off-
resonance 1D 1H NMR spectrum of the ADDL&SE sample (blue) and the on-
resonance spectrum of ADDLs and SE extract (red) show very few differences. The 
difference spectrum or STD spectrum is shown in green. 
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Figure 5.16. Control STD experiment of SE extract. In blue, off-resonance 
spectrum, in red the on-resonance spectrum and in green the STD spectrum. 
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Figure 5.17. 1D 1H NMR spectra of SE extracts before (red) and after (blue) 
clarification. 
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The experiment was repeated under the conditions of Airoldi et al. (2013) who 
had successfully identified rosmarinic acid as an active compound in a 
different extract. We therefore repeated our experiment in their conditions, 
adding either SE extract (Figure 5.18) or rosmarinic acid as a control (Figure 
5.19). 
 
Although some evidence of saturation transfer is present in the rosmarinic 
acid control, the lack of strong signals in the STD experiments with SE extract 
suggested that the concentration of bound species was insufficient to create a 
large enough signal or the rate of transfer between the free and bound 
species was too slow. It could also be that the species that the active 
compound binds to is present at too low a concentration. Furthermore, it is 
possible that there is a complete lack of interaction between compounds in 
the extract and oligomeric Aβ1-42. Analysis by electron microscopy of the 
species observed before and after incubation with SE extracts or rosmarinic 
acid is shown in figure 5.20 and shows remarkably little morphological 
change. This could be explained by the ADDLs not being the correct species 
model for observing any interaction between SE extract and amyloid.  
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Figure 5.18. STD experiment of “soluble” Aβ1-42 incubated with clarified SE 
extract according to Airoldi et al (2013). Off-resonance spectrum (blue), on-
resonance spectrum (red). In green, the STD spectrum shows essentially no signal. 
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Figure 5.19. STD experiment of “soluble” Aβ1-42 incubated with rosmarinic acid 
according to Airoldi et al (2013). 1D 1H NMR spectra of rosmarinic acid (top blue) 
and Aβ1-42 with rosmarinic acid (purple) are shown for comparison to the STD 
difference spectra in green. The STD off resonance spectra for Aβ1-42 is shown in red 
and the on resonance spectra is shown in blue at the bottom of the figure.  
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Figure 5.20. Aβ  ADDLs before NMR and after 24 hour NMR experiment. Top 
micrographs show freshly prepared Aβ ADDLs before addition of extract. Middle 
micrographs show ADDLs after 24 hour incubation with SE extract. Bottom 
micrographs show ADDLs after 24 hours incubation with rosmarinic acid.   
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STD is not a valid method for observing interaction of extracts with Aβ1-42 
oligomers 
A number of control experiments were performed which helped explain the 
observations of Airoldi et al. but also discounted their protocol as a valid route 
to identification of the active compound in our conditions. Given the mixture of 
large and low molecular weight species in the Aβ1-42 sample, saturation 
transfer is occurring both between the extracts and the oligomers and 
between the soluble Aβ1-42 species and the oligomers, meaning that the 
frequencies observed in the STD spectrum not only overlapped with Aβ1-42 
signals but were Aβ1-42 signals. This was verified in a control not containing 
the SE extract (Figure 5.21). While one possible solution to this problem could 
be to subtract the control spectrum from that with the SE extract, thereby 
removing the spectrum of any soluble Aβ1-42 species able to interact with the 
oligomers. However, as shown in figure 5.22 this is not possible since the 
spectra observed for Aβ incubated with SE extract is remarkably different 
from that of Aβ alone. This suggests that the nature of the species present in 
the control experiment was, perhaps unsurprisingly, different to that observed 
in the presence of the SE extract. 
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Figure 5.21: Control STD experiment of Aβ1-42 alone. The off resonance 
spectrum is shown in blue, on resonance in red and the difference spectrum is 
shown in green.  
 
.  
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Figure 5.22: From the top: 1D 1H NMR spectrum of Aβ1-42 incubated with SE 
extract (red), 1D 1H NMR spectrum of SE extract (blue), 1D 1H NMR 
spectrum of Aβ1-42  (purple), STD difference spectrum of Aβ1-42 incubated with 
SE extract (green) STD difference spectrum of SE extract (red) and STD 
difference spectrum of Aβ1-42.  
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A NOESY experiment comparing SE extract alone with Aβ mixed with SE 
extracts was carried out to see if NOEs could be detected between species in 
the Aβ sample and the SE extract (Figure 5.23). Very small peaks may be 
detectable but it was unclear whether these were outside the noise of the 
experiment. A more concentrated sample of SE extract and a sample of Aβ 
with more “binding partner” would be needed to examine this further using this 
technique. 
 
DOSY measures the diffusion coefficient of different species in solution and 
when bound, a shift is expected to a lower value (towards the top of the 
spectrum in Figure 5.24). Although some shifts are seen, it is difficult to 
dissect those which are solely due to binding between Aβ and compounds in 
the SE extract as interactions with any other Aβ species would result in the 
same shifts. This is because the chemical shifts of Aβ overlap with those of 
the compounds in the SE extract. 
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Figure 5.23: NOESY spectrum of SE extract incubated with Aβ ADDLs. Left hand 
spectrum shows SE extract incubated with Aβ. Small ligands display a different sign when 
in solution (positive) to when they are bound to a receptor protein (negative). There are 
small changes in the spectrum when Aβ is not present (right hand spectrum). 
Figure 5.24: DOSY spectrum of SE extract incubated with Aβ ADDLs. Black is SE extract 
and Aβ. Red is SE extract alone.  1D 1H NMR spectrum of the sample is shown in green. The 
experiment was inconclusive due to an overlap between the spectra.  
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5.4.5 What is the active compound(s) in SE extract responsible for anti-
amyloid activity? 
  
Due to the difficulties encountered with NMR such as the lack of a 
homogeneous Aβ1-42 sample and the possibility of protein being present in the 
extracts, a protocol was devised whereby bound ligands to Aβ1-42 fibrils could 
be analysed by mass spectrometry. 80µM Aβ1-42 fibrils were incubated with 
high concentrations (10mg/ml) SE extract for 10 minutes before five repeated 
rounds of centrifugation were used to separate the compounds bound to the 
fibrils from those remaining in solution. Four washes, a supernatant and a 
final solubilised pellet sample were collected and analysed directly by mass 
spectrometry. A full method can be found in section 5.2.5. A control sample of 
SE extract spun down on its own in the absence of Aβ1-42 was also analysed. 
 
Table 5.1 shows the molecular weights identified in different samples 
analysed by mass spectrometry. Masses present in both the control pellet and 
the Aβ containing samples were discounted. Only the solubilised pellet 
samples contained masses which were also present in the control. The 
experiment seemed to distinguish very well between weakly bound species 
and higher affinity binders because the compound masses present in washes 
1 & 2 were generally distinct from those found in washes 3 & 4. The full mass 
spectra and tables of masses for all samples can be found in the appendix. 
The analysis therefore focused on compound masses in washes 3 & 4 and 
the solubilised pellet since these represented the ligands with the highest 
affinity for the Aβ fibrils. The human metabolome database was searched for 
matches (http://www.hmdb.ca/, last accessed August 2016). The reasoning 
for this is the ease of use of this library and its previous application to 
searches for plant phenolics in strawberries, grains and olive oil (Rohloff, 
2015).  
 
Likely candidates for some of the identified masses are listed in Table 5.1. It is 
notable that rosmarinic acid is absent from this list. For a number of masses, 
there may be more than one possibility even within this library. However, 
given the similarity of the compounds, it is just as likely that both compounds 
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exist in the mixture. The phenolic nature of the proposed compounds and in a 
number of cases, their known plant origin, validated the analysis further. 
 
Potential constituents include molecules that resemble known anti-
amyloidogenic compounds but also include a number of new substances. For 
example, oleacein, which is also found in olive oil is found in this analysis and 
has been reported previously to have anti-amyloid properties (Rigacci et al, 
2010). Oxidised camphor was also found here but, to our knowledge has not 
been directly reported as having anti-amyloid activity although it is used in a 
number of existing medicinal products such as “vaporubs”. At least 2 of the 
compounds are easy to source from chemical suppliers such as Sigma-
Aldrich and so a next step in this analysis would be to validate their individual 
activities. These include β-Sitosterol β-D-glucoside (similar in structure and 
functional groups to β-Sitosterol 3-O-β -D-galactopyranoside) and Camphoric 
acid.  
 
In addition to the Q-tof mass spectrometry presented here, gas phase mass 
spectrometry would allow for further analysis of these samples as it would 
enable more accurate identification of the components by analysing their 
fragmentation products: different compounds yield different and predictable 
patterns of breakdown products.  
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Name of 
Compound 
Chemical 
Formula 
Structure Average 
MW 
Description 
β-Sitosterol 3-O-β 
-D-
galactopyranoside 
 
C35H60O6 
 
 
576.8473 
 
Found in 
many herbs 
and spices. 
Has been 
identified as 
an anti-
oxidant and 
anti-
inflammatory 
(Naressi et 
al. 2015, 
Cakir et al. 
2003).  
Schottenol 3-
glucoside 
 
C35H60O6 
 
 
576.8473 
 
Has been 
identified as 
an anti-
cancer agent 
from 
Baccharis 
coridifolia 
and 
Ipomopsis 
aggregate 
(plants native 
to South 
America) 
(Arisawa et 
al. 1985).   
  	  
Table 5.1 Possible constituents of Aβ  pellet wash as determined by analysis of 
masses using the Human Metabolome Database 
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Name of 
Compound 
Chemical 
Formula 
Structure Average 
MW 
Description 
(S)-Oleuropeic 
acid 
C10H16O3 
 
184.232
2 
Component of fats 
and oils, including 
olive oil. Has been 
previously studied 
due to its antioxidant 
activity (Perez-
Bonilla et al. 2014) 
(1’R)-Nepetalic 
acid 
C10H16O3 
 
184.232
2 
Found in many 
herbs and spices, 
including Nepeta 
cataria (Catnip), an 
ancient chinese 
remedy. Extracts 
from this plant have 
been used in cancer 
studies (Emami et 
al. 2016) and 
antimicrobial/antioxi
dant studies 
(Adiguzal et al. 
2009) 
(±)-Camphoric 
acid 
C10H16O4 
 
200.231
6 
Oxidised form of 
camphor. Camphor 
has been studied as 
a dietary agent in 
the prevention and 
therapy of cancer 
(Aggarwal & 
Shishodia, 2006). It 
is already in 
medicinal use as a 
constituent of Vicks 
VapoRub.  
Hesperaline C14H22NO4 
 
268.328
8 
Known constituent 
of plants in the of 
Brassica family 
which includes 
broccoli, cabbage 
and kale.  
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Niazirin C14H17NO5 
 
279.288
5 
Is found in 
Brassicas.  Is also a 
known constituent of 
the leaves of the 
horseradish 
 tree (Moringa 
oleifera) which has 
been studied as a 
cancer therapeutic 
(Dayal et al. 2013).  
Helipyrone C17H20O6 
 
320.337
1 
Helipyrone is found 
in many herbs and 
spices but is a well 
known constituent of 
Helichrysum italicum 
(curry plant). It has 
been studied for its 
antioxidant activity 
(Rosa et al. 2007), 
as an anti-
inflammatory and a 
HIV therapeutic 
(Appendino et al. 
2007).  
Oleacein C17H20O6 
 
320.337
1 
Oleacein is a known 
constituent of olive 
oil. It has been 
studied as an anti-
amyloid 
thereapeutic (see 
chapter 1).  
(R)-
Pronuciferine 
C19H21NO3 
 
311.374
9 
(R)-Pronuciferine is 
a plant alkaloid 
which has been 
studied for its 
anticholinesterase 
inhibitory activity 
(Dong et al. 2015) 
and as a cancer 
therapeutic (Wang 
et al. 2004).  
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Table 5.2 Possible constituents of Wash 4 as determined by analysis of 
masses using the Human Metabolome Database 
 
 
 
 
 
Piperettine C19H21NO3 
 
311.374
9 
Piperettine is a 
natural plant 
alkaloid. It has been 
studied as a cancer 
therapeutic (Reshmi 
et al. 2010).   
N-[2-Methoxy-
2-(4-
methoxyphenyl
)ethyl] 
cinnamide 
C19H21NO3 
 
311.374
9 
A known constituent 
of Aegle marmelos, 
a plant used for its 
medicinal properties 
in parts of Asia. 
Extracts from this 
plant have been 
used in anti-
diabetes, anti-
malaria, anti-fungal, 
anti-venom and anti-
bacterial studies 
(Chakthong et al. 
2012).   
8-
Methyldihydroc
helerythrine 
C22H21NO4 
 
363.406
4 
Found in plants and 
fruits. Has been 
studied for its affect 
on breast cancer 
cell lines (Chen et 
al. 1994).  
Di-4 
coumaroylputre
scine 
C22H24N2O4 
 
380.437 Is a known 
constituent of many 
herbs and plants 
incuding 
(sunflower), Pyrus 
communis (pear), 
Rubus idaeus 
(raspberry) and 
Vicia faba. It has 
been studied as an 
acetylcholinesterase 
inhibitor  (Matochko 
et al. 2010).  
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Name of 
Compound 
Chemical 
Formula 
Structure Average 
MW 
Description 
Graveolone C14H12O4 
 
244.2427 Found in 
many herbs 
and spices 
and has 
been 
previously 
extracted 
from Parsley 
(Beier et al. 
1994) 
Suberone C14H12O4 
 
244.2427 Found in 
herbs and 
spices. It 
belongs to 
the 
Coumarin 
family which 
have been 
well studied 
for their 
therapeutic 
use in 
cancer, 
oedema, 
and as an 
anti-
inflammator
y (Jain & 
Joshi, 
2012). 
Coumarin 
analogs 
have also 
been found 
to inhibit Aβ 
aggregation 
(Soto-
Ortega et al. 
2011 
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(R)-Apiumetin C14H12O4 
 
244.2427 Also a 
member of 
the 
coumarin 
family.  
3,3',4'5-
Tetrahydroxys
tilbene 
(Piceatannol) 
C14H12O4 
 
 Is a 
metabolite 
of 
resverterol 
and has 
also been 
studied for 
its anti-
amyloidoge
nic activity. 
This 
polyphenol 
has been 
shown to 
inhibit the 
aggregation 
and prevent 
the 
cytotoxicty 
of Aβ and α-
synuclein 
(Riviere et 
al. 2007, 
Temsamani, 
2016) 
4'-
Methoxychalc
one 
C16H14O2 
 
238.2812 Has been 
shown to 
have anti-
angiogenic 
and anti-
tumour 
properties 
(Lee et al. 
2006).  
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Benzyl 
cinnamate 
C16H14O2 
 
238.2812 Benzyl 
cinnamate 
has been 
isolated 
from various 
plant 
species. It 
has been 
shown to be 
an inhibitor 
of 
angiotensio
n II induced 
hypertensio
n (Ohno et 
al. 2008).  
 
 
Table 5.3 Possible constituents of Wash 3 as determined by analysis of 
masses using the Human Metabolome Database 
 
5.4.6 Conclusion 	  
Salvia sclareoides plant extracts contain a number of active compounds which 
act on a variety of protein amyloids, from prions to Aβ, α-synuclein and 
cystatin B. The work presented here highlights its use as a general anti-
amyloid and furthermore proposes that it exerts its activity using more than 
one mechanism. While components of Salvia sclareoides do indeed bind 
soluble protein, the selectivity of this activity is intriguing and warrants further 
research. The data presented here suggest that this activity does not, as 
previously thought, stabilise soluble forms directly, but instead can lead to 
segregation of amyloidogenic forms into higher aggregates. At the same time, 
while no one ingredient was identified as binding specifically to soluble 
oligomers, another strong activity of these plant extracts was to dissolve 
existing amyloids of many types, resulting not in soluble monomers but 
instead in amorphous aggregates. Mass spectrometry analysis was most 
powerful at providing a clue to possible active amyloid-binding components, a 
number of which had no previous association with anti-amyloidogenic 
activities. This project is now well underway to isolating new active 
compounds from these plants as a route to increasing our understanding of 
how to regulate toxic amyloidogenic processes. 
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5.4.7 Future Work 
 
Although not strictly saturation transfer ‘difference’ NMR, the Clore group has 
used saturation transfer NMR to look at the mechanism of Aβ protofibrils 
formation from Aβ monomers. They used saturation transfer from the large 
NMR invisible aggregates to the binding monomer state and then instead of 
looking at relative saturation transfer, measuring 15N spin–spin R2 relaxation 
of the monomer residues. They call this dark-state exchange saturation 
transfer (DEST) and used this to identify regions of the Aβ monomers that 
remained in close contact with the protofibril and, therefore, develop their 
three-state model of Aβ aggregation (Fawzi et al. 2011).  A variation on this 
technique could perhaps be used in the future to look at binding of Salvia 
compounds to Aβ oligomers and more importantly, fibrils. 
 
As mentioned in 5.4.5 at least two of the compounds listed in tables 5.1-3 are 
available to purchase from Sigma Aldrich. These pure compounds could be 
tested for their anti-amyloid activity using both the in vitro and cell-based 
techniques discussed in this chapter.  
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Chapter 6: Conclusion 
 
6.1 Cystatin B mutation and characterisation 
 
Cystatin B WT and G4R constructs were successfully mutated to reinstate 
cysteine at position 3 and were purified using the same protocol as the 
original C3S variant used by the Staniforth lab. The N-terminus of the 
molecule is important to amyloid assembly since the presence of the cysteine 
leads to an increased tendency for the cystatin B protein to form amyloids. 
The presence of cysteine also adjusts the ratio of cystatin B species purified 
from E.coli as the monomeric form seems to be marginally favoured over the 
dimer. Mass spectrometry confirmed this and also showed no evidence for 
disulphide formation in protein preparations. 
 
6.2. Chaperone catalysed cystatin B inclusion formation 
 
Chapter 4 presents a study of the oligomeric species of cystatin B. Uniquely, 
this work has revealed information about the structure of this oligomers. 
Further to showing that Hsp70/DnaK does indeed promote the formation of 
these oligomers, this research has shown the Mg-ATP dependence of the 
oligomeric structures by electron microscopy. When Mg-ATP is present, the 
oligomers are more homogeneous and ordered. When DnaK, ATP and co-
chaperones are present (DnaJ and GrpE) larger, more amorphous oligomers 
are formed. Under these conditions, due to the presence of co-chaperones, 
Mg-ATP would be converted to Mg-ADP more rapidly such that the state of 
the chaperones on the grids is actually Mg-ADP bound rather than Mg-ATP. 
The oligomers formed in the presence of DnaK alone can also adopt a range 
of structures and there are also large, amorphous species present. This could 
indicate that DnaK is included in the structure of oligomers formed without 
Mg-ATP and that DnaK recycling is important in the formation of these 
structures. One could use a technique such as gold labeling of the DnaK and 
analysis by electron microscopy to ascertain whether DnaK remains within the 
oligomers after their formation.  
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SEC-HPLC data also revealed that a range of oligomeric structures are 
formed. Figure 4.7 shows that a decrease in monomer is linked to an 
apparent increase in the DnaK elution peak. This indicates that oligomers are 
forming but they elute as a range of sizes underneath the DnaK peak. This 
DnaK peak also gains a shoulder (Fig 4.6) indicating the presence of 
significantly different molecular weight species, larger than a simple DnaK and 
cystatin B monomer complex.  
 
Another important factor in the formation of these oligomers is the presence of 
copper. Previous work by our group has shown that metal ions such as 
copper are able to destabilize the N-terminal of cystatin B (Paramore et al, 
2012). The N-terminal is important in the formation of these oligomers, since 
WT oligomers were only produced once cystatin B had been mutated to have 
a cysteine residue at position 3 (previously mutated to a serine for 
crystallographic purposes). It is also of note that the N-terminal antibody was 
not as successful as the C-terminal antibody at highlighting the oligomers by 
western blotting. This again indicates that the N-terminal is modified during 
oligomer formation, either by becoming hidden or being involved in some 
structural transition such as copper binding. It would be interesting to explore 
this interaction between copper and the N-terminus of WT S3C Cystatin B 
further.  
 
It is also important to consider a physiological function for these structures, 
since oligomers similar to those formed in the DnaK, Mg-ATP and co-
chaperone conditions could be purified straight from E. coli. It is interesting 
that the presence of copper is important in their formation. It may be that 
these structures are not oligomers as studied in other amyloid diseases. They 
could instead be seen as cellular inclusions or compartments more similar to 
the Bunina or Marinesco bodies discussed in section 1.6 of this thesis. One 
physiological function for these structures could be as copper storage 
compartments. The Alberti group (Alberti & Hyman, 2016) has linked such 
compartmentalisation of proteins to an increase in cellular metal ion 
concentration. Such metal ion storage compartments have also been found in 
bacteria. Recently, it has been shown that bacteria do have organelles which 
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are surrounded by a protein shell rather than a membrane. One such 
organelle, Encapsulin, is an iron storage compartment (McHugh et al. 2014).  
 
It also interesting that the formation of these structures by Hsp70 is specific to 
cystatin B, since Hsp70 was not successful at producing oligomers or 
inclusions of α-synuclein. This could also indicate another physiological role 
for such structures as a way of compartmentalising excess cystatin B. 
Cystatin B, due to its many functions, needs to be well regulated and its 
compartmentalisation by Hsp70 could be an important part of this regulation. 
The proposal here would be that Hsp70 functions by reversibly binding to and 
stabilising structure in the external shell of these inclusions which, according 
to the above, is likely to expose a more structured C-terminal end. The core of 
these inclusions may be disordered as evidenced by the loss of secondary 
structure observed by CD. 
 
In future studies, it would be useful to explore the toxicity of these different 
cystatin B structures (+/- Mg-ATP) as a lack of toxicity to cells or to our vesicle 
model could indicate that they do indeed have a physiological function and 
they are not the toxic oligomers seen in amyloid disease.  
 
6.3. Oligomeric species as a drug target – the mechanism of action of 
natural compounds from Salvia sclareoides.  
 
Chapter 5 studied the role of compounds from Salvia sclareoides as novel 
amyloid therapeutics and revealed some key findings about the therapeutic 
target for such compounds. Previously, it had been hypothesised that such 
compounds may work by stabilising oligomeric forms of amyloid proteins such 
as Aβ. However, the data presented here shows that this is not the case. 
Electron microscopy showed no morphological changes to Aβ ADDLs after 
24hr incubation with SE extract from Salvia. There was also no evidence of 
binding of compounds from this extract with ADDLs or Aβ oligomers by NMR.  
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However, electron microscopy data did show that SE extract is able to 
remodel amyloid fibrils into non-toxic amorphous aggregates. The fibrils, 
themselves, may therefore be a good therapeutic target for these natural 
therapeutic compounds from Salvia. Whilst the fibrils themselves are often 
seen as a non-toxic species, they are in equilibrium with toxic oligomer 
species and smaller species and therefore their removal may reduce the 
overall toxic protein load.  
 
It has also been shown that SE extract is able to reduce Aβ disruption of 
membranes using a lipid vesicle model and that the extract itself is not toxic to 
cells at therapeutic concentrations (Fig 5.7 and 5.9).  
 
Further to this, a number of compounds within the SE extract have been 
identified which may be the active component responsible for its activity. The 
next stage in this work would be to purchase some of these intriguing 
compounds (e.g. hesperaline) and repeat the above experiments.  
 
To answer the original question posed at the start of this thesis, “Are the 
oligomeric species a good therapeutic target?” evidence points to other 
species such as the fibrils also being a good target, especially when looking at 
natural therapeutics such as the polyphenols discussed in Chapter 1 and the 
compounds in Salvia discussed in Chapter 5. Chapter 4 also highlights that 
oligomeric species may inhabit a range of different structures and that such 
polymerisation of protein may also have a physiological non-toxic function.  
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Appendix- Mass spectrometry of Aβ1-42 fibrils incubated with 
SE extract 
 
The full mass spectra and a table of masses are presented for each sample 
prepared for analysis (see 5.2.5). The mass spectra are cut off at 600 Da as 
above this mass compounds would not be classed as small molecules. While 
all the masses are presented in the tables, none of the higher masses above 
600 Da were identified in the human metabolome database (see section 
5.4.5). The origin of these higher masses is likely to be peptide breakdown 
products from the Salvia (SE) extract. Masses present in both the sample and 
the control are highlighted in yellow as these were discounted from further 
analysis.  
 
1. Mass spectrometry of the solubilised pellet 
 
m/z Abund 
99.9878 3660.03 
102.0136 10564.4 
106.005 19079.74 
115.0371 12000.72 
125.9875 2960.39 
130.0086 18142.93 
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130.1597 7082.4 
143.04 14470.75 
145.0313 2929.15 
146.0206 6345.67 
149.9962 3838.28 
150.1132 167089.2 
151.1161 11252.92 
157.0838 3175.69 
158.0025 12543.4 
158.9649 175315.25 
159.9686 4027.67 
172.095 19196.36 
173.0827 5358.57 
174.0155 3522.67 
179.9909 4312.84 
185.1158 215751.4 
186.1191 18312.61 
193.9746 41249.71 
194.1204 6209.74 
196.9556 3023.75 
197.9953 5579.2 
205.0692 11146.52 
217.1058 3338.19 
225.9912 11770.76 
229.1392 4929.8 
235.0013 74236.14 
236.004 5326.26 
239.0202 4499.48 
239.1622 4132.79 
244.9955 4396.94 
261.1314 4177 
267.0173 8795.85 
274.9342 3233.44 
284.3326 10442.17 
293.9789 11109.33 
294.9402 35677.91 
299.9598 3640.65 
301.1429 9481.46 
329.9496 23188.12 
332.3325 3557.15 
332.9373 7154.99 
335.0057 59245.92 
336.0079 5427.02 
360.3638 6657.83 
360.9326 4331.6 
367.9467 7348.25 
372.3487 7846.27 
376.2605 9875.7 
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393.2869 8941.23 
398.2437 201141.3 
399.2466 47452.65 
400.2489 6632.6 
400.3797 6190.31 
402.3601 6158.32 
410.9141 3336.05 
414.2215 4636.53 
421.3185 6972.38 
424.8981 17971.49 
425.2211 4692.04 
428.9199 9401.08 
430.3901 12310.21 
430.9154 83280.76 
431.3944 3910.54 
431.9188 5674.25 
449.3488 3250.79 
467.9512 5576.95 
500.937 3277.23 
505.4124 8857.46 
534.2197 6075.38 
534.2875 3018.84 
560.8736 16896.51 
566.8898 23539.08 
581.3667 3181.8 
592.888 4945.45 
598.8724 3251.98 
599.4284 3426.26 
625.393 3039.93 
660.8776 14178.99 
696.8491 12817.06 
700.8676 3654.8 
702.8658 17770.97 
773.4962 8316.61 
774.4985 4206.6 
796.8536 11513.67 
832.8243 9048.66 
838.8406 13302.18 
968.7994 11306.88 
974.8155 8802.72 
1104.7734 6826.96 
1110.7901 5906.6 
1234.7318 4966.64 
1240.7476 5352.29 
1246.7644 3710.72 
1376.7229 4440.67 
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2. Mass spectrometry of wash 4 
 
 
m/z Abund 
113.108 1596.97 
115.0366 1881.78 
118.0869 1110.91 
118.1226 1480.39 
128.1437 1059.05 
129.0524 2839.54 
130.1597 37807.75 
131.1629 3396.51 
132.1024 3433.86 
135.0033 6870.41 
139.0505 14024.71 
140.0561 1119.63 
150.013 882.32 
150.1117 110807.16 
150.9768 1245.16 
151.1145 7098.22 
155.1284 2281.35 
156.0759 1038.06 
157.0838 6766.28 
158.9645 7286.89 
161.0316 2466.55 
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171.0624 1147.35 
171.0996 2374.08 
172.0951 98661.48 
173.0968 7092.95 
175.1184 1202.66 
180.0869 1363.83 
185.1153 520423.46 
185.2272 30548.08 
186.119 44428.16 
187.1194 4634.72 
188.069 4234.39 
198.0879 1509.63 
201.0895 41350.63 
202.079 5442.02 
203.0809 3657.08 
205.0716 918.29 
207.0991 1023.19 
217.1058 3143.72 
223.0944 2334.86 
224.0516 2282.17 
225.1088 2106.57 
227.1231 1037.69 
229.1409 3173.26 
249.1079 1147.31 
251.126 8282.49 
252.1319 961.49 
261.1304 2804.96 
265.1169 1113.44 
267.1171 2626.26 
272.1296 1244.64 
275.1456 1080.88 
277.1119 904.51 
289.1535 1284.61 
291.1446 919.73 
295.1452 959.23 
297.1442 900.55 
305.1498 2803.77 
307.1524 2917.02 
309.1624 2398 
321.1336 1798.93 
323.1463 2635.6 
325.1567 1694.54 
329.1859 3030.43 
333.1739 1388.06 
335.1779 1499.65 
339.1349 1176.99 
349.1768 2049.19 
351.1754 1732.93 
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363.177 939.25 
365.1139 4822.34 
367.1743 1152.28 
373.1945 1049.2 
376.2601 3412.51 
377.2603 998.11 
379.185 877.69 
381.1807 908.06 
389.1925 1199.71 
391.2055 1515.42 
393.209 2051.37 
393.2861 13867.58 
394.2888 3457.63 
395.1956 885.41 
398.2423 59739.37 
399.2448 14174.96 
400.2474 2085.98 
405.1871 1326.2 
407.2005 2040.25 
409.2049 1723.09 
414.216 9500.55 
415.2182 2493.23 
416.2178 1068.79 
421.1844 938.6 
423.1936 1535.6 
425.2039 1157.17 
437.2231 1121.14 
505.4119 5057.56 
506.4147 1717.36 
773.4931 1856.38 
774.4972 899.81 
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3. Mass spectrometry of wash 3 
 
 
m/z Abund 
80.9482 3543.35 
82.9454 1059.27 
90.9769 1971.97 
96.9217 500.39 
113.1077 717.2 
115.0367 7079.43 
118.123 1053.04 
128.1433 342.85 
129.0519 1535.8 
135.0026 896.37 
138.9064 729.74 
139.0496 1644.33 
140.9035 489.31 
142.948 6772.34 
148.9352 434.53 
157.0831 2583.57 
158.9215 460.36 
158.9643 4488.7 
161.0314 891.29 
164.9293 4674.04 
171.0621 1299.45 
171.0975 1720.11 
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172.0949 1593.97 
173.0779 1705.11 
174.1595 1089.67 
180.9029 719.87 
185.1152 150590.36 
186.1187 12766.53 
187.1182 1030.27 
196.8663 523.94 
198.8614 403.94 
201.0887 9518.04 
202.0883 786.81 
202.1802 791.23 
203.0512 529.8 
203.0857 789.8 
206.8936 872.66 
208.8896 545.81 
216.9225 1884.85 
217.1046 1183.94 
218.9194 656.67 
222.8871 1409.68 
224.8837 548.58 
226.9516 1814.4 
227.1209 341.5 
229.1402 1135.02 
230.0245 558.54 
232.9086 598.29 
234.0547 370.51 
239.1675 335.48 
245.0813 471.69 
249.1452 949.46 
254.8238 399.55 
256.8202 436.32 
258.8626 386.16 
261.0886 531.44 
261.1279 770.42 
262.9063 555.8 
265.1265 336.65 
274.881 524.17 
276.8765 339.24 
278.9207 405.54 
280.8457 744.43 
282.8426 543.18 
284.9045 859.64 
294.9393 744.52 
300.8999 560.56 
305.1571 393.14 
332.838 334.95 
336.8757 344 
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338.8038 367.25 
340.7995 393.73 
342.8539 503.31 
349.1831 379.66 
352.8959 452.76 
358.8581 481.97 
365.1066 1134.75 
366.1941 412 
376.2591 1592.89 
393.285 5399.8 
394.2879 1491.7 
398.2417 29413.07 
399.2448 7091.04 
400.2472 978.29 
411.0936 473.17 
414.215 5472.63 
415.2182 1338.84 
416.2161 585.16 
420.8797 377.8 
429.2034 503.04 
435.3076 1541.84 
480.2808 552.8 
485.1113 372.43 
502.2639 1167.34 
503.2653 401.65 
518.2406 617.8 
543.2411 444.2 
561.2525 411.09 
959.9655 2234.12 
960.9704 370.99 
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4. Mass spectrometry of wash 2 
 
 
 
m/z Abund 
80.949 539.38 
86.0969 336.76 
90.977 2641.17 
113.1075 1336.03 
115.0366 7304.01 
118.0859 1146.73 
118.1219 1025.31 
128.1439 475.3 
129.0516 1379.31 
132.0996 1049.3 
135.0029 4257.73 
139.0495 3552.11 
140.0651 1171.74 
142.9472 980.01 
143.0323 421.76 
150.0115 427.64 
155.0526 701.7 
156.0417 1086.21 
156.0728 581.99 
157.0834 4218.95 
157.1698 456.37 
158.9644 3477.85 
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161.0312 1538.77 
164.9279 781.65 
167.0072 422.6 
171.0625 862.71 
171.0983 3052.19 
172.0947 3285.34 
173.0794 1844.68 
175.1186 538.01 
185.1153 173369.54 
186.1183 14537.93 
187.1184 1500.98 
198.0892 319.32 
201.0892 5956.66 
202.0853 552.32 
202.1804 1000.77 
202.225 433.46 
202.9915 367.33 
203.053 7077.96 
203.1419 366.62 
204.0555 412.54 
205.063 342.72 
213.1473 443.8 
216.9224 1357.99 
217.1052 462.99 
218.9199 417.15 
220.167 382.98 
225.0349 624.95 
226.9514 3082.57 
227.1224 597.97 
229.1388 1033.47 
230.0248 428.13 
239.1029 655.11 
239.164 1129.83 
241.0704 532.8 
245.0808 597.42 
253.0231 406.4 
261.0884 1101.29 
261.1229 871.18 
270.9774 1184.64 
271.1883 342.44 
284.9097 462.58 
285.1441 513.78 
294.9394 1394.09 
302.1956 420.17 
305.1552 406.96 
338.9647 388.74 
349.1805 364.56 
352.8962 437.68 
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362.9265 722.56 
365.1055 12440.65 
366.1091 1740.44 
367.1137 351.2 
376.2592 3326.76 
377.2603 727.73 
381.0796 1143.62 
393.2856 12350.9 
394.2883 3033.7 
395.2912 347.03 
398.2416 32581.69 
399.2445 7781.06 
400.2456 1121.37 
411.0957 598.12 
413.2334 2929.58 
414.2191 3423.47 
415.2215 853.64 
420.8839 360.75 
429.2027 430.63 
430.9137 564.86 
433.0908 361.44 
435.3072 844.54 
450.3062 390.92 
480.2796 348.2 
485.1128 708.19 
501.0868 347.7 
502.2627 482.41 
527.1584 883.61 
559.1307 348.72 
773.4922 682.74 
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5.  Mass spectrometry of wash 1 
 
 
 
m/z Abund 
80.9486 17974.67 
82.9456 5589.05 
96.9223 3975.45 
98.9194 1438.57 
112.8963 2603.11 
114.8933 1234.04 
115.0366 1199.99 
118.1234 1197.55 
136.0754 1540.13 
138.907 6422.31 
140.904 4265.85 
142.1095 2382.1 
142.9484 16459.15 
158.9221 1480.83 
158.9646 7360.78 
164.9296 13527.76 
173.0571 1988.55 
180.9031 3013.61 
185.1158 90543.44 
186.1193 7744.64 
196.866 3934.46 
198.8626 3695.89 
200.8596 1192.53 
200.9049 917.1 
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201.0892 9367.06 
203.0861 993.67 
206.894 1010.38 
210.1353 986.85 
211.0193 1585.45 
212.8397 888.07 
216.9226 1198.94 
222.8876 5355.56 
224.8842 1768.51 
230.0255 1129.11 
233.0638 1512.91 
238.8615 1588.63 
247.13 1447.04 
249.1418 3322.94 
254.8249 3503.26 
255.0462 900.04 
256.8215 4456.74 
258.8193 2134.08 
258.8636 1955.3 
260.8623 1266.05 
262.9067 1276 
265.1247 1526.07 
270.7983 886.7 
272.796 1208.81 
274.8801 1265.77 
280.847 4092.49 
282.8434 2664.8 
284.8876 1209.35 
296.82 1416.07 
298.8177 985.97 
312.7851 1518.35 
314.0862 869.06 
314.7809 2463.48 
316.7781 1542.87 
334.8362 886.51 
338.806 2483.12 
340.8023 2151.21 
342.8403 1441.08 
354.7788 1019.56 
356.7764 1108.1 
370.7435 1014.88 
372.7399 1802.37 
374.7396 1495.06 
388.7131 947.51 
396.7649 1618.22 
398.2425 16989.86 
398.7608 2139.59 
399.2471 4819.28 
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400.7787 1059.66 
413.1113 1008.56 
414.2155 9109.54 
414.7352 1051.07 
415.2198 2762.94 
416.2182 1027.77 
430.6989 1667.69 
432.6982 1418.84 
435.3092 9336.86 
436.3126 3288.82 
446.6724 863.72 
448.6697 859.3 
454.7243 1198.43 
456.7197 1962.26 
458.727 1237.66 
472.6941 951.68 
488.6589 975.36 
490.6552 1016.34 
514.6791 1389.13 
516.6798 1002.88 
525.2378 1056.84 
543.2424 2215.32 
561.253 2377.61 
572.6385 1018.35 
574.6382 1003.68 
630.5972 857.32 
632.5941 923.61 
959.9711 1213.61 
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6. Mass spectrometry of the supernatant 
 
 
m/z Abund 
80.9487 20720.74 
82.9457 6966.86 
96.9226 4724.34 
98.9198 1825.98 
112.8964 3300.89 
114.8937 1628.43 
118.1235 2100.99 
128.9541 2906.64 
136.0746 3091.19 
137.0798 1334.34 
138.9073 7735.22 
140.9043 4889.71 
142.1093 4618.51 
142.9486 11405.8 
143.955 1327.35 
158.9222 1017.85 
158.965 9604.02 
164.9294 13866.77 
173.0593 1341.32 
178.8998 1729.16 
180.9015 3576.4 
195.04 4326.62 
196.867 4297.28 
198.8633 3891.6 
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200.8604 1211.64 
211.0189 1925.67 
216.9234 1451.47 
219.0995 1712.77 
222.8879 5537.65 
224.8842 1862.84 
236.8596 1175.62 
238.8596 2547.53 
240.8571 975.94 
247.1315 2960.07 
249.1441 6693.35 
250.1485 1616.72 
254.8256 3552.6 
256.8224 4460.73 
258.8202 2109.36 
258.8615 1481.18 
262.9051 966.62 
263.1143 1191.71 
265.1315 2697.06 
272.7961 1259.37 
274.8815 1243.88 
280.8466 3843.39 
282.8435 2548.88 
284.8867 1411.01 
295.1853 1054.79 
296.8184 2028.44 
298.8156 1324.48 
302.8308 1097.12 
312.7862 1756.52 
313.1798 971.6 
314.7817 2427.36 
316.782 1493.04 
333.2053 1259.78 
338.806 2248.58 
340.8025 2053.65 
342.8408 1420.15 
349.1867 1764.76 
354.7765 1456.94 
356.775 1291.97 
370.7457 1144.09 
372.7416 1773.01 
374.74 1216.46 
393.2137 1761.32 
396.765 1592.72 
398.2442 2786.9 
398.7606 1879.87 
399.2569 1473.72 
400.7829 971.37 
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412.7355 1229.47 
414.2152 1579.65 
414.7328 1367.3 
415.1369 1029.25 
415.225 1133.68 
430.7009 1681.43 
432.6996 1376.01 
433.1467 1206.87 
435.3092 1336.52 
436.314 1250.81 
437.2364 1307.66 
443.1321 948 
454.7245 1045.01 
456.7204 1473.59 
458.7291 990.59 
472.6923 1055.29 
473.145 1430.88 
488.6602 1032.23 
514.6806 977.06 
525.2474 1766.67 
527.2481 942.5 
541.2311 1321.72 
543.2432 3607.03 
544.2484 1841.62 
545.2552 1309.4 
561.2528 3682.75 
562.2593 2121.71 
563.2642 1141.8 
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7. Mass spectrometry of the control sample-a solubilised pellet of the SE 
extract in the absence of Aβ.  
 
 
m/z Abund 
84.01 4312.07 
99.9877 9832.69 
102.0138 11460.51 
106.005 8734.28 
125.0365 9849.68 
143.0408 14830.15 
146.0206 5112.49 
149.9947 3458.94 
152.9478 4466.34 
157.0837 4814.11 
158.9647 95359.59 
177.9967 7718.7 
179.9914 3613.79 
185.1154 505927.61 
185.2273 29122.28 
186.1191 43662.29 
187.1201 4582.65 
193.9748 112020.9 
194.9774 4961.07 
197.9926 4682.84 
205.069 5638.41 
206.4994 4382.47 
	   229	  
211.9852 6393.63 
214.4877 2928.88 
217.1058 3033.13 
219.0238 111582.26 
220.0252 21712.72 
221.0219 13605.44 
229.1324 5173.28 
235.0014 174549.16 
236.0041 12247.38 
237.0315 3878.81 
239.0122 4446.5 
239.1634 5093.14 
253.0112 7956.61 
276.0271 3389.09 
284.3326 58398.23 
285.3357 11742.35 
293.9792 8059.96 
294.9399 16171.21 
301.142 5789.7 
304.3022 3057.67 
312.3638 10371.75 
313.9722 9693.34 
315.0745 5050.34 
326.3784 3344.53 
329.9497 35074.3 
332.9363 2952.38 
335.006 48743.66 
336.0084 4381.29 
340.395 8214.75 
351.9689 7257.41 
367.947 13199.27 
368.4266 16697.7 
369.4292 4714.3 
376.2609 14670.11 
377.2634 3554.57 
393.2873 15891.08 
394.2901 3965.04 
398.2432 267171.51 
399.2464 64521.89 
400.2489 8789.65 
414.2181 5464 
421.3187 4173.36 
424.8981 20295.98 
428.9209 3908.1 
430.9153 26683.6 
435.309 3143.54 
443.9305 7140.05 
459.9081 11133.94 
	   230	  
468.9795 20232.06 
469.9809 7124.06 
470.9802 7091.18 
484.957 37214.19 
485.9588 8997.2 
486.9598 6738.95 
500.9343 22754.27 
534.2181 7384.77 
544.8949 6645.73 
560.8728 13596.49 
563.9288 3006.66 
566.8902 7188.98 
579.9051 7602.75 
595.8825 6414.14 
660.8781 5458.7 
674.8562 4064.52 
680.8712 3467.07 
690.831 3664.43 
696.8489 7910.6 
702.8652 4707.84 
734.8999 3226.15 
750.889 3329.29 
773.4953 5356.66 
796.8526 3743.16 
832.8233 4444.07 
838.8404 3051.94 
869.8665 5430.78 
946.804 3837.72 
968.7993 4990.58 
1234.7322 7387.51 
 
 
 
 
 
